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Abstract 
Chapter 1 gives a brief outline of the relevance of carbohydrates in biological 
systems. Special attention has been given to the roles of glucosamine and N-acetyl 
glucosamine. 
Chapter 2 details the synthesis of novel glucosamine-based serine glycolipids, which 
were tested for their immunomodulatory ability. The experimental conditions 
investigated are discussed in detail. 
Chapter 3 describes the synthesis of a glucosamine-based serine building block, and 
its incorporation into a series of glycopeptides, via SPPS techniques, with potential 
as a kinase inhibitor. The experimental conditions for the synthesis and purification 
of these peptides are discussed in detail. 
Chapter 4 describes an investigation into the introduction of functionalities at the C-
6 position of the sugar moiety, with the aim of synthesising an azido-functionalised 
glucosamine derivative. The experimental details of this investigation are described. 
Chapter 5 describes the synthesis of a glucosamine-based dopamine derivative, 
which has potential as a dopamine prodrug. The various approaches taken in this 
synthesis, and the experimental conditions are discussed in detail. 
Chapter 6 gives the experimental details and characterisations for the compounds 
reported throughout this thesis. 
Chapter 7 contains appendices describing 
1
H NMR assignation, and also 
experimental details of attempted experiments. 
Chapter 8 contains the bibliographic information used as references in this thesis. 
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Chapter 1: An Introduction to N-Acetyl Glucosamine 
1.1     Introduction: Carbohydrates in the Development of Novel 
Therapeutics 
Sugars are ubiquitous in the human body, and in nature. They have been found to be 
integral to many different processes in living organisms such as cell recognition, 
development, growth, function and survival.
[1, 2] 
For these reasons, oligosaccharides 
have become interesting in the search for new therapeutics. 
Glycosylation is the process of attachment of a sugar moiety to the hydroxy, or other 
group, of another molecule. In the body, the sugar moiety is attached enzymatically 
to lipids (glycolipids), other sugars (oligosaccharides), or proteins (glycoproteins). 
Glycosylation of proteins is one of the most important post translational 
modifications (PTM) in the human body. The resulting linkage can lead to either the 
α or β stereoisomer. This linkage can be one of several different kinds when attached 
to a protein. One type is an N-glycosidic linkage, in which the oligosaccharide 
moiety is bound to the nitrogen of an asparagine amino acid residue. A second is an 
O-glycosidic linkage, where the sugar is attached to the hydroxy group of an amino 
acid, usually serine or threonine.
[3]
 Each of these glycoproteins serve different 
purposes in the body, such as forming a protective biofilm on epithelial cells, or as 
anchors for proteins in cell membranes. For the purposes of this discussion only the 
O-glycoproteins will be addressed. 
Glycoproteins derived from natural sources are a complex mixture, due to the 
process of PTM. The glycoproteins in this mixture are composed of the same peptide 
backbone, but have slight variations in the nature and site of glycosylation. These are 
known as glycoforms. A pure glycoform is, therefore, hard to obtain from natural 
sources, and a synthetic approach is one of the ways in which to achieve a pure, 
homogenous glycan. These pure forms are necessary for investigation of structure-
activity relationships, and also due to the different properties which these glycoforms 
exhibit.
[4]
 New synthetic techniques and methods have made this feat more 
achievable.
[5-7]
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Changes in the glycosylation pattern of cell surface proteins can be a marker for 
disease. Cancer cells have been found to have altered cell surface glycosylation 
patterns compared to normal cells. A high abundance of abnormal glycans have been 
detected on these cells, such as sialyl-Le
x
, Globo-H and TF.
[8]
 These antigens are 
known as tumor-associated carbohydrate antigens (TACA), and are associated with 
adhesion and invasion of cancer cells, contributing to the metastasis process. 
Although normal cells do express some of these antigens in low levels, they are 
much more abundant in abnormal cells. These facts make TACAs a good target for 
diagnostic purposes, and also as a therapeutic template. Globo-H has been evaluated 
as an anticancer vaccine in the treatment of breast and prostate cancer (Fig. 1.1).
[9] 
 
Figure 1.1 Globo-H 
Cell-surface carbohydrates play a major role in recognition of antibodies, as 
receptors for bacterial adhesion, and in cell-cell interactions. HNK-1 glycan is a 
glucuronylated and sulphated carbohydrate, which is expressed in a cell-type specific 
manner. Studies have been carried out into the tumor suppressant activity of HNK-1 
glycan. This glycan has been shown to play an important role in cell-cell interaction 
and in cell migration. Studies have found that, in patients suffering from astrocytic 
tumors, higher HNK-1 expression was associated with increased survival of patients. 
C6 glioma cells were engineered with HNK-1 positive cells, and these were injected 
into mouse brains in a controlled study. It was observed that, in the HNK-1 positive 
mice, the size of tumors were 60 % smaller than in the control mice, which had just 
been injected with the glioma cells. These results all indicate that HNK-1 glycan 
functions as a tumor suppressant.
[10]
  
1.2     N-Acetyl-D-Glucosamine 
The 2-deoxy-2-amino pyranoses are widely found in nature. These sugars have been 
found to play important roles in vital processes. D-Glucosamine (1.1) is the most 
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abundant of these amino sugars, and it exists as the N-acetyl derivative (1.2) in most 
cases (Fig. 1.2). The β-glycosidic linkage has been found to be prevalent in many 
glycoproteins (1.3).
[11]
  
 
Figure 1.2 D-Glucosamine, N-aceytl-D-glucosamine and β-glycoprotein 
D-Glucosamine (GlcN) has become of interest to the pharmaceutical and 
neutraceutical industries over the past few decades.
[12]
 One of the areas of high 
interest is in the treatment of osteoporosis and osteoarthritis (OA). OA is a disease 
which affects the joints of the elderly. The cartilage matrix of the joints is mainly 
composed of collagen and proteoglycan, which GlcN is a large constituent of. This 
disease is characterized by inflammation, pain and swelling of cartilage. In-vitro 
studies have shown GlcN to suppress mediators which cause these effects. GlcN has 
been classified as a neutraceutical supplement in many countries, although some 
controversy exists as to the beneficial effects touted by manufacturers of these 
supplements.
[13]
 
GlcN has also been investigated for its anti-oxidative and immunostimulating 
properties. Studies have found that GlcN exhibited strong chelating effects on 
ferrous ions, and inferred protection onto some macromolecules, such as proteins, 
from oxidative damage by hydroxyl radicals. These antioxidative activities make 
GlcN an attractive candidate for therapeutic development. N-Acetyl glucosamine 
(GlcNAc) was investigated, but showed almost no chelating effects. GlcN 
demonstrated impressive immunostimulating properties also, by enhancement of 
serum antibody levels in mice.
[12]
  
Glycoproteins possessing the O-linked β-N-acetylglucosamine (O-GlcNAc) 
modification were discovered relatively recently by Torres and Hart in 1984.
[14]
 They 
described it as a new PTM which is found abundantly on cytoplasmic and nuclear 
proteins. There are several reasons for this late discovery of such an integral player 
in most biological systems. Firstly, the O-GlcNAc moiety is small and uncharged, 
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and so is not picked up by many detection systems. It does not usually alter the 
migration of proteins in gel electrophoresis. The second reason is that all cells 
contain hydrolases which cleave O-GlcNAc from intracellular proteins once the cells 
are damaged. Yet another reason is that the degree of protein glycosylation is 
substoichiometric at each site, and so is difficult to detect by means such as mass 
spectrometry. Finally, the glycosidic linkage of O-GlcNAc is very labile, especially 
upon ionisation. This means that the sugar is often lost at the ionisation source, and 
not detected.
[15]
 Developments in detection methods have made this task more 
manageable.  
O-GlcNAc is part of some structural polysaccharides, such as chitin (Fig. 1.3). 
Chitin forms part of the exoskeleton of invertebrates such as insects and arthropods, 
and also is a constituent of fungal cell walls.  
 
Figure 1.3 The polysaccharide chitin 
Enzymes which can hydrolyse chitin are known as chitinases, but humans are 
deficient in these enzymes. These chitinases could be candidates in the development 
of insecticides and drugs against pathogens such as Candida albicans or 
Pseudomonas falciparum.
[16]
 Chitinase inhibitors have also been investigated for 
their anti-fungal properties. Chitinases play an essential role in the life cycle of 
pathogenic fungi, degrading the chitin found in the cell wall. They can also cleave 
random β-(1,4)-glycosidic bonds within the oligosaccharide, resulting in fragments 
of varying lengths. Introduction of a chitinase inhibitor could potentially disrupt the 
natural processes in fungal cells.
[16]
 
Human milk contains many soluble oligosaccharides, such as lacto-N-neotstraose 
(Fig. 1.4). These are known as human milk oligosaccharides (HMO). This collection 
of sugars is not found in the milk of other mammals. HMOs mainly consist of a 
lactose moiety as the reducing terminal, and a lactosamine/ isolactosamine at the 
non-reducing terminal. They are a mixture of linear and branched structures. These 
oligosaccharides are of major interest due to the properties they infer on the milk. 
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They can reach the large intestine, where they are easily absorbed into the 
bloodstream, as they are resistant to hydrolysis. They play roles as prebiotics, and as 
competitive ligands to pathogenic microorganisms.
[11]
 Adherence is the first step in 
the pathogenic cycle of invading bacteria. Many of these HMOs have been shown to 
act as soluble receptor analogues of epithelial cell-surface carbohydrates, and so act 
as receptor decoys, preventing bacterial adhesion.
[17]
  
 
Figure 1.4 Human milk oligosaccharide lacto-N-neotstraose 
1.3     The Role of O-GlcNAcylation in the Regulation of Protein 
Function 
To date more than 1000 proteins have been found to be glycosylated with O-GlcNAc 
residues.
[18]
 This dynamic process is carried out by O-GlcNAc transferase (OGT), 
which glycosylates the hydroxy side chain of serine and threonine residues of 
proteins (Fig. 1.5). The gene which encodes for OGT is located near the centromere 
Xq13, which is a chromosomal region linked to several neurological diseases, such 
as Parkinson’s dystonia.[15] The substrate for OGT attachment of O-GlcNAc is 
known as UDP-O-GlcNAc (uridine-5’-diphosphate O-GlcNAc). Cleavage of O-
GlcNAc residues from an amino acid is facilitated by a glycosidase enzyme, known 
as O-GlcNAcase. The interplay between these two enzymes allows regulation of 
many different processes in the body. 
 
Figure 1.5 Dynamic action of O-GlcNAc transferase and O-GlcNAcase 
O-GlcNAcylation plays an essential role in cell signalling pathways which regulate 
nuclear and cytoplasmic proteins. Demonstration of the vital nature of O-
GlcNAcylation is noted in studies where O-GlcNAc cycling has been blocked. In 
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one investigation, galactosyl transferase was used to cap the O-GlcNAc moieties 
with a galactose residue, thereby blocking recognition by enzymes like OGT and O-
GlcNAcase. This modification to the cell resulted in apoptosis.
[19]
 In another study 
carried out by O’Donnell et al, OGT knockout mice were engineered. Embryonic 
cells were modified to be deficient in the gene encoding for OGT. This alteration 
resulted in mice lacking in O-GlcNAc, with the outcome of T-cell apoptosis, 
neuronal tau hyperphosphorylation, and fibroblast growth arrest. Another interesting 
part of this study was found within the female mouse population. OGT is an X-
linked enzyme, and, in female mice, there was no observed alteration in OGT 
production. This suggests that cells preferentially deactivate the OGT gene deficient 
chromosome in early development, further demonstrating the necessity of O-
GlcNAcylation.
[20]
  
Numerous proteins from many functional classes have been found to be O-
GlcNAcylated, including kinases, transcriptional factors, and even some viral 
proteins (Fig. 1.6). 
 
Figure 1.6 Different functional classes of proteins found to be O-GlcNAcylated
[15]
  
Regulation of protein function is controlled by several different mechanisms. These 
include mediating protein phosphorylation, protein degradation, protein-protein 
interactions, adjusting localisation of proteins, and mediation of transcription.
[21]
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O-GlcNAcylation has a reciprocal nature with phosphorylation (Fig. 1.6). Both are 
important PTM, and occur on serine/threonine residues of proteins. A complex 
relationship exists between these two processes, and each is seen as a regulatory 
mechanism for the other.  
 
Figure 1.6 Dynamic interplay between glycosylation and phosphorylation 
There are at least four different types of interplay which have been identified 
between O-GlcNAcylation and phosphorylation. These include competitive 
occupancy, where phosphorylation occurs at the same residue as glycosylation (Fig. 
1.4), and alternative occupancy, where different residues are targeted by each 
process.
[15]
 Numerous studies have been carried out to investigate this relationship, 
with the observation that activation of phosphate kinases resulted in a decrease in O-
GlcNAcylation. Conversely, when those same kinases were inhibited, an increase in 
O-GlcNAcylation was observed.
[22]
 This relationship can be seen in patients who 
suffer with Alzheimer’s disease (AD). Hyperphosphorylation of the microtubule 
bundling protein tau is a hallmark of AD, while tau is known to be heavily O-
GlcNAcylated in the normal human brain.
[23]
  
Protein degradation is required to regulate cell function. O-GlcNAcylation can alter 
the rate of protein degradation in two ways. The first is by altering the targeting of 
certain proteins to the proteasome, and the second is by altering the activity of the 
proteasome. Many sites of O-GlcNAcylation are located in sequences possessing a 
high PEST score. These sequences are rich in proline, glutamic acid, serine and 
threonine residues, which has been shown to mediate protein degradation.
[24, 25]
 A 
study carried out into murine estrogen receptor-β (mER-β) demonstrated the 
importance of O-GlcNAcylation and phosphorylation in protein degradation. It was 
shown that Ser
16
 of mER-β is the site for both PTMs to occur. Mutant strains of 
mER-β, in which the hydroxyl amino acid had been removed at this locus, were 
glycosylation and phosphorylation deficient. The result of this was a slower rate of 
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degradation of mER-β, showing the importance of glycosylation and 
phosphorylation to protein degradation and activity.
[26]
  
Many transcription factors have been found to be O-GlcNAc modified. When 
extracellular concentrations of glucose/glucosamine are altered, the transcription of 
multiple genes is up- and down-regulated.
[21]
 β-Catenin is a protein which has a vital 
role in intracellular adhesion and regulating gene expression. Increased 
transcriptional activity of β-catenin has been associated with the progression of 
many cancers. Sayat et al have shown that O-GlcNAcylation of β-catenin negatively 
regulates its levels in the nucleus. They found that normal prostate cells display 
higher amounts of O-GlcNAcylated β-catenin than prostate cancer cells. O-
GlcNAcylation of β-catenin significantly reduced its transcriptional activity, making 
this modification interesting in the development of cancer treatments.
[27]
 
UDP-O-GlcNAc is a terminal by-product of the hexosamine biosynthetic pathway 
(HBP), and is a donor substrate for O-GlcNAcylation, as mentioned earlier (Scheme 
1.1).
[23]
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Scheme 1.1 Hexosamine biosynthetic pathway
[15]
 
When the rate of HBP flux varies, this causes changes in the level of UDP-O-
GlcNAc, which in turn alters the extent of O-GlcNAcylation of numerous proteins. 
HBP is an important pathway in the regulation of insulin levels in the body, acting as 
a “fuel sensor”. It senses the levels of glucose and free fatty acids, and breaks them 
down into substrates which can be stored within the body. Glucose is rapidly 
converted to glucose-6-phosphate, and then to fructose-6-phosphate. This is followed 
by conversion to glucosamine-6-phosphate, which is catalysed by glutamine: 
fructose-6-phosphate amidotransferase (GFAT). Glucosamine-6-phosphate is next 
converted to UDP-O-GlcNAc, which is the endpoint of the HBP pathway (Scheme 
1.1).
[28]
 UDP-O-GlcNAc is then used as the donor substrate for O-GlcNAcylation of 
proteins. If there is an abnormal increase in the degree of O-GlcNAcylation, this 
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disrupts the normal dynamic between O-GlcNAcylation and O-phosphorylation. 
This, in turn, disturbs signalling, transcription, and other cellular functions, leading 
to the toxicity associated with type II diabetes, and other diseases.
[15]
 When the HBP 
flux is increased for prolonged periods of time, over-glycosylation has been shown 
to occur. This may contribute to impaired cardiac contractile function during the 
onset of insulin resistance. High circulating free fatty acids observed in obese 
individuals may chronically activate the HBP, leading to development of insulin 
resistance. In a study carried out by Rajamani et al, it was observed that increasing 
the HBP flux in a rat model of diet-induced hyperglycaemia/insulin resistance 
elicited myocardial apoptosis.
[28]
 
The presence of O-GlcNAc has been shown to play many vital roles in the 
functioning of the cell, and regulation of numerous processes. Its integral part in 
such diverse and important areas make it interesting as a therapeutic target, or as a 
template for drug design. The prevalence of the labile β-glycosidic bond in nature, 
and also the added complication of four hydroxy groups of similar reactivity, mean 
that each step of any synthesis must be carefully planned and carried out. New 
developments in synthetic carbohydrate chemistry are paving the way for this task,
[7]
 
for example, the introduction of less labile, non-native linkages, such as C-
glycans.
[29, 30]
 In any case, the synthesis of GlcNAc derivatives is of interest in order 
to study biological processes, and in the search for new therapeutics. 
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Chapter 2: The Synthesis of Glycosylated-Serine Glycolipid 
Derivatives 
2.1     Introduction: Glycolipids 
In biological systems, lipids exist as amphiphilic molecules, which consist of a 
hydrophilic and a lipophilic portion. The hydrophilic part can be either a phosphate 
group, in the case of phospholipids, or a carbohydrate moiety in the case of 
glycoglycerolipids or glycosphingolipids. The lipophilic part is composed of either 
1,2-di-O-diacylglycerol or N-acylsphingosine (Fig. 2.1).
[3]
 
 
Figure 2.1 Structures of some phospholipids and glycolipids 
2.1.1     Sphingolipids 
Sphingolipids contain an amine functionality, and when this is acylated it results in 
the hydrophobic family of compounds, called ceramides, which are a component of 
most glycosphingolipids (GSLs). The majority of ceramides contain a trans C4-C5 
double bond in the lipid chain. Sphingolipids which lack this double bond are known 
as sphinganines, and those which are hydroxylated on C-4 are known as 
phytosphingosines (Fig. 2.2).
[31]
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Figure 2.2 Structures of the different sphingolipids 
Sphingolipids are produced in the body by either of two different mechanisms. The 
first is by de novo biosynthesis from L-serine and fatty acids, the second is through a 
salvage pathway, which involves the recycling of building blocks (sphingosine from 
lysosomal degradation).
[32]
 
2.1.2     Glycosphingolipids 
Glycosylated sphingolipids are known as glycosphingolipids (GSL). These are 
bioactive molecules which are ubiquitous in eukaryotic cell membranes. They are 
essential to many biological processes such as cellular trafficking, signalling,
[33]
 
proliferation, apoptosis,
[34]
 and cell recognition. 
Hundreds of different GSLs have been characterised, which vary greatly in respect to 
the nature of the hydrophobic chains in the ceramide moiety, and also in regard to 
the carbohydrate portion. GSLs have been loosely divided into several 
classifications. Cerebrosides contain one sugar residue per ceramide, and are widely 
distributed in the plasma membranes of neuronal cells. Sulphatides, or 
sulphoglycosphingosines, consist of a sugar residue which has been sulphated. 
Gangliosides are complex GSLs, which contain sialic acid residues. And finally, 
neutral GSLs, or globosides, which contain only neutral oligosaccharides, two or 
more sugar residues in length.
[3]
 
The composition of GSLs is cell-type specific. For example, gangliosides are a large 
component of the nervous system, making up 10-12 % of the lipid content, and 
playing an important part in its crucial processes.
[35]
 The lipid chains of the 
gangliosides are embedded into the outer leaflet of the plasma membrane, with the 
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complex glycan moiety extending out into the extracellular space.
[36]
 Gangliosides 
are involved in regulation of the immune system, metabolic regulation, and in cancer 
progression. They play an important role in cell-cell recognition, due to binding 
interactions between the extended glycan and complementary glycan binding 
proteins (lectins) on other cells. An example of this is the interaction between the 
sialic acid residues of a ganglioside, and the inhibitory Siglec-7 receptor on natural 
killer cells, which regulates their cytotoxicity. They can also regulate signalling 
proteins in their own membranes, as in the case of epidermal growth factor, by 
interacting laterally.
[37]
 Brain gangliosides GD1a and GT1b bear a sequence 
(NeuAcα-2-3Galβ1-3GalNAc) which is recognised by myelin-associated 
glycoprotein (MAG). This cell-cell interaction is required for axon-myelin stability 
and axon regeneration. Further study of this interaction may provide a way to aid 
recovery after nerve damage.
[38]
 
2.1.3     The Role of Glycosphingolipids in Disease  
The enzymatic degradation of glycosphingolipids by lysosomal hydrolases takes 
place in endosomes and lysosomes. This is a process which involves several steps, 
and the failure of any one step can cause accumulation of the lipid substrates in the 
endosomal compartment. Many symptoms of different diseases have been attributed 
to this build-up of material, such as Krabbe disease and Fabry disease, and these 
diseases are collectively known as sphingolipidoses.
[39]
 
Krabbe disease is an inherited autosomal disorder which is caused by a deficiency of 
galactosylcerebrosidase. This enzyme catalyses hydrolysis of galactose from 
galactosylceramide and galactosylsphingosine, and its absence causes an 
accumulation of these glycolipids. An excess of galactosylsphingosine results in the 
loss of myelin and oligodendrites in the brains of Krabbe disease sufferers. A study 
was carried out by Pannuzzo et al into a galactose free diet for twitcher mice (the 
mouse model for Krabbe disease). The dietary regime resulted in delayed onset of 
symptoms in the mice, and may show promise for management of certain forms of 
the disease.
[40]
 
While being implicated in various disorders, glycosphingolipids have also been 
investigated as a potential treatment for disease. Sulfatide (Fig. 2.3) and its precursor 
β-galactosylceramide (β-GalCer) are native GSLs found in pancreatic β-cells. It has 
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been shown that sulfatide decreases, and β-GalCer increases, the production of 
proinflammatory cytokines, such as IL-1 β and TNF-α.[41] 
 
Figure 2.3 Sulfatide 
2.2     Non-Ceramide Containing Glycolipids as Therapeutics 
Synthetic non-ceramide analogues have been made which display anti-human 
immunodeficiency virus (HIV) activity. These derivatives appear to be mainly 
sulfated glycolipids. Dextran sulphate, heparin, and other sulphated polysaccharides 
have been reported to be highly selective inhibitors of HIV replication.
[42]
 
Achiwa and co-workers have synthesised a number of non-ceramide analogues, 
which were tested for their anti-HIV activity. They made several different sugar 
derivatives, which displayed varying amounts of activity. The activity of these 
compounds was determined by measuring the concentration of the compound 
(µg/mL) at which 50 % of MT-4 cells expressed HIV-1 antigens. Glycolipids shown 
in Fig. 2.4 were the most active in this study, and were non-cytotoxic. The glucose 
derivative 2.1 was the most potent. In the same study, sulphated galactose and 
glucose serine-based glycolipids were also tested, but showed no anti-HIV 
activity.
[43]
 
 
Figure 2.4 Glycolipid derivatives which display anti-HIV activity 
Several glycolipid derivatives have been described so far, with potential for use in 
the treatment of disease. The area of immune stimulation has attracted huge interest 
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in recent years, with work being carried out into the development of glycolipid 
therapeutics. 
2.3     Glycolipids as Immunomodulators 
2.3.1     The Immune Response   
There are two elements to the human immune response; the innate and the adaptive 
immune systems. The innate immune system deals with many of the pathogens and 
foreign molecules which the body encounters. It includes physical barriers such as 
the skin, or epithelia covering vital organs, and also cells like macrophages, dendritic 
cells, neutrophils, and natural killer (NK) cells. These lymphocytes have the ability 
to recognise an invading molecule as foreign, and to mount a non-specific attack in 
order to remove the pathogen from the body. It is a fast response to an unknown 
pathogen, and is a sufficient barrier in most cases. If the innate immune system 
becomes overwhelmed, or circumvented, the adaptive immune response is activated. 
The adaptive immune system is a more specific response, it recognises almost any 
pathogen. The response is a slower one, as the adaptive system needs to produce 
lymphocytes with specific antigen receptors, such as T-cell receptors (TCR) and 
immunoglobulins. These lymphocytes, such as memory T-cells, retain a memory of 
the invading pathogen. This response provides the host with the ability to recognise 
these pathogens in the case of reinfection, and so a faster response can be 
mounted.
[44]
 
2.3.2     Natural Killer T Cells  
Natural killer T (NKT) cells are a class of T-lymphocytes which can be considered a 
hybrid of natural killer (NK) cells and memory T-cells. T-Cells are produced in the 
thymus, and usually detect peptide antigens which are presented by conventional 
major histocompatibility (MHC) molecules. NKT cells possess a T-cell receptor 
(TCR), but differ from traditional T-cells, in that they recognise lipid antigens 
presented by the non-traditional MHC molecule, CD1d.
[45]
 CD1d is carried by 
antigen presenting cells, such as dendritic cells or macrophages. NKT cells play an 
important role in the regulation of the immune response. They have been shown to 
be involved in host defence against microbial infections, in maintaining immune 
tolerance,
[46]
 and in the elimination or control of malignant cancers.
[45]
 These 
Chapter 2: The Synthesis of Glycosylated-Serine Glycolipid Derivatives 
Page | 16  
 
regulatory properties are due to the release of a variety of different cytokines, and 
activation of cells in the innate and adaptive immune systems. NKT cells are CD1d 
reactive. The production of cytokines is stimulated by the presentation of specific 
classes of glycolipids, by the CD1d receptor, to the NKT cells (Fig. 2.5).
[47]
 
 
Figure 2.5 A simplified illustration of NKT cell stimulation by binding to CD1d/Glycolipid 
complex 
The CD1d molecule is composed of an α1 helix and an α2 helix, which flank a β-
sheet floor. There are two hydrophobic pockets, or channels, in the molecule. 
Binding of specific glycolipid antigens to CD1d is facilitated by the insertion of the 
lipophilic glycolipid tails into these pockets. The binding is further strengthened by 
hydrogen bonds formed between the external polar sugar moiety and amino acid 
residues at the mouth of the binding pocket. It is this protruding glycan which acts as 
the TCR binding region. Several features contribute to the specificity of CD1d 
towards the glycolipid ligand. The lipid chains of the ligand must be of a certain 
length to fit snugly into the hydrophobic channels; too short and the binding will not 
be tight enough, too long and the lipid tail will not fit into the pocket. The second 
factor is the amino acid residues at the binding pocket; these infer specificity for the 
sugar functionality.
[48, 49]
 
Once NKT cells are activated by binding to this CD1d/glycolipid complex, they can 
activate the release of different cytokines. The pattern of cytokine release is 
associated with different immune responses, for example the type 1 and 2 helper T 
cell based (Th1 and Th2) pathways. It is these two pathways which have received the 
main focus in the literature. Stimulation of the Th1 response results in the release of 
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cytokines such as Interferon-γ (IFN-γ) and Interleukin-12 (IL-12), which have been 
shown to have positive effects on mouse models of malaria and tumor metastasis.
[50]
 
Activation of the Th2 pathway induces the release of cytokines such as IL-4 and IL-
5, which are regulators of inflammation.
[51]
 As the effects of these two pathways are 
opposing, the search for a glycolipid which could induce a biased response has 
become important. Selective activation of either the Th1 or Th2 pathway could be 
vital for the treatment of many diseases, such as type 1 diabetes or multiple 
sclerosis.
[52]
 
The native ligand for CD1d mediated activation of NKT cells is not known, but 
several glycolipids have been suggested. One such glycolipid is 
isoglobotrihexosylceramide (iGb3), which has been shown to increase the CD1d 
restricted immune response of human and mouse NKT cells (Fig. 2.6). Using this 
evidence, synthetic analogues were investigated in order to test the importance of 
certain parts of the iGb3 molecule to CD1d binding. A structure-activity relationship 
study showed that the hydroxyl groups on C-2 and C-3 of the galactose moiety were 
vital for recognition by NKT cells, while the hydroxy groups on C-4 and C-6 were 
not as important.
[53]
 The α-anomer of iGb3 was found to be recognised by NKT 
cells, and also to stimulate a more potent in-vitro response than the natural β-
anomer.
[54]
 Recent research has suggested that iGb3 is not the natural ligand, as it has 
not yet been found in either mice or humans. Another piece of evidence is the lack of 
iGb3 synthase in humans, but perhaps the synthesis of iGb3 may be carried out by 
another enzyme in the absence of iGb3 synthase.
[55]
  
 
Figure 2.6 Structure of iGb3  
Very recent work carried out by Brennan et al has described another possible 
endogenous ligand for CD1d, β-D-glucosylceramide (β-GlcCer). This ligand was 
tested on mouse and human NKT cells, and was found to stimulate release of both 
IFN-γ and IL-4. The activity of β-GlcCer was found to be dependent on the 
composition of the N-acyl chain. Several naturally occurring forms of β-GlcCer were 
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tested, with some derivatives, such as 2.4, displaying potent stimulatory activity, and 
2.5 showing no activity (Fig. 2.7).
[56]
 Some other studies by Stanic et al have 
reported β-GlcCer as being non-antigenic, but the length and degree of saturation of 
the hydrocarbon chains was different to those tested here.
[57]
 
 
Figure 2.7 Endogenous β-GlcCer derivatives  
While the endogenous ligand for CD1d is almost certainly a β-linked glycolipid, 
much evidence in the literature points to the potent NKT stimulatory abilities of α-
glycolipids. The glycoside which has received the most attention in recent years is α-
galactosylceramide. 
2.3.3     α-Galactosylceramide  
α-Galactosylceramide (α-GalCer) is an α-anomeric glycolipid, which is not present 
in the mammalian body (Fig. 2.8). It was originally isolated from the marine sponge 
Agelas mauritianus, but α-GalCer used in most biological studies is now synthesised 
in the lab instead, and is known as KRN7000. KRN7000 is usually referred to as α-
GalCer, and this convention will be used for the purposes of this discussion. It has 
been demonstrated that α-GalCer has potent immunomodulatory activity, and much 
investigation has gone into the use of this glycolipid for the treatment of diseases 
such as tuberculosis, cancer, and malaria.
[58, 59]
 
 
Figure 2.8 Structure of α-GalCer 
The stimulation of NKT cells by CD1d molecule presentation of α-GalCer rapidly 
produces various cytokines, such as IL-4, IL-10, IFN-γ, and tumor-necrosis factor 
(TNF). In-vivo administration of α-GalCer to mice has shown a characteristic 
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pattern. IL-4 tends to be the main cytokine secreted in the first 24 h, changing to an 
IFN-γ dominated population after this time.[60] 
While α-GalCer has shown promise as a potent immunomodulator, studies have 
shown that administration can stimulate both the Th1 and Th2 immune responses. 
This is a problem in the treatment of many diseases, such as autoimmune conditions, 
where Th1 cytokines are thought to exacerbate symptoms.
[53]
 Other unwanted side-
effects such as liver toxicity and aggravation of atherogenesis in mice have also been 
recorded.
[61]
 
Copious studies have been carried out into the response generated by α-GalCer 
administration to mouse and human subjects. The potential of α-GalCer is widely 
acknowledged, but a biased immune response is required for therapeutic 
applications. This has spurred work into the development of analogues of α-GalCer 
and other glycolipids. 
2.3.4     Synthetic Analogues; The Nature of the Lipid Chains 
One point of structural variation is the length of the lipid chains. The hydrophobic 
pockets of the CD1d molecule are of a specific size, and, by altering the length of the 
lipid chain, the “fit” of the glycolipid tails can be modified. The length of the 
hydrocarbon chain may also cause changes in the conformation of CD1d, which 
could result in a different immune response upon NKT cell activation. Small 
structural changes could help to generate a biased Th1 or Th2 response. One of the 
first truncated glycolipid analogues which was tested is known as OCH (Fig. 2.9). 
This glycolipid contains a shorter sphingosine chain; C5H11 compared to that of α-
GalCer, which is C14H29.  
 
Figure 2.9 Structure of the truncated analogue OCH
[62]
 
OCH has been shown to skew the release of cytokines towards a Th2 profile, with 
IL-4 being the main cytokine produced. This kind of bias has been beneficial in 
suppressing the myelin-antigen specific Th1 response in the mouse model of 
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multiple sclerosis. There is an obvious difference in cytokine stimulation by OCH, 
compared to the unbiased response of α-GalCer administration.[62] This is thought to 
be because the shorter sphingosine chain of OCH is not as tightly bound into the 
hydrophobic pocket of the CD1d molecule. The sugar moiety is then angled 
differently, lessening interactions with amino acid residues of CD1d, resulting in a 
shorter association time for the glycolipid/CD1d complex. The release of Th1 
cytokines appears to require a longer period of NKT stimulation.
[63, 64]
 
Other truncated analogues of α-GalCer have been synthesised, with several showing 
a biased Th2 response. Shortening of the acyl chain, for example to C7H15, also 
stimulates an increase in the release of Th2 cytokines.
[65]
 
Care must be taken when considering much of the results of these tests. Often a 
skewed response is noted when working with mouse cell lines, but when the testing 
is carried out on human cell lines this skewing is not observed. An example of this 
can be seen in a study carried out by Veerapen et al. This group synthesised several 
truncated OCH glycolipid analogues (Fig. 2.10). They found that several were 
active, and displayed a biased Th2 response with mouse iNKT (invariant NKT) cells. 
The same compounds were active when tested with human iNKT cells, but a 
nonbiased response was stimulated, with secretion of both IL-4 and IFN-γ.[66] It has 
been found that mouse NKT cells are phenotypically different to those expressed by 
humans, with a different subset of NKT cells being present. This is especially noted 
among human iNKT cells, which can be CD4
+
, CD8
+
, or CD4
-
CD8
-
. Mouse iNKT 
cells lack the CD8
+
 subtype. Healthy mice also possess more iNKT cells than 
healthy humans. These differences can account for the variation in activity between 
mouse and human NKT cells.
[67]
 
 
Figure 2.10 Truncated OCH analogues synthesised by Veerapen et al
[66]
 
Changes in the nature of the lipid chains described so far have mostly elicited a 
biased Th2 response, but analogues have also been synthesised which encourage a 
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Th1, or IFN-γ, based response. Work carried out by Wong and co-workers has 
produced compounds which stimulate a biased Th1 response in human iNKT cells. 
They have carried out modifications to introduce a more polar phenyl ring onto the 
end of the hydrophobic chain, with several compounds displaying the desired 
activity (Fig. 2.11). These glycolipids were the first of such compounds to stimulate 
a more potent release of IFN-γ than α-GalCer, and could have potential as adjuvants, 
or antiviral agents. They also synthesised shorter chain derivatives, but these did not 
show a biased response, indicating the need for the spacer chain.
[68]
 
 
Figure 2.11 Glycolipid derivatives synthesised by Wong and co-workers
[68]
 
Serine-based analogues have been investigated, such as that synthesised by Fan et al 
(Fig. 2.12). This glycolipid was found to activate mouse NKT cells, but the response 
was non-biased, and mild, with release of small amounts of both IL-4 and IFN-γ. 
The fucosyl ceramide, and glucosyl-serine derivatives were also synthesised, but 
showed no immune-activity.
[69]
 
 
Figure 2.12 Serine-based glycolipid synthesised by Fan et al
[69]
 
2.3.5     Synthetic Analogues; Glycosidic Bond Derivatives 
Another modification which has been carried out is the replacement of the glycosidic 
oxygen with a different atom, such as carbon, nitrogen, or sulphur.  
One of the first such analogues was α-C-GalCer, 2.6, synthesised by Schmieg et al 
(Fig. 2.13). In this derivative carbon replaces the more electrophilic oxygen atom. In 
mouse studies α-C-GalCer was found to be 1000-fold more potent than its oxygen 
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counterpart, stimulating a biased Th1 cytokine response. The efficacy of this 
analogue has been attributed to the resistance of the non-native carbon linkage to 
enzymatic hydrolysis.
[70]
 When α-C-GalCer was tested with human iNKT cells the 
results were a lot less promising. Further modifications involving C-glycosides 
include the introduction of an alkene at the glycosidic linkage as in 2.7 (Fig. 2.13). 
This derivative was shown to have potent human NKT stimulating effects, with a 
bias towards a Th1 response.
[71]
 
 
Figure 2.13 C-Glycosidic derivatives 
Thio-derivatives have also been of interest. Thioglycoside analogues are those in 
which the glycosidic oxygen has been replaced by a sulphur atom. An α-S-GalCer 
derivative, synthesised by Zhu and co-workers, was found to stimulate the 
production of cytokines by human NKT cells, with a comparable potency to α-
GalCer (Fig. 2.14). It was found that the thioglycoside did not stimulate mouse NKT 
cells. This analogue shows promise as a positive control in biological studies, and 
may be a more suitable derivative than α-GalCer, which also stimulates mouse NKT 
cells.  Although this derivative did stimulate cytokine release, a biased response was 
not obtained.
[72]
 
 
Figure 2.14 Thioglycoside derivative synthesised by Zhu and co-workers
[72]
 
Another popular modification of the glycosidic linkage is to synthesise β-glycolipid 
analogues. These are of great importance, as, although α-glycolipids have been 
shown to be potent immunostimmulators, there are no α-glycosphingolipids known 
in the human body, to date. The native ligand for CD1d must, therefore, be a β-
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glycolipid, as discussed earlier, for example β-GlcCer.[56, 73] Much investigation has 
been carried out into the stimulation of NKT cells by β-glycolipids, and it has been 
found that they are capable of this activation, albeit in a lower potency than their α-
linked analogues. In the binding cleft of the CD1d molecule α- and β-linked sugars 
adopt different orientations. Observations by Pellicci et al show that, even though 
the sugars orientation at the binding cleft is different, the TCR of the NKT cell is 
capable of flattening the glycan so that both anomers possess a similar conformation. 
This is also true for oligosaccharides, like iGb3. The less potent activity of β-
glycolipids is attributed to the energetic penalty which is incurred in order to distort 
them into the shape of an α-linked glycoside.[74] These results were strengthened by 
Yu et al who carried out a similar study.
[75]
 
2.3.6     Synthetic Analogues; β-Glucosylceramides 
β-Glucosylceramides (β-GlcCer) are a naturally occurring family of glycolipids 
found in the human body. β-GlcCer occurs in many different, closely related forms, 
with variations on the hydrocarbon chains. Only certain forms are found in the body, 
and, as discussed earlier, endogenous β-GlcCer derivatives have been found to have 
NKT stimulatory properties.
[56]
 
Kobayashi et al examined the effects of synthetic β-GalCer and β-GlcCer derivatives 
on murine NKT cells. They found that the β-glycolipids did stimulate NKT cells, but 
at a much lower level than their α-equivalents.[76] 
Work carried out by Oku et al has shown that β-GlcCer (2.8) displays specific 
cytotoxicity to tumor cells in-vivo. They also found that β-GalCer (2.9) has the same 
effect, suggesting that the mode of action is not dependent on the specific sugar 
structure (Fig. 2.15). These glycolipids were derived from malt feed. The effect of 
the ceramide portion alone was investigated, and these compounds showed no 
cytotoxicity towards cancer cells, indicating the need for the glycan component. This 
may also be due to the hydrophobicity of the ceramide, which would alter its 
solubility. Glycosylation of the ceramide would introduce a more hydrophilic nature 
to the compound. This cytotoxicity is not attributed to the production of IFN-γ, as is 
the case with some other glycolipid derivatives.
[77]
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Figure 2.15 β-Glycolipid derivatives which display cytotoxicity to tumor cells 
Ya’acov et al have synthesised a thio-derivative of β-GlcCer, and have tested both 
the O- and S- glycosides for their immunoregulatory activity (Fig. 2.16). They found 
that both β-GlcCer and β-S-GlcCer led to a decrease in STAT-1 phosphorylation, 
and a decrease in IFN-γ levels. This result is of importance in the treatment of auto-
immune diseases, for example in the alleviation of ConA immune-mediated 
hepatitis. The thio-analogue was less susceptible to enzymatic degradation, and was 
shown to increase the suppression of intra-hepatic NKT lymphocytes.
[73]
 
 
Figure 2.16 The structures of β-GlcCer 2.10 and β-S-GlcCer 2.11 
Several β-linked glycolipid derivatives have been tested for their immunostimulatory 
ability, but, for the main part, they have shown weaker activity than their α-linked 
counterparts. This should not be seen as a deterrent, as, even with weak activity, as 
long as the immune response generated is biased, there may still be a use for β-
glycosides as immunomodulators. 
2.3.7     Synthetic Analogues; Modification of the Carbohydrate Moiety 
Modification of the sugar moiety is another area which has been investigated. 
Several 6’-modified α-GalCer derivatives have been shown to stimulate cytokine 
release from mouse NKT cells. The analogue synthesised by Trappeniers et al, 
shown in Fig. 2.17, was found to induce a strong Th1 biased response.
[78]
 This 
compound was later tested for activation of human NKT cells, and was found to 
stimulate the release of cytokines.
[79]
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Figure 2.17 6’-Modified analogue synthesised by Trappeniers et al[78] 
Substitution of the galactose sugar moiety for a different sugar has been carried out. 
An example of this is β-mannosylceramide (β-ManCer), which has been shown to 
activate both mice and human NKT cells (Fig. 2.18). Unusually, β-ManCer infers 
some tumor immunity in mouse studies, but does not stimulate the release of IFN-γ, 
which is thought to be the source of most analogues anti-tumor properties. It also 
does not induce release of IL-4, or other commonly stimulated cytokines. The mode 
of action of β-ManCer was investigated, and found to be due to the stimulation of 
NOS (Nitric Oxide Synthase) and TNF-α. Mouse models were given an NOS 
inhibitor called N-nitro-D-arginine-methyl ester. This NOS inhibition had no effect 
on the tumor formation in mice treated with α-GalCer, showing that the immunity 
given by α-GalCer is not dependent on NOS production. Conversely, the protection 
brought about by β-ManCer was completely eradicated in these mice, showing the 
NOS-dependent manner of protection by this analogue. NOS can be induced by 
TNF-α. Blocking of TNF-α was also found to reverse tumor immunity.[80] 
 
Figure 2.18 The structure of β-mannosylceramide 
A non-glycosidic analogue, known as threitolceramide, has also been synthesised 
(Fig 2.19). This derivative demonstrates stimulation of NKT cells, even without the 
sugar moiety. The levels of cytokine release were lower than that of α-GalCer, but 
the levels of NKT cell-mediated lysis of the antigen bearing cells (dendritic cells) 
was also lowered. This is due to the lower affinity of the NKT cell TCR for 
threitolceramide than for a glycan.
[81]
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Figure 2.19 Non-glycosidic analogue threitolceramide 
2.3.8     A Multitude of Analogues 
The glycolipid analogues discussed above are just a small selection of the work 
which has been carried out in this area. Several reviews exist which detail many 
more derivatives, some with promising effects.
[53, 82]
 It is a field which holds great 
potential in the treatment of disease, and work will continue in the effort to 
synthesise, or discover, a glycolipid which induces a strong biased response in 
human models. 
2.4     L-Serine  
Serine is a naturally occurring amino acid, and is found in many proteins (Fig. 2.20). 
Glycosylated serine is not often found in glycolipids, but is very common in 
glycoproteins.
[8]
 
 
Figure 2.20 The structure of L-Serine 
Serine provides an attractive option to develop ceramide analogues, as it allows the 
use of simple, well established peptide coupling methodology to introduce different 
functionalities. Several serine-based glycolipids have emerged, which have been 
demonstrated to be bioactive. 
Achiwa and co-workers synthesised galactosamine and glucosamine serine-based 
glycolipids (Fig. 2.21). The non-sulphated derivatives, 2.12 and 2.13, displayed no 
anti-HIV activity, but the sulphated analogues, 2.14 and 2.15, showed good anti-HIV 
activity, and were non-cytotoxic.
[83]
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Figure 2.21 Serine-based glycolipid derivatives 
Huang et al have synthesised some serine-based glycolipids, and tested their activity 
as Toll-like receptor 4 (TLR4) activators (Fig. 2.22). Lipopolysaccharides (LPS) are 
amphiphilic glycolipid component of the outer membrane of Gram-negative bacteria. 
When these bacteria enter the body, they are recognised by TLR4, which stimulates 
the innate and adaptive immune systems. Compounds 2.16, 2.17 and 2.18 were all 
shown to activate TLR4. Changes in the sugar moiety, and conversion to the β-
linkage in the glucosyl derivative 2.18 were tolerated. The β-anomer of the 
galactosyl derivative resulted in a loss of activity.
[84]
 
 
Figure 2.22 Serine-based glycolipids showing TLR4 activation 
Anionic β-glycolipids 2.19 and 2.20 were synthesised by Faroux-Corlay et al, and 
were found to display anti-HIV activity (Fig. 2.23). Binding studies carried out on 
these glycolipids found that, on addition of gp120 (the envelope glycoprotein of 
HIV), the gp120 inserted into monolayers of the galactolipids. This binding may be 
responsible for the anti-HIV properties of these analogues.
[85]
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Figure 2.23 Anti-HIV glycolipids synthesised by Faroux-Corlay et al
[85]
 
Serine-based glycolipid derivatives have also been used for a slightly different 
purpose, with the β-GalCer analogue shown in Fig. 2.24 displaying potential for 
inclusion in cosmetics and medicines, to improve skin barrier function. This 
derivative increases β-glucocerebrosidase activity in-vitro, which is associated with 
the skin barrier function. β-Glucocerebrosidase produces acylceramide, which is an 
important lipid in the prevention of various skin diseases, such as dermatitis.
[86]
 
 
Figure 2.24 β-GalCer derivative synthesised by Fukunaga et al[86] 
2.5     Aim 
The aim of this section was to synthesise some glucosamine-based serine glycolipid 
derivatives (Fig. 2.25), and to have them tested on human NKT cell lines to assess 
their potential as immunomodulators. 
 
Figure 2.25 Glucosamine based serine glycolipid derivatives (n = 8 or 22) 
As mentioned earlier, there are several advantages to incorporating serine into 
glycolipids. The hydrocarbon chains can be introduced using peptide coupling 
methodology of TBTU/HOBt, which is a well-established procedure. Serine is 
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structurally similar to ceramide, and it was postulated that small changes in this part 
of the molecule may induce favorable differences in activation of NKT cells. 
Glucosamine has been demonstrated to be involved with many regulatory processes 
in the body.
[18]
 We wanted to synthesise glucosamine-based glycolipids in order to 
investigate the effect that the acetamide group, at the C-2 position of GlcNAc, would 
have on the glycolipids affinity for the CD1d molecule. It is thought that the 
acetamide functionality may change the binding affinity, and may also alter the 
profile of cytokine release by the activated NKT cell, as compared to that of 
galactose or glucose-based analogues. 
As discussed previously, it has recently emerged that the endogenous ligand for 
CD1d cells could be β-GlcCer, and so it is important for new, synthetic β-glycolipid 
analogues to be made.
[56]
 
2.6     Synthesis of Glycosyl Building Block 2.22 
 
Scheme 2.1 Retrosynthetic approach to the synthesis of glycosyl building block  
The retrosynthetic scheme for the synthesis of a suitable building block is shown in 
Scheme 2.1. These glycosides, 2.21 and 2.22, have been synthesised by multistep 
procedures in the literature, but it was thought that a more succinct synthesis could 
be possible.
[87]
 The protected serine acceptor, 2.24, was synthesised following 
literature procedures, by alkylation of the carboxylic acid functionality of 
commercially available L-Boc serine, with benzyl bromide, to produce the benzyl 
ester 2.24 (Scheme 2.2).
[88]
 The free acid is protected to prevent undesired 
glycosylation from occurring at the carboxylic acid position. 
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Scheme 2.2 Synthesis of glycosyl acceptor 2.24. Reagents and conditions:                                                   
i) BnBr, K2CO3, DMF, overnight, rt, 68 % 
N-Troc glucosamine derivative 2.26, the first glycosyl donor prepared for the 
synthesis of 2.21, was obtained following literature procedures.
[89]
 The N-Troc 
protecting group was chosen for its stability to mildly acidic and basic conditions. It 
is removed under very specific conditions, and is orthogonal to the other protecting 
groups used. D-Glucosamine hydrochloride was first N-Troc protected at the amine 
functionality, by reacting with trichloroethoxycarbonyl chloride (TrocCl), in the 
presence of NaHCO3. This was followed by acetylation of the hydroxy groups with 
acetic anhydride, in the presence of pyridine, to give the anomeric mixture of 2.26 
(Scheme 2.3). This protection is necessary, as D-glucosamine contains four hydroxy 
groups, each of which could act as the glycosyl acceptor, although the hydroxy 
group at the C-1 position is the most reactive. 
 
Peracetylated donors are well documented in the literature,
[90]
 and glycosylation of 
2.24 directly from 2.26 was attempted, using BF3.OEt2 as the promoter. This was 
unsuccessful from our donor, with full recovery of starting materials (Scheme 2.3). 
 
Scheme 2.3 Glycosylation directly from N-Troc protected donor 2.26. Reagents and conditions: i) 
TrocCl, H2O, NaHCO3, 2.5 h, rt; ii) Ac2O, pyr, overnight, rt, 87 % over two steps; iii) BF3.OEt2, 
DCM, rt, overnight 
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As the above route was unsuccessful, an alternative donor was investigated. 
Glycosyl halides are popular donors for the Köenigs-Knorr reaction.
[91]
 The glycosyl 
halide is activated with metal salts, and the halide (Br or Cl) is substituted by an 
alcohol. If there is neighboring group participation with the functionality at C-2, the 
new glycosidic bond will be in the β configuration. Peracetylated glucosamine 2.30 
was synthesised by reacting D-glucosamine hydrochloride with acetic anhydride, in 
the presence of pyridine. 2.30 was treated with HBr/AcOH in an attempt to form 
glycosyl donor 2.31 (Scheme 2.4). Some glycosyl halides, such as glycosyl iodides, 
are very reactive and unstable, they are generally reacted in-situ.
[92]
 In contrast, 
glycosyl bromides are usually relatively stable, and, for most sugars, can be prepared 
in advance.
[93]
 In this case, using N-acetyl glucosamine, the bromide was never 
isolated. It was found that, instead of detecting the bromine containing compound 
2.31 as expected, the oxazoline derivative 2.32 was formed. This was confirmed by 
MS, and also 
1
H NMR data was in agreement with reported values.
[94] 
It has been 
reported in the literature that this oxazoline ring can be opened, in the presence of a 
Lewis acid, to react with an alcohol acceptor.
[95]
 This reaction was attempted using 
two different Lewis acid promoters, TMSOTf or BF3.OEt2. These reactions were 
unsuccessful, and the starting material was recovered (Scheme 2.4). 
 
Scheme 2.4 Attempted synthesis of glycosyl building block 2.21. Reagents and conditions:i) Ac2O, 
pyr, rt, overnight, 34 %; ii) 33 % HBr/HOAc, DCM, 0 ˚C → rt, overnight, 44 % of 2.32; iii) TMSOTf 
or BF3.OEt2, DCM, rt, overnight 
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As these syntheses were unsuccessful, it was decided to follow the well-established 
trichloroacetimidate donor route. This synthesis involves several more steps than 
those previously attempted, but the use of the imidate donor, by Schmidt and 
coworkers, lends itself well to glucosamine.
[87]
 
Although the reactions to synthesise glucosyl building block 2.22 have been reported 
in literature,
[87, 89] 
some optimization was required. N-Troc protected 2.26 was 
synthesised as described above. Selective deacetylation at the anomeric position 
resulted in an anomeric mixture of hemiacetal 2.33. This reaction was initially 
carried out in the presence of benzylamine. Dimethylamine later replaced 
benzylamine, as an alternative nucleophile. This improved the purification of 
compound 2.33. Synthesis of hemiacetal 2.33 was also carried out using hydrazine 
acetate, which reduced the reaction time from overnight to 4 h. The free hydroxyl 
group of 2.33 was treated with trichloroacetonitrile and sodium hydride to give 
exclusively the α-imidate 2.34, which would serve as the glycosyl donor (Scheme 
2.5). The α-anomer is the expected product of this reaction, due to the influence of 
the anomeric effect on an electronegative substituent, and also encouraged by the use 
of a strong base for deprotonation of the anomeric hydroxyl group. Imidate 2.34 was 
also synthesized using DBU as an alternative base to NaH. The yields obtained were 
comparable to the synthesis carried out with NaH (86 % with NaH, compared to 72 
% with DBU), but DBU would be preferable to work with, as NaH is highly 
flammable when exposed to water. Glycosylation of Boc protected serine acceptor 
2.24 by glycosyl donor 2.34 was then carried out, using a 0.04 N solution of 
TMSOTf in DCM as the promoter (Scheme 2.5).  
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Scheme 2.5 Synthesis of glycosyl building block 2.22. Reagents and conditions: i) TrocCl, H2O, 
NaHCO3, 2.5 h, rt; ii) Ac2O, pyr, overnight, rt, 87 % over two steps; iii) NH(CH3)2, THF, 
overnight, reflux, 81 %; iv) Cl3CCN, DBU or NaH, 2h, rt, 86 %; v) 0.04 N TMSOTf, DCM, 
overnight, rt, 49 % 
It is important that the glycosylation reaction is carried out under anhydrous 
conditions. The presence of water can severely reduce the yield of the desired 
product by attacking the activated glycosyl donor, in place of the glycosyl acceptor, 
and decomposing it to hemiacetal 2.33. To minimise the amount of moisture in the 
reaction several steps were taken; the glassware was dried in an oven overnight, the 
reaction was carried out under a nitrogen atmosphere, and the reactants 2.34 and 2.24 
were dried under vacuum for several hours. The glycosylation mechanism is shown 
in Scheme 2.6, and examination of this mechanism illustrates how an unwanted side 
reaction could occur in the presence of water. The water molecule could also attack 
the glycosyl cation which is formed during the reaction, resulting in the synthesis of 
hemiacetal 2.33. 
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Scheme 2.6 Mechanism of TMSOTf promoted glycosylation  
The first step in the reaction involves attack on the silicon by the anomeric oxygen. 
This places a positive charge onto the oxygen, in turn making the anomeric center 
more electrophilic. The lone pair on the ring oxygen aids the departure of the leaving 
group, and stabilises the oxocarbenium ion, 2.36, which is formed. The reaction 
proceeds in an SN1 type fashion. The presence of the N-Troc protected neighbouring 
group on C-2 of the sugar ensures that a β-glycosidic linkage is formed. The oxygen 
lone pair of the N-Troc group attacks the anomeric center, forming an oxazoline-type 
intermediate, 2.37. This neighbouring group participation only allows the alcohol 
acceptor 2.24 to attack at the upper face of C-1, resulting in the β-glycoside 2.22 
(Scheme 2.6).  
2.7     Synthesis of Glycolipids 2.71 and 2.74 
2.7.1     Route A 
Orthogonal protecting groups are those which can be selectively removed, without 
interfering with other protecting groups present in the molecule. This allows for 
selective adaption of a specific functional group. The next stage in the synthesis 
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involved removal of these orthogonal protecting groups, from the glucosyl building 
block, 2.22, to allow introduction of the hydrocarbon chains. 
Selective removal of the benzyl ester protecting group from 2.22 was carried out by 
hydrogenolysis, using a Pd/C catalyst, under H2, to give acid 2.38. This was 
followed by introduction of the tetradecylamide chain, using standard coupling 
conditions of TBTU and HOBt, in the presence of Et3N, resulting in 2.39 (Scheme 
2.7).  
 
Scheme 2.7 Synthesis of hydrocarbon chain amide derivative 2.39. Reagents and conditions: 
i) Pd/C, H2,EtOAc, 2 h, rt, 75 %; ii) HOBt, TBTU, NH2C14H29, DCM, overnight, rt, 77 % 
TBTU is often used in peptide synthesis methodologies as it greatly reduces the risk 
of racemisation, and is useful for hindered couplings. The rate of reaction is quite 
fast, preventing unwanted side reactions from occurring.
[96]
 The use of HOBt also 
helps to prevent racemisation, and speeds up the rate of the reaction.
[97]
 
TBTU is known as a “uronium” based coupling reagent, but it has been 
demonstrated that, in the crystalline state, TBTU exists as the guanidinium N-oxide 
derivatives 2.41 and 2.40.
[98]
 Another closely related reagent, HATU, also exhibits 
this property. In solution both forms of the TBTU molecule are thought to be 
present, and either can react with a carboxylate to form an activated ester.
[99]
 The 
mechanism proceeds with attack of the carboxylate nucleophile 2.40 on the TBTU 
carbocation to form the acyloxyuronium species 2.43. This intermediate immediately 
reacts with the released BtO
-
 2.44, at the carbonyl carbon, to form the activated ester 
2.45. The amino containing compound 2.46 can now attack the carbonyl carbon of 
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2.45 to form the amide bond, resulting in 2.48 (Scheme 2.8). The acid is generally 
activated by stirring with base and the activating agent, i.e. TBTU, for 5-10 mins, to 
ensure formation of the activated ester before addition of the amine.  
 
Scheme 2.8 Mechanism of amide formation using the TBTU coupling reagent 
Initially, N-Boc deprotection of 2.39 was attempted using the standard reaction 
conditions of TFA in DCM (Scheme 2.9). The N-Boc group is an acid labile 
protecting group, and should be easily removed under these conditions. The reaction 
was carried out by adding a solution of 50 % TFA in DCM to a solution of 2.39, in 
DCM, on ice, then allowing the reaction mixture to reach rt and stir for 2 h. Free 
amine 2.49 was not produced in this reaction, with full recovery of the starting 
material. The reaction was repeated, adding neat TFA to a solution of 2.39 in DCM 
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at rt, and left to stir overnight at rt. Starting material was still present after this 
treatment, and none of the deprotected 2.49 was observed. 
 
Scheme 2.9 Attempted deprotection of the N-Boc protecting group of 2.39. Reagents and 
conditions: i) 50 % TFA, DCM, 1-24 h 
It was postulated that the orientation of the long hydrocarbon chain may have been 
presenting a steric hindrance, and so preventing removal of the N-Boc group. In 
order to confirm this, a shorter chain propyl derivative, 2.50, was synthesised. The 
N-Boc group was easily removed from this derivative, under the standard conditions 
of TFA at rt overnight, to give 2.51 (Scheme 2.10). This was confirmed by MS 
analysis, and also by the disappearance of the characteristic N-Boc CH3 peak at 1.4 
ppm in the 
1
H NMR spectrum. 
 
 
Scheme 2.10 Removal of N-Boc protecting group from propyl derivative 2.50. Reagents and 
conditions: i) 50 % TFA, DCM, overnight, rt, 97 % 
2.7.2     Route B 
As the presence of the long hydrocarbon chain appeared to have prevented N-Boc 
deprotection, the order of introduction of the hydrocarbon chains was modified. 
From building block 2.22, N-Boc deprotection was carried out, with the addition of 
TFA in DCM carried out on ice, and the reaction mixture allowed to stir at 0 ˚C for 1 
h. The reaction was successful, resulting in compound 2.52 in good yield. This was 
followed by coupling of decanoic acid to the amine 2.52, using the TBTU/ HOBt 
methodology to give 2.53. Hydrogenolysis of the benzyl ester 2.53 was then carried 
out, using Pd/C and H2, resulting in acid 2.54. Introduction of the second 
hydrocarbon chain was attempted using the standard TBTU/HOBt coupling 
conditions, but this reaction was unsuccessful (Scheme 2.11). 
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Scheme 2.11 Synthesis of protected glycolipid derivative 2.55. Reagents and conditions: i) 50 % 
TFA, DCM, 0 ˚C, 1 h, 90 %; ii) HOBt, TBTU, Et3N, C9H19C(O)OH, DCM, overnight, rt, 88 %; iii) 
Pd/C, H2, EtOAc, 2 h, rt, 98 %; iv) HOBt, TBTU, Et3N, NH2C14H29, DCM, overnight, rt 
2.7.3     Various Coupling Conditions Investigated From Free Acid 2.54  
The initial attempts to introduce a second hydrocarbon chain at the free acid, using 
the standard coupling conditions shown above, were unsuccessful (Scheme 2.11). 
The attempted coupling reaction resulted in degradation of compound 2.54. On 
examination of the 
1
H NMR spectral data, and also by TLC analysis, hemiacetal 2.33 
was identified. This was isolated by column chromatography, and was confirmed by 
MS. The presence of 2.33 indicated that degradation had occurred during the 
reaction. It was postulated that this degradation could have resulted from either 
cleavage of the glycosidic bond by hydrolysis at the anomeric centre, or by α-H 
elimination via a retro-Michael-type mechanism. Hydrolysis of 2.54 would result in 
hemiacetal 2.33 and the functionalised serine 2.56 (Scheme 2.12). However, 
hydrolysis of an acetal is normally observed under strongly acidic conditions, while 
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this reaction was carried out in a basic environment. Compound 2.56 was not 
isolated, and was not detected in MS analysis of the crude reaction material. 
 
Scheme 2.12 Degradation mediated by hydrolysis at the anomeric center 
On the other hand, the retro-Michael reaction would yield a dehydroalanine type 
product, 2.57, as well as hemiacetal, 2.33. The presence of the dehydroalanine 
compound 2.57 was confirmed by MS analysis, which indicated that this degradation 
was due to α-elimination (Scheme 2.13). On further examination of the literature, it 
was found that these types of glycosylated serine compounds are indeed base 
sensitive, with degradation occurring over ~ pH 10.5.
[100, 101]
 In fact, some groups 
carry out this elimination on purpose, as the dehydroalanine acts as a protected form 
of serine, which can be used in peptide synthesis.
[102]
 2.54 was stirred overnight in 
DCM, in the presence of Et3N, without addition of the coupling reagents 
(HOBt/TBTU). Degradation to the hemiacetal did not occur, with recovery of 
starting material. This experiment demonstrated that the α-proton of 2.54 was not 
acidic enough to be removed before being converted into the activated ester by 
TBTU. The mechanism of the elimination observed with 2.54 is known as E1cB. 
E1cB elimination is usually catalysed by a strong base, like KOH or Et3N, and is 
made possible by an anion-stabilising group, like a carbonyl. The proton which is 
adjacent to the activated carbonyl is very acidic. The base can remove this proton, 
without a leaving group departing at the same time, due to delocalisation of the 
negative charge onto the carbonyl group. The carbonyl stabilises the anion which is 
formed, but elimination of a leaving group will still occur. The electrons flow back 
down from the carbonyl oxygen, and the result is formation of an alkene containing 
compound, and an elimination of the adjacent group (Scheme 2.13). This elimination 
is promoted by the formation of the activated ester during the first stages of the 
coupling reaction. The α-proton is made more acidic, and is easily deprotonated, 
even in the presence of a mild base like pyridine (pKaH ~5.2). The activated ester 
will quickly hydrolyse to the corresponding carboxylic acid, 2.57. 
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Scheme 2.13 Mechanism of E1cB elimination  
In order to further confirm the presence of the dehydroalanine degradation 
compound 2.57, a trapping experiment was performed, which involved carrying out 
the standard coupling reaction in the presence of 2.2 equivalents of NBS (Scheme 
2.14). The dehydroalanine compound, 2.57, can be unstable, due to addition 
reactions at the double bond. The NBS acted as a source of electrophilic bromine, 
which could “trap” the dehydroalanine as it is formed, by addition of bromine across 
the alkene bond to give compound 2.58.
[103]
 The presence of this compound was 
confirmed by MS. 
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Scheme 2.14 NBS trapping of dehydroalanine 2.57. Reagents and conditions: i) HOBt, TBTU, 
Et3N, DMF, NBS, 2 h, rt 
Various different conditions to avoid the undesired elimination, as outlined in Table 
2.1, were investigated for this coupling reaction. Entry 1 shows the standard 
conditions which were initially investigated. Entry 2 was carried out in the absence 
of HOBt, to investigate if this additive may be enhancing the degradation, but 
hemiacetal 2.33 was still detected after the reaction. Entry 3 shows the reaction 
carried out with less equivalents of the base Et3N, which made no difference to the 
reaction, with MS showing the presence of hemiacetal 2.33, and also some 
remaining starting acid 2.54. Entry 4 was carried out in the presence of a more 
hindered base, DIPEA, to see if this would prevent the elimination, but hemiacetal 
was again detected in this experiment. Entries 5 and 6 show the reaction carried out 
in less basic conditions, using pyridine and N-methyl morpholine respectively, but 
hemiacetal 2.33 was again produced in both reactions. From this data it is clear that 
the nature of the base is not important. Deprotonation of the α-H occurred in all 
cases where the activated carboxylic acid, 2.58, described earlier, was being 
generated using the TBTU and HOBt coupling conditions. It was then decided to 
change the method of coupling, and the acid chloride of 2.54 was synthesised. This 
was carried out by reaction of the acid 2.54 with oxalyl chloride, in DMF, followed 
by addition of the long chain tetradecylamide, in the presence of pyridine (entry 7). 
These alternative conditions did not yield the desired product, 2.55, but, again, the 
presence of starting acid 2.54 and dehydroalanine 2.57 were confirmed by MS.  
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Entry Coupling reagent HOBt Base (equiv.) 
1 TBTU Y NEt3 (2) 
2 TBTU N NEt3 (2) 
3 TBTU Y NEt3 (1.2) 
4 TBTU N DIPEA (2) 
5 TBTU N Pyridine (2) 
6 TBTU N N-methyl-morpholine(2) 
7 (COCl)2 N Pyridine (2) 
 
Table 2.1 Investigation of the coupling conditions using compound 2.54 
In order to investigate if the observed E1cB elimination would occur with any 
functionality in the amide position, lysine derivative 2.59 was synthesised. 
Introduction of the tetradecylamine chain was attempted using the standard 
TBTU/HOBt conditions (Scheme 2.15). This was also unsuccessful, with hemiacetal 
2.33 again being isolated. This suggested that activation of any amide containing 
derivative of 2.54 would result in degradation.  
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Scheme 2.15 Attempted coupling of second chain to lysine derivative 2.59. Reagents and 
conditions: i) HOBt, TBTU, Et3N, NH2C14H29, DCM, overnight, rt 
Another approach which was taken in the synthesis of 2.55 was to carry out the 
glycosylation on an acceptor which had already been functionalised with both 
hydrocarbon chains, 2.63 (Scheme 2.17). The synthesis of this acceptor is shown in 
Scheme 2.16, below. The tetradecylamine chain was introduced using TBTU and 
Et3N, to give 2.61. This was followed by deprotection of the N-Boc group, using a 
50 % solution of TFA (v/v) in DCM, to give the free amine, 2.62. Interestingly, this 
deprotection did not present the difficulty which had been encountered in the 
presence of the sugar moiety in 2.39. The second hydrocarbon chain was introduced 
into the molecule, again using TBTU and Et3N, resulting in 2.63 (Scheme 2.16). 
 
Scheme 2.16 Synthesis of lipid 2.63. Reagents and conditions: i) TBTU, Et3N, DCM, 
NH2C14H29, rt, overnight, 75 %; ii) 50 % TFA, DCM, 5 h, rt, 91 %; iii) TBTU, C9H19C(O)OH, 
DMF, Et3N, overnight, rt, 32 % 
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Scheme 2.17 Attempted glycosylation of acceptor 2.63. Reagents and conditions: i) 0.04 N 
TMSOTf or BF3.OEt2, DCM, overnight, rt 
Direct glycosylation of a serine acceptor, which had been functionalised with one 
hydrocarbon chain, has shown success in the literature,
[43]
 using BF3.OEt2 as the 
promoter. For our acceptor the reaction did not yield any of the desired product, with 
recovery of hemiacetal 2.33, and the functionalised serine. It was postulated that this 
reaction did not progress due to a steric hindrance caused by the presence of the 
second hydrocarbon chain.  
In view that degradation was observed, even in the presence of a very mild base such 
as pyridine, introduction of the second chain to the free acid was carried out in the 
absence of base (Scheme 2.18). This reaction produced the desired product 2.55, 
which was confirmed by MS, but in low yield of 13 %. 
 
Scheme 2.18 Coupling of tetradecyl chain in the absence of base. Reagents and conditions: i) 
TBTU, HOBt, NH2C14H29, DCM, overnight, rt, 13 % 
From glycolipid 2.55 the removal of the N-Troc protecting group was attempted, 
using the standard conditions of Zn, Ac2O and Et3N described by Zhu and Schmidt 
(Scheme 2.19).
[104]
 This reaction was unsuccessful, and starting material was 
recovered. It was thought that, again, the presence of the long hydrocarbon chains 
was posing a steric hindrance.  
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Scheme 2.19 Attempted deprotection of N-Troc from 2.55. Reagents and conditions: i) Zn, Ac2O, 
Et3N, overnight, rt 
2.7.4     Route C 
It was observed in route B that degradation occurred when activating the carboxylic 
acid of 2.54 to introduce the second hydrocarbon chain. It had also been observed, as 
discussed in route A, using the N-Boc protected building block 2.22, that 
functionalisation could not be carried out at the acid functionality first, due to 
problems with N-Boc deprotection. For this reason N-Cbz protected glycosyl 
acceptor 2.65 was synthesised. Only one hydrocarbon chain was introduced into this 
acceptor, and so the problem encountered with acceptor 2.63 could be avoided. The 
N-Cbz protecting group is removed by hydrogenolysis, which would not be 
orthogonal to the benzyl protecting group of the serine acceptor, 2.24, utilised in 
earlier syntheses. For this reason, introduction of the tetradecyl chain was carried out 
before glycosylation, removing the need for benzyl ester protection (Scheme 2.20).  
 
Scheme 2.20 Coupling of the tetradecyl chain to N-Cbz serine. Reagents and conditions: i) 
TBTU, HOBt, Et3N, NH2C14H29, DCM, overnight, rt, 55 % 
Imidate glycosyl donor 2.34 was used for the glycosylation reaction. TMSOTf was 
again used as the promoter for the reaction, resulting in 2.67. This was followed by 
deprotection of the N-Troc protecting group using standard conditions of freshly 
activated zinc, and acetic anhydride to give 2.68. Hydrogenolysis of the N-Cbz 
protecting group was then carried out, using Pd/C under a H2 atmosphere, to give 
amine 2.69 (Scheme 2.21). The order of deprotection is crucial to this synthesis. 
When hydrogenolysis of the N-Cbz group was attempted from 2.67, prior to 
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reduction of the N-Troc group, this step was unsuccessful, with return of starting 
material (Scheme 2.22). Also, it was previously noted in compound 2.55 (Route B) 
that reduction of the N-Troc protecting group could not be carried out once the 
compound was functionalised with both lipid chains. 
Coupling of decanoic acid to the free amine 2.69 was carried out using TBTU and 
HOBt, in the presence of Et3N, to give the protected glycolipid 2.70. This was 
followed by selective hydrolysis of the O-acetyl protecting groups, leaving the N-
acetyl group intact, using MeOH/H2O/Et3N (Scheme 2.21). Standard Zemplén 
conditions of NaOMe/MeOH for deacetylation were not used, as these were 
anticipated to be too harsh, and may also remove the N-acetyl protecting group.  Fig. 
2.26 shows the 
1
H NMR spectrum of the deprotected glycolipid 2.71. The doublet at 
approx. 8.8 ppm is attributed to the NHAc amide proton, with the signal at 8.5 ppm 
being attributed to the amide protons of both hydrocarbon chains. The resonance of 
the α-anomeric H-1 is observed at 5.3 ppm, while the β-anomeric H-1 is seen at a 
lower ppm of 5.1, which is characteristic of each of these anomers. The singlet at 2.1 
ppm represents the methyl protons of the NHAc group, and integrates for three 
protons. Most of the long hydrocarbon chain CH2 protons are observed as a multiplet 
at 1.2 ppm. The analysis was carried out in deuterated pyridine, as residual solvent 
peaks from deuterated DMSO would have obscured the sugar peaks. Solubility was 
also poor in other solvents, and a sharp, clear spectrum was obtained in pyridine.  
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Scheme 2.21 Synthesis of glycolipid 2.71. Reagents and conditions: i) 0.04 N TMSOTf, DCM, rt, 
overnight, 53 %; ii) Zn, Et3N,  Ac2O, rt, 5 h, 70 %; iii) H2, Pd/C, EtOAc, 2 h, rt, 95 %; iv) HOBt , 
TBTU, Et3N, C9H19C(O)OH, DMF, overnight, rt, 40 %; v) Et3N/MeOH/H2O, 40 °C, overnight, 41 % 
 
 
Scheme 2.22 N-Cbz deprotection from 2.67. Reagents and conditions: i) H2, Pd/C, EtOAc, 
overnight, rt 
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Figure 2.26 
1
H NMR spectrum of deprotected glycolipid 2.71 in C5D5N 
A longer hydrocarbon chain derivative, 2.74, was synthesised, which would be more 
comparable to other glycolipids which have been tested for their immunomodulatory 
activities, like α-GalCer. Tetracosanoic acid was coupled to 2.69, using TBTU and 
HOBt, in the presence of Et3N, to give glycolipid 2.73. The low yield of this reaction 
is due to the poor solubility of tetracosanoic acid in either DCM or DMF. This 
glycolipid analogue was then subjected to the same deprotection conditions as the 
shorter chain derivative, resulting in deprotected glycolipid 2.74 (Scheme 2.23). 
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Scheme 2.23 Synthesis of tetracosonoyl glycolipid derivative 2.74. Reagents and conditions: i) 
TBTU, HOBt, Et3N, C23H57C(O)OH, DMF, overnight, rt, 17 %; ii) Et3N/MeOH/H2O, 45 °C, 
overnight, 57 % 
2.8     Biological Evaluation of Glycolipids 2.71 and 2.74 as 
Immunomodulators 
Deprotected glycolipids 2.71 and 2.74, and also lipid 2.63 were tested by Dr. Derek 
Doherty, Andreea Petrasca, and Niamh Murphy at St. James’ Hospital, Dublin for 
their potential as immunostimulators (Fig. 2.27). Glycolipids 2.71 and 2.74 are novel 
glycolipids and differ only in the length of one hydrocarbon chain, while 2.63 has 
been recorded in the literature,
[105]
 and does not contain the sugar moiety. 2.63 was 
included in the testing to investigate if the sugar moiety was required for iNKT 
stimulation and cytokine release, or if a different cytokine profile would be induced 
by the glycosides. 
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Figure 2.27 Lipids tested for immunostimulatory activity 
The aim of this study was to investigate the potential of these glycolipids to 
stimulate iNKT cells to mediate cytotoxicity, T helper function and cytokine 
secretion.  
2.8.1     Materials and Methods used for Testing
[106]
 
iNKT cell lines were co-cultured with cancer cells in the presence of the above 
glycolipids, and assessed using flow cytometry and ELISAs (enzyme-linked 
immunosorbent assays). Two different types of cell line were transfected with CD1d; 
HeLa cells were derived from cervical cancer cells, and C1R cells are a mutant 
lymphoblastoid cell line. Testing was carried out using literature procedures, 
described by Hogan et al.
[72]
 α-GalCer was used as the positive control, and gave a 
positive result for all ELISAs. The negative control was HeLa-CD1d cells with 
iNKT cells but no compound added (vehicle). This gave a baseline result with which 
to compare the results of the novel glycolipids.  
2.8.2     Ability of Glycolipids to Induce Cytotoxicity 
iNKT cells have the ability to induce an immune response and also to mediate 
cytotoxicity, which accounts for their antitumor activity. In this study, cytotoxicity 
was evaluated by flow cytometric analysis of CD107a positive cells. CD107a is a 
lysosomal protein which lines the surface of cytolytic granules and lysosomes, and it 
becomes exposed to the surface during degranulation. This makes it an ideal marker 
for assessing cytotoxic activity.
[107]
 Glycolipids 2.71 and 2.74, and lipid 2.63 were 
tested for their ability to prime iNKT cell lines for cytotoxicity, using iNKT cells 
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from four different donors. In the presence of C1R cells only α-GalCer was able to 
cause CD107a externalisation, the other lipids did not induce any cytotoxicity 
against this cell line. In the presence of CD1d-HeLa cells, 2.71 and 2.74 were able to 
externalise CD107a in just one iNKT cell line, while 2.64 induced CD107a 
expression by two cell lines (Fig. 2.28). These results indicate that the cells are 
undergoing degranulation, and so are mediating cytotoxicity. 
 
Figure 2.28 iNKT cell cytotoxicity in four different donors (BC1-4) after exposure to HeLa 
cells presenting various lipids 
These lipids were also tested for induction of CD40L expression by iNKT cells, 
which is located on B-cells, dendritic cells and macrophages. This protein is 
important in T-cell activation and also plays other roles in immune stimulation.
[108]
 
2.71, 2.74 and 2.63 did not induce expression of CD40L, indicating that these 
compounds would not play a part in induction of T-helper function (data not shown). 
The iNKT cell lines which gave a CD107a
+
 result were examined to find out what 
subsets they contained. It has been reported that therapeutic outcomes can vary in 
patients expressing different subset compositions. iNKT cells can be CD4
+
, CD8
+
 or 
CD4
-
CD8
- 
(Double negative, DN); CD4
+
 iNKT cells expand more readily than the 
others upon mitogen stimulation, while CD8
+
 and CD4
-
CD8
- 
iNKT cells most 
potently killed CD1d
+
 cell lines and primary leukaemia cells.
[109]
 In this study the 
CD107a
+
 cells were found to be mostly CD8
+
, and CD107a expression for each of 
the subsets is illustrated in Fig. 2.29 below. CD40L
+
 cells were found to be mainly 
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CD4
+
, which could account for the lack of CD40L expression by the glycolipids 
tested. 
 
Figure 2.29 Expression of CD107a by iNKT subsets in two cell lines 
2.8.3     Analysis of the Cytokine Release Profile Induced by Glycolipids 
The extracellular cytokine expression induced by the different lipids was determined 
using ELISAs to measure cytokine concentrations in the supernatant, 24 h after lipid 
stimulation of iNKT cells. α-GalCer was the only lipid tested that showed evidence 
of IL-4, IFN-γ, IL-13 and GM-CSF secretion (Fig. 2.30). 
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Figure 2.30 Effect of glycolipid stimulation on extracellular cytokine secretion 
The intracellular cytokine profile was also examined by flow cytometry. This 
intracellular cytokine assay only measures the percentage of cytokine-secreting cells, 
and so does not actually quantify how much cytokine secretion is induced. 
Glycolipid 2.71, which is the shorter chain derivative tested, was shown to weakly 
induce secretion of Th2 cytokine IL-4 in each of the four cell lines (BC1-4), and also 
IFN-γ and TNF-α secretion in two cell lines (BC1-2). The percentage of IFN-γ 
positive cells induced by 2.71 was higher than that induced by α-GalCer in cell lines 
BC1-2. The longer chain derivative 2.74 and the non-glycosidic 2.63 failed to induce 
an intracellular secretion of any of these cytokines (Fig. 2.31).  
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Figure 2.31 Intracellular cytokine profile 
As our glycolipids did not illicit a strong release of the typical cytokines examined 
for immunostimulation, they were tested for their ability to produce IL-10. This 
cytokine has become of interest in the area of immunoregulation, and is known as a 
suppressor cytokine.
[110]
 IL-10 has been found to display immunosuppressive 
properties, including inhibition of inflammatory cytokine production (such as IL-4), 
which could be used in the treatment of certain diseases, such as allergic responses. 
Immunostimulatory abilities of IL-10 were also noted, for example proliferation and 
differentiation of B cells.
[111]
 All of our glycolipids tested induced secretion of IL-10, 
with 2.74 showing the highest release of IL-10, followed by 2.71, and a lesser 
stimulation was noted with the non-glycosidic derivative 2.63 (Fig. 2.32). This again 
shows the importance of the sugar moiety in cytokine release. 2.71 induced a more 
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potent response than α-GalCer at a concentration of 100 ng/mL. 2.73 also induced a 
strong response, but, as the 100 ng/mL measurement was not carried out, it cannot be 
said with certainty that the level of IL-10 released was higher than α-GalCer. The 
suppressive nature of IL-10 could account for the failure of these lipids to stimulate 
the release of IL-4 in the earlier studies. The testing was carried out at different 
concentrations of the lipids to investigate if the response was dose dependant. Some 
measurements were not carried out due to the amount of sample available. From Fig. 
2.32 it can be observed that the response did not increase with higher dosage levels. 
In this study medium alone was used as the negative control, and phorbol myristate 
acetate (PMA) with ionomycin was used alongside α-GalCer as the positive control. 
 
Figure 2.32 Stimulation of IL-10 production by novel glycolipids 
2.8.4     Summary of Immunological Results 
2.71, the decanoic acid derivative, was shown to illicit a non-biased release of 
cytokines, with induction of both Th1 (IFN-γ and TNF-α) and Th2 (IL-4) responses. 
2.71 was found to lack strong cytotoxicity. This lack of cytotoxicity may be due to a 
structural change induced when 2.71 binds to the CD1d molecule, which stimulates 
cytokine release, but makes it non-cytotoxic. The tetracosanoic acid derivative, 2.74, 
and the non-glycosidic 2.63 both failed to activate the iNKT cells in this study. As 
2.63 is structurally similar to 2.71, with equivalent lipid length and character, the 
lack of iNKT cell activation by this compound demonstrates the necessity of the 
glycan moiety. 
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All of the lipids 2.63, 2.71 and 2.74 induced release of IL-10, the suppressor 
cytokine. The non-glycosidic 2.63 did not illicit as potent a response as the glycosyl 
derivatives. This result indicates a possible use in the treatment of Th2 aggravated 
diseases. 
2.9     Chapter Conclusion 
To summarise, two glycolipid derivatives, 2.71 and 2.74, were successfully 
synthesised, and showed some interesting biological results, such as the stimulation 
of the release of Il-10. Several barriers were overcome throughout the synthesis, 
including the problems presented by the lipid chains in the removal of protecting 
groups. Another issue which was encountered during the synthesis of these 
derivatives was the elimination of the sugar moiety, under basic coupling conditions. 
This synthesis demonstrated the importance of the order of reactions in the synthetic 
scheme.  
Future work could include the synthesis of a derivative in which the length of the 
other hydrocarbon chain, tetradecyl in each of our glycolipids, is modified. The α-
anomeric analogue could also be synthesised, in order to compare the biological 
activity of this glycolipid.  
As will be discussed in chapter 4, functionalisation at the C-6 position of the sugar 
could be carried out. The introduction of other biologically relevant groups at this 
position may enhance the immunomodulatory activity of the glycolipid. 
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Chapter 3: The Synthesis of a Series of Glycopeptides  
3.1     Introduction: Glycopeptides 
A large amount of peptides in the body have been found to be glycosylated. 
Glycosylation involving N-acetyl glucosamine (GlcNAc) plays an important part in 
the regulation of protein function, for example in the stability or targeting of a 
glycoprotein. This has already been discussed in detail in chapter 1. The protein 
which we will be focusing on is the tau protein, which has been implicated in the 
development of neurodegenerative disorders, such as Alzheimer’s disease.    
3.2     Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 50-
60 % of all cases. It is a progressive neurological condition, which is manifested by 
debilitating effects. It can become more and more difficult for sufferers of AD to 
remember, reason and use language. The loss of memory of recent events is often 
one of the first difficulties to be noticed. The person may also become disorientated, 
be at a loss for a word when speaking, and have increasing difficulty with simple 
daily tasks, such as using the phone. The risk of developing AD increases with age, 
with more than 25 % of those over the age of 80 suffering from the disease. 
Although it is rare, AD can also occur in people under 65.
[112]
  
AD is a complicated disease, with multiple factors influencing its onset. The brains 
of people that suffer from AD display pathological hallmarks of the disease: 
Neuronal and synaptic loss, neurofibrillary tangles, and β-amyloid (Aβ) plaques. 
These plaques were first reported in 1907 by Alois Alzheimer.
[113]
 Neurofibrillary 
tangles (NFT) are twisted, stringy fibres of tau protein, which accumulate inside 
brain cells, and disrupt normal brain cell function. These will be discussed in more 
detail later. Aβ plaques are insoluble deposits of β-amyloid peptide, and are thought 
to accumulate due to mutations in the amyloid precursor protein. Studies carried out 
by Shankar et al have shown that the plaques did not impair cognitive function, but 
that soluble Aβ dimers which were released from the plaques could cause AD-like 
symptoms.
[114]
 Misfolding of Aβ may trigger events which result in aggregation of 
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the tau protein.
[115]
 A third abnormality, degeneration of cholinergic neurons, has 
also been reported. This neuronal death leads to the cognitive impairment associated 
with AD. Therapies targeting this pathological marker of AD aim to promote the 
activity of surviving cholinergic neurons.
[116]
 
For the purposes of this discussion, the molecular target which is focused on will be 
the hyperphosphorylation of the tau protein, and development of NFT.  
The treatment of AD is complicated for several reasons. The first is the contribution 
of different factors to the development and progression of the disease, as mentioned 
above. The second reason is the lack of diagnostic techniques. A person suffering 
from AD is often not diagnosed until the later stages, when the disease has 
progressed, and symptoms, such as memory loss, have become pronounced. New 
techniques are being pioneered for the diagnosis of AD. The use of neuroimaging-
biomarkers will allow for earlier diagnosis, although the pathological markers of AD 
mentioned above need to have developed. Techniques such as high-field MRI of 
brain atrophy, and in-vivo amyloid plaque imaging, using radio-labelled ligands, may 
allow for diagnosis of AD at a stage where its progression could be curbed.
[117]
 
3.3     Tau Protein 
Tau is a microtubule-associated protein (MAP) which is expressed throughout the 
central nervous system (CNS), but is mostly found in neuronal axons. Tau plays an 
important part in the organisation of microtubules in these axons. Microtubules are 
involved in cell shape maintenance and serve as channels for axonal transport. Tau 
association reduces the probability that a microtubule will shift from the growing 
phase to the shrinking phase. Partial phosphorylation of serine and threonine 
residues of tau is important to regulate the growth of microtubules by decreasing the 
affinity that tau has for the microtubule lattice. It has been shown that 
hyperphosphorylation of the tau protein causes destabilisation of microtubules by 
preventing binding.
[118]
 Phosphorylation of tau is carried out by phosphate kinases, 
such as glycogen synthase kinase 3 (GSK-3), extracellular signal-regulated kinase 2 
(ERK-2), and cyclin-dependant kinase 5 (CDK-5) (Scheme 3.1). Phosphate kinases 
use adenosine-5’-triphosphate (ATP) as their source of phosphate.[119]  
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The tau protein is also modified by addition of O-GlcNAc to specific serine or 
threonine residues in the sequence.
[120]
 As mentioned in chapter 1, glycosylation is 
carried out by the enzyme O-GlcNAc transferase (OGT). Glycosylation has been 
shown to occur at many of the same sites as phosphorylation, and also to regulate the 
phosphorylation of adjacent sites. Studies have demonstrated that inhibition of tau 
phosphorylation results in increased glycosylation, and that targeted deletion of OGT 
causes hyperphosphorylation of tau.
[121]
 This is yet another example of the dynamic 
interplay observed between glycosylation and phosphorylation of proteins, which 
was discussed in chapter 1 (Scheme 3.1).  
 
Scheme 3.1 The dynamic relationship between tau phosphorylation and glycosylation 
Tau protein is translated from a single gene located on chromosome 17. Six different 
isoforms of tau have been found, each generated from alternative mRNA splicing at 
chromosome 17. These isoforms range from 352-441 amino acids in length. A 
highly conserved repeat region of 31 or 32 amino acids has been determined in all of 
these isoforms. This region also repeats itself several times within a single 
isoform.
[122]
 Further study into the repeat region has revealed a strong Pro-Gly-Gly-
Gly motif, which has been shown to represent the tubulin binding domain. The 
longest isoforms of tau contain up to 79 serine and threonine residues at which 
phosphorylation can occur. Only about 30 of these residues are actually 
phosphorylated at one time under normal physiological conditions.
[123]
  
3.4     Tau and AD 
In patients with AD, tau shows abnormal hyperphosphorylation, which causes it to 
aggregate into paired helical filaments (PHF) and form neurofibrillary tangles 
(NFT). When this happens, the microtubules disintegrate, collapsing the neuron's 
transport system. This may result first in communication malfunctions between 
neurons, and later in cell death (Fig. 3.1).
[115] Tau has also been implicated in other 
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neurodegenerative diseases, such as Parkinson’s disease and Pick’s disease. These 
diseases are collectively known as tauopathies.[124] 
 
Figure 3.1 a) The stabilising effect of the tau protein on a healthy microtubule, and b) Collapse 
of a diseased neurons transport system
[115]
 
Studies have shown that NFT contain all six hyperphosphorylated isoforms of the 
tau protein. A total of 25 serine/threonine sites of abnormal phosphorylation have 
been identified in AD.
[125]
 It has been observed that almost all of these sites of 
phosphorylation are also found in non-aggregated tau, but that the tau protein which 
is found in NFT is phosphorylated to a higher extent.
[126]
 
While there are many factors which contribute to the progression of AD, the loss of 
function of the tau protein is the main element. Initially, it was thought that the cause 
of AD progression was either Aβ plaques or NFT formation. After many years of 
investigation, it appears that there is a definite interplay between these two 
pathological markers, and that neither is independent of the other. In a study carried 
out by Roberson et al, reduction of endogenous levels of tau protein has prevented 
the behavioural deficits originally associated with Aβ plaques, but the extent of Aβ 
plaque formation is not affected.
[127]
 This study, and other evidence, point to a 
synergistic relationship between tau and Aβ, but also show the central role played by 
the tau protein in AD.
[128, 129]
  This makes tau an interesting molecular target for 
treatment of AD, and other tauopathies. 
Han et al have carried out work which shows the importance of the site of 
phosphorylation of tau. They found that, by encouraging phosphorylation in-vitro at 
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ser
202
, of wild-type (WT) tau and four tau mutants, the microtubule assembly-
promoting ability of tau was inhibited. This phosphorylated species has been isolated 
from the brains of AD sufferers. It is suggested that phosphorylation at Ser
202
 is a 
major event which leads on to NFT development in AD, and also in other 
tauopathies. Phosphorylation was carried out by the cyclin-dependant protein kinase 
5 (CDK-5).
[130]
   
Bramblett et al have shown that tau protein isolated from PHF is 
hyperphosphorylated, it does not bind to microtubules or promote microtubule 
assembly in-vitro. Once this tau protein has been dephosphorylated, it recovers the 
ability to bind to, and promote, microtubule assembly. They also demonstrate the 
inhibitory effect that hyperphosphorylation at Ser
396
 of tau has on binding 
microtubules.
[131]
  
Several other sites of phosphorylation have been implicated in the development of 
the pathological markers of AD, such as Ser
262
, Ser
356
, and Thr
231
. It is thought that a 
combination of phosphorylated residues, and not just a specific one, is responsible 
for the neurotoxic effects of tau.
[132]
 Mutation of 14 sites of phosphorylation in the 
tau protein to alanine, in place of serine and threonine, resulted in a lack of tau-
induced toxicity. When individual residues were mutated to alanine, toxicity was still 
observed. This study indicated that no particular site was responsible for tau 
toxicity.
[133]
   
Transgenic mice which have been made to express human tau have shown 
neurological deficits and neuronal loss, accompanied by the appearance of NFT.
[134]
 
It had been assumed that these NFT were responsible for the cytotoxic effects of tau 
protein, but recent findings, using a mouse model of AD, appear to show that this is 
not the case. Santacruz et al have engineered mice to express a repressible human tau 
variant. These mice developed progressive age-related NFT, neuronal loss, 
behavioural impairments and decreased cognitive function. When this human tau 
was suppressed, the mice recovered cognitive function and neuron numbers 
stabilised. In older mice models NFT continued to accumulate, but behavioural 
impairments did not return. This study showed that NFT alone are not enough to 
cause neuronal loss or behavioural impairments. It is more likely that the loss of 
normal function of the tau protein, due to hyperphosphorylation, and its aggregation 
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into soluble oligomers, are the causes of neuronal and cognitive function loss. It also 
raises the question as to whether the NFT are markers of the disease, or if they are a 
protective mechanism of the body’s, allowing transformation of a neurotoxic species 
(soluble, hyperphosphorylated tau) into a less toxic form, as seen for the Huntington 
protein.
[135]
 In some neurodegenerative disease models this aggregation into a less 
toxic species, followed by elimination from the body by proteasomal activity, or 
autophagy, has been observed, but this has yet to be proven in AD.
[136]
 
3.5     Current Tau–Focused Strategies for the Treatment of AD 
While much work is being carried out which targets Aβ plaques and cholinergic 
neurons, this discussion will focus on tau-based strategies for the treatment of AD.  
3.5.1     Microtubule Stabilising Strategies 
The role of the tau protein in the CNS is the stabilisation of microtubules, as 
mentioned above. When tau becomes hyperphosphorylated and aggregates into NFT 
this function is lost. Several therapeutics have been investigated to fill this role, and 
stabilise the neuronal transport system. 
The microtubule-stabilising drug, Paclitaxel, was administered to transgenic mice 
that displayed microtubule and motor deficits. Palitaxel is an antimitotic agent used 
in the treatment of cancer. An improvement in microtubule density and motor 
function was noted upon administration of this drug, demonstrating how small-
molecule microtubule stabilisers could be a possible treatment in AD. Palitaxel does 
not readily cross the blood brain barrier, but the effects observed were attributed to 
uptake at peripheral neuromuscular junctions.
[137]
 Taxane based derivatives which 
display microtubule-stabilising abilities have been investigated, but, as for Palitaxel, 
they are often not able to cross the BBB, and would require high doses to illicit the 
desired effect. It would be desirable to keep the peripheral levels of microtubule-
stabilising drugs as low as possible, as they are antimitotic agents and can cause 
adverse effects in the body. For these reasons, Taxanes are not ideal drug candidates 
for the treatment of neurological diseases.
[115]
  
An octapeptide, known as NAP, with a sequence of Asn-Ala-Pro-Val-Ser-Ile-Pro-
Gln, has been shown to promote microtubule assembly. It has the ability to cross the 
BBB, and may be a possible candidate for the treatment of neurodegenerative 
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disorders. In mouse models of AD, a reduction in tau hyperphosphorylation and 
levels of Aβ plaques was also observed. NAP administration reduced 
hyperphosphorylation at Thr
231
, which is a site known to influence microtubule 
binding.
[138]
 
3.5.2     Reduction of the Level of Hyperphosphorylated Tau in the Brain 
Utilising autophagy, one of the mechanisms used by the body to degrade misfolded 
protein, is another possible tau-based strategy for the treatment of neurodegenerative 
disease (Fig. 3.2). Misfolded protein is prone to formation of the aggregates 
associated with diseases like AD. Autophagy is carried out by encapsulation of these 
proteins by an autophagosome, followed by fusion with a lysosome to degrade the 
protein aggregates.
[139]
 Chemical inducers of autophagy are of interest in the 
treatment of neurodegenerative diseases. As mentioned earlier, in the case of AD, the 
aggregated NFT are not thought to be the toxic species, while non-aggregated, 
soluble forms of hyperphosphorylated tau may be the cause of tau-toxicity.
[132]
 This 
approach may enhance elimination of hyperphosphorylated tau. 
 
Figure 3.2 Autophagy of aggregated proteins
[139]
 
Several chemical inducers of autophagy are being investigated for the treatment of 
neurodegenerative diseases. The naturally occurring disaccharide, trehalose, has 
been shown to increase the removal of abnormal proteins by promotion of autophagy 
in mouse models (Fig. 3.3). After treatment with trehalose the levels of 
phosphorylated tau and Aβ plaques were reduced. Trehalose is free of toxic effects at 
high concentrations, so may be a potential candidate for human trials.
[140]
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Figure 3.3 Naturally occurring disaccharide Trehalose 
Another method of reducing the levels of hyperphosphorylated tau in the brain is by 
tau immunotherapy. Mice which had been engineered to express tau pathology were 
immunised with a small, phospho-tau peptide. Three different sequences, each based 
around known phosphorylated sites of the tau protein, of between 13-18 amino acids, 
which are phosphorylated at one site, were used in this study. It was observed that 
the mice produced antibodies that entered the brain, and could reduce tau pathology, 
as well as improving cognitive impairments.
[141]
 
3.5.3     Inhibition of Tau Oligomer Assembly 
When tau becomes hyperphosphorylated it begins to bundle together, and form 
soluble oligomers. These oligomers aggregate together further, to form the insoluble 
NFT associated with AD. As discussed above, it is thought that the soluble 
aggregates of hyperphosphorylated tau are the toxic species (Fig. 3.4). For this 
reason, inhibiting the formation of these oligomers is an area of interest in the 
treatment of AD. Decreasing the levels of oligomeric, hyperphosphorylated tau 
protein could also contribute to microtubule stabilisation by increasing the levels of 
monomeric tau.
[115]
 
 
Figure 3.4 The aggregation of hyperphosphorylated tau and the postulated toxicity of each stage 
Methylene blue has been used to treat many different diseases, varying from malaria 
to depression (Fig 3.5). Recently there has been evidence that methylene blue could 
have potential as a treatment for AD. It has been observed that methylene blue 
inhibits the aggregation of tau protein, and also Aβ species. Methylene blue has been 
used for decades for the treatment of other diseases, and so its safety in humans has 
been well assessed. The drug has undergone some clinical trials, under the trade 
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name Rember™, and has shown beneficial effects, with reduction of aggregation of 
both tau and Aβ, along with other aggregation-prone proteins in the body. Rember™ 
may be available as a registered drug as soon as this year.
[142]
  
 
Figure 3.5 The structure of methylene blue 
3.5.4     Inhibition of Tau Hyperphosphorylation 
A major area of tau-focused strategies in the treatment of AD and other tauopathies 
is the inhibition or reduction of tau hyperphosphorylation. This is essentially the 
reason that tau loses the ability to stabilise microtubules, leading to cell death.  
The main method which has been investigated is the administration of kinase 
inhibitors. Kinases are enzymes which catalyse the transfer of a phosphate group 
(PO3
-
) from a donor molecule, such as the terminal PO3
-
 of adenosine-5’-triphosphate 
(ATP), onto a receiving molecule, such as a protein. Often, the phosphorylated 
products of these reactions play important roles in cellular processes, and their 
deregulation contributes to a wide range of pathological conditions.
[143]
 
Many different phosphate kinases are present in the body, but the main kinases 
which have been associated with AD and tau phosphorylation are the proline 
directed kinases GSK-3, CDK-5 and ERK-2, and also the non-proline directed 
kinase microtubule affinity-regulating kinase (MARK). It has been observed that 13 
of the phosphorylated sites of the tau protein are followed by proline, and so are 
potential targets for the proline directed kinases.
[119]
 The microtubule binding region 
of tau is associated with the Pro-Gly-Gly-Gly motif, as mentioned earlier, and so this 
region of the tau protein is important for maintaining microtubule integrity. Many 
known sites of O-GlcNAcylation in proteins are also sites which are phosphorylated 
by proline-directed kinases.
[144]
 For these reasons, inhibition of the proline-directed 
kinases is interesting in the search for treatments of AD. 
Extracellular signal-regulated kinase 2 (ERK-2) is also known as mitogen-activated 
protein kinase 1 (MAPK-1), and is a serine/threonine kinase. ERK-2 has been found 
to be upregulated in AD, and in other neurodegenerative diseases, even some that do 
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not involve tau hyperphosphorylation. Some studies have suggested that ERK-2 may 
be used as a marker for these diseases, as the levels of this kinase in cerebrospinal-
fluid were elevated in patients with neurodegenerative disorders, such as CJD.
[145]
  
Inhibition of ERK-2 in mouse models of AD has been shown to have a beneficial 
effect. Caffeine has an inhibitory effect on ERK-2, which, in turn, has been observed 
to decrease the levels of Aβ plaques and tau hyperphosphorylation. Caffeine also 
inhibits other kinases, and so improvements in neuronal survival may be due to a 
contributory effect.
[146]
  
Inhibitors of cyclin-dependant kinase 5 (CDK-5) have also been investigated. This 
kinase requires association with a regulatory subunit, either p35 or p39 proteins, to 
activate it. CDK-5 is essential in neuronal development, but deregulation of this 
kinase has been observed in AD.
[147]
 The neurodegenerative effects associated with 
deregulation of CDK-5 appear to be observed when it is associated with a shorter 
form of p35, which is known as p25. The cleavage of p35 to the truncated form, p25, 
is mediated by the calcium dependant protease, calpain. The p25 fragment is more 
stable than p35, and is generally formed under conditions of cell stress or injury. The 
CDK-5/p25 complex displays aberrant activity, and carries out abnormal 
phosphorylation of substrates, including the tau protein.
[148]
 Inhibitors of CDK-5 
must target the CDK-5/p25 complex. Jain et al have synthesised a series of 
inhibitors, but only one compound displayed acceptable inhibition of the CDK-5/p25 
complex (Fig. 3.6). Structural modifications were carried out to investigate the SAR 
between the inhibitor and CDK-5. It was found that the terminal hydroxyl group, and 
also the ethyl group, are required for activity. The inhibitor did not show an 
increased affinity for CDK-5 over other kinases, which may be expected, due to 
exploitation of binding interactions within the ATP binding pocket, as will be 
discussed later.
[149]
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Figure 3.6 Binding interactions between the inhibitor and amino acid residues of CDK-5
[149]
 
One CDK inhibitor which has shown promising results is R-roscovitine, which is 
involved in clinical trials for the treatment of cancer (Fig. 3.7). This compound 
shows potent inhibition of CDK-5, as well as other kinases in the CDK family. 
Again, interactions within the ATP binding pocket are utilised.
[150]
 
 
Figure 3.7 The structure of CDK-5/p25 inhibitor, R-roscovitine 
While inhibition of CDK-5 has shown some success, it may not be an effective target 
in the treatment of AD. When CDK-5 was inhibited in mouse models of AD, there 
was a noted decrease in the production of Aβ, but an increase in tau phosphorylation. 
It was demonstrated that, upon inhibition of CDK-5, an up-regulation of GSK-3 
occurs. This indicates that CDK-5 may not be suitable for the treatment of AD, as, 
even if selective inhibition can be achieved, GSK-3 will carry out phosphorylation in 
place of CDK-5.
[151]
 Another issue with inhibiting CDK-5 is the central role it plays 
in neuronal development, as mentioned earlier. Blocking of this function could 
produce unwanted side-effects, interfering with cell cycle progression.
[152]
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The evidence leads to the postulation that GSK-3 is the ideal phosphate kinase to 
inhibit, in order to decrease hyperphosphorylation of the tau protein. In a study 
carried out by Wang et al, the relationship between GSK-3 and O-GlcNAcylation of 
tau was demonstrated. Inhibition of GSK-3 by lithium resulted in an increase in O-
GlcNAcylation of several sites on tau, while a decrease in O-GlcNAcylation has 
been noted in the brains of people with AD.
[144]
 Most in-vivo studies which have 
been carried using phosphate kinase inhibitors have been targeted at GSK-3 activity, 
highlighting the importance of this kinase in tau hyperphosphorylation.
[115]
 These 
results make GSK-3 an interesting target in the treatment of AD. GSK-3, and current 
inhibitors of this kinase, will be discussed in detail below. 
Many different kinase inhibitors have been investigated. These inhibitors have been 
both ATP competitive and non-competitive. As phosphate kinases use ATP as their 
source of phosphate, they all possess an ATP binding pocket, and some inhibitors 
exploit this binding site in their design (Fig. 3.8). These types of inhibitor are known 
as ATP competitive, such as those discussed above for CDK-5 inhibition (Figs. 3.6 
and 3.7). 
 
Figure 3.8 The structure of adenosine-5’-triphosphate 
In order to make an inhibitor more selective, these molecules may take advantage of 
residues surrounding the ATP pocket, which are unique to each kinase, to increase 
their binding affinity.
[153]
 ATP-competitive inhibitors often display poor activity and 
selectivity in-vivo. The high sequence homology among kinase ATP pockets reduces 
specificity, sometimes producing unwanted side effects. Competition with 
intracellular levels of ATP also contributes to reduced activity when compared to in-
vitro studies.
[154]
 
Non-ATP competitive inhibitors have shown some specificity for certain kinases. 
These compounds do not depend on the ATP binding pocket to increase their 
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affinity, but use other residues to make binding interactions. Although elucidation of 
the SAR between other sites on the kinase and the potential inhibitor may be more 
difficult, this approach is more attractive. It will infer greater kinase specificity on 
the inhibitor, which, in turn, means that there will be less interference with other 
ATP mediated processes in the body.  
Non-ATP competitive inhibitors generally work by inducing a conformational shift 
in the kinase, which prevents it from functioning. There are three different 
approaches to non-ATP competitive inhibitor design. The first involves compounds 
which bind to the inactive form of the kinase, stopping it from activating, and so 
preventing it from binding ATP. The second is binding to sites on the kinase other 
than those surrounding ATP binding cleft, inducing a conformational change in the 
kinase. The third involves binding to the cysteine residue at the ATP binding cleft, 
preventing ATP from binding, and so making the kinase inactive. The last approach 
does not make the inhibitor as selective as the other approaches, unless other sites on 
the kinase are also utilised for binding.
[155]
 
3.6     Glycogen-Synthase Kinase-3  
GSK-3 is a serine/threonine kinase which is involved in many processes in the body, 
including glucose metabolism, gene expression, structural regulation (microtubules), 
cell growth, cell survival, cardiac hypertrophy, oncogenesis and apoptosis. GSK-3 is 
found as two isoforms, GSK-3α and GSK-3β, which are similar in their structure, 
substrate specificity, and mechanisms of regulation. They share a 98 % sequence 
homology in their catalytic domains.
[156]
 Deregulation of GSK-3 has been associated 
with several disorders such as diabetes,
[157]
 some forms of cancer, schizophrenia, and 
in the development of neurodegenerative diseases like AD. It is highly expressed in 
the brain, and it has been proven that GSK-3 phosphorylates specific amino acid side 
chains of the tau protein.
[158]
 This kinase mediates tau hyperphosphorylation and Aβ-
induced toxicity.
[159]
 Studies have shown that GSK-3 activity may increase with age, 
which is in agreement with the age-dependant development of AD. Inhibition of 
GSK-3 in-vivo has resulted in reversal of both tau hyperphosphorylation and 
behavioural defects in mouse models of AD.
[160]
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A lot of work has been carried out into the development of GSK-3 inhibitors for the 
treatment of diseases like AD and diabetes. These inhibitors have been both ATP-
competitive, and non-competitive. Elucidation of the crystal structure of GSK-3 has 
led to a better understanding of the different functions of the kinase. This may also 
help to design drugs that inhibit specific roles of GSK-3, without interfering with 
other important processes.
[161]
 
Some of the first non-ATP competitive GSK-3 inhibitors were synthesised by 
Martinez et al. These drugs are small heterocyclic thiadiazolidinones, and display 
potent inhibition of GSK-3. The most promising compound is shown in Fig. 3.9. 
They displayed good specificity for GSK-3, and did not show inhibitory activity for 
other protein kinases tested in this study.
[162]
 Later studies with mouse models have 
shown neuroprotective and antidepressant effects, with improved cognitive function. 
This molecule is currently in clinical trials for AD, and can cross the BBB.
[163]
 
 
Figure 3.9 Thiadiazolidinone with potent GSK-3 inhibitory properties 
Another family of inhibitors are the paullones, the most selective of which, 
Cazpaullone, is shown below in Fig. 3.10. Members of this group have been shown 
to decrease tau hyperphosphorylation, and reduce Aβ production in-vitro, but in-vivo 
testing has been limited. This type of compound has displayed high specificity for 
GSK-3 inhibition, even over other proline-directed kinases, like CDK-5.
[164, 165]
 
Paullones are ATP-competitive inhibitors, but also take advantage of kinase specific 
residues at the ATP binding cleft to infer selectivity. Interactions between paullones 
and Val
135
 of GSK-3 are much stronger than with Cys
83
 of CDK-5, and this 
increased binding may account for the specificity of these inhibitors.
[166]
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Figure 3.10 Cazpaullone, a selective GSK-3 inhibitor 
Lithium has been investigated as a GSK-3 inhibitor. Lithium has been used for 
decades as a treatment for bipolar disorder, and so has been shown to be safe to 
administer for prolonged periods. Lithium is a potent GSK-3 inhibitor, acting 
through competition with magnesium ions, and binding to the kinase. Lithium 
treatment in-vivo, in mice, has displayed a reduction in tau hyperphosphorylation, 
and decreased Aβ toxicity. These results are promising, but one consideration is that 
lithium inhibits other enzymes apart from GSK-3, and can be neurotoxic due to 
alteration of neurotransmitter levels.
[167]
 Lithium treatment of mouse models of AD 
has demonstrated pathological improvements, but memory deficits were not 
recovered. Human trials were carried out on a small scale, for 10 weeks, but these 
trials did not show encouraging results, with no pathological or behavioural 
improvements.
[168]
 
While many inhibitors of GSK-3 contain aromatic groups in their structure, there has 
been evidence to suggest that short peptides can selectively inhibit protein kinases. 
The structure of these peptides can be based on “natural” sequences which are 
known to be targeted by the kinase, and so make the inhibitor selective.
[169]
 As GSK-
3 is essential in many processes in the body, a weak-to-moderate inhibition is 
desirable. By synthesising a peptide sequence which mimics the natural substrate of 
GSK-3, there will be competitive binding, resulting in partial inhibition of the 
kinase. Substrate-competitive inhibitors are more selective than ATP-competitive 
inhibitors, and so this strategy is attractive for clinical use.
[163]
 As mentioned earlier, 
the crystal structure of GSK-3 has been obtained. Examination of this structure 
indicates the presence of a substrate peptide binding site, which is specific for this 
kinase.
[161]
  
Plotkin et al have synthesised a phosphorylated peptide inhibitor of GSK-3, for use 
in the treatment of diabetes. These peptides are substrate-competitive, and in-vivo 
mouse models of diabetes have shown a marked improvement. The membrane 
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permeable inhibitor showing the most potential is known as L803-mts. The sequence 
was derived from a GSK-3 substrate, heat shock factor-1, and contains the GSK-3 
recognition motif S
1
XXXS
2
. S
1
 is the site which is known to be phosphorylated by 
GSK-3, S
2
 is the priming site, and X is any amino acid. The sequence of the 
phospho-peptide, L803-mts, is shown in Fig. 3.11, with S
1
 and S
2
 underlined. The 
site of phosphorylation in the natural sequence has been substituted with alanine.
[157]
 
 
Figure 3.11 Sequence of L803-mts 
Structural variations in the peptide revealed that elimination of the phosphate group 
prevented inhibition, and also that shortening the sequence to just S
1
XXXS
2
 
eliminated the inhibitory capacity.
[157]
 This peptide was found to have 
neuroprotective effects in-vitro.
[170]
 Closer examination revealed that the substrate 
and inhibitor binding sites were not identical, while both occupied the phosphate 
binding pocket, the other residues involved in binding were different. The residues 
are located near to the ATP-binding site, and the phosphate binding pocket which 
interacts with the phospho-serine of the substrate. The substrate was found to interact 
with the cavity bordered by Gln
89
 and Asn
95
, while L803-mts mainly interacted with 
Phe
93
 and a hydrophobic surface located away from the ATP-binding site. The Pro
8
 
residue of L803-mts was observed to be involved in the interaction with Phe
93
. It was 
thought that this difference in binding was crucial to the inhibitory capacity of the 
peptide. Alterations in the peptide sequence were later carried out, and resulted in a 
3-10 fold increase in GSK-3 inhibition. The increased activity of the inhibitors was 
attributed to the presence of more hydrophobic groups, and also to increased 
interaction with Phe
93
.
[171]
 From this information it is evident that peptides have 
potential as selective inhibitors of GSK-3. The natural substrates of GSK-3 are 
proteins, and, by mimicking the sequence of these substrates, a peptide inhibitor 
could be designed which selectively blocks unwanted functions of GSK-3. 
3.7     Solid-Phase Peptide Synthesis 
The synthesis of complicated glycopeptides can be hard to achieve in the traditional 
“solution-phase”. These coupling reactions can often be poor yielding, and the 
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intermediates difficult to purify. The advent of “solid-phase” peptide synthesis 
(SPPS) was pioneered by Bruce Merrifield in the 1960’s as a new approach to 
peptide synthesis, with the first resin being called Merrifield resin. Many advances 
have happened in the area of SPPS since then, but the same methodology is in use 
today.
[172]
 SPPS involves the formation of amide bonds, under standard coupling 
conditions, where the growing peptide is anchored to a solid support (resin). 
SPPS has many advantages over solution phase chemistry. It allows the use of large 
excesses of reagents, which help to drive these poor yielding reactions almost to 
completion. The reactions are also faster than the liquid phase chemistry, peptide 
couplings can be accomplished in less than 30 mins.
[173]
 There is no need for 
purification at each stage, as the peptide remains on the solid support until the final 
deprotection step, and excess reagents are simply washed off. SPPS also has the 
advantage, as with solution phase, of lending itself to the well-established coupling 
methodologies of TBTU/HOBt. One of the major advantages of SPPS is that it is 
suitable for automation. Peptide sequences can be programmed into an automated 
synthesiser, providing non-chemists with access to biologically relevant peptides.
[101]
 
There are two different propagation methods used in SPPS, the Boc/Bzl and 
Fmoc/tBu strategies. The original resins were designed to be used in conjunction 
with the Boc/Bzl strategy. As the Boc group is removed under acidic conditions, 
repeated use of TFA is required in the deprotection steps, which may be too harsh for 
some peptides, especially glycopeptides.
[174]
 The development of the Fmoc/tBu 
strategy has allowed SPPS to be carried out using milder chemistry. The Fmoc group 
is removed under mildly basic conditions, generally by piperidine, but even milder 
bases have been utilised. Most SPPS today is carried out using the Fmoc/tBu 
methodology, and has been complimented by the development of suitable resins and 
side-chain protecting groups.
[172]
 
An important element of SPPS is the choice of resin. As mentioned above, the 
original Merrifield resin is suitable for the Boc/Bzl strategy, and the finished peptide 
is cleaved from the resin under basic conditions. Newer resins, such as the Wang or 
RINK amide resins, contain a linker which is acid-labile. There is a wide variety of 
resins available, which are composed of a polymeric support, such as polystyrene, to 
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which a linker is attached. Choice of resin is dependent upon the strategy being used, 
and also on the nature of the peptide.
[175]
  
SPPS has become an integral part of peptide synthesis, with many advantages. It has 
made possible the synthesis of complicated structures, which otherwise may not have 
been accessible. Recent work in the area of SPPS has led to the development of a 
solid-phase approach to oligosaccharide synthesis, but this is a much more 
complicated endeavour, and is not suited to all carbohydrate syntheses.
[176]
 
3.8     Aim 
The aim of this section was the synthesis of glucosamine based glycopeptides, which 
have potential kinase inhibitory properties (Fig. 3.12). The kinase which was 
targeted in the design of this glycopeptide is GSK-3, which has been highly 
implicated in the development of AD, as discussed earlier.  
 
Figure 3.12 General structure of target glycopeptide 
It was decided to synthesise a non-ATP competitive inhibitor, in order to infer more 
selectivity for GSK-3. O-Linked-N-acetyl glucosamine (GlcNAc) was incorporated 
into the glycopeptide to investigate the effect that the sugar moiety would have on 
the affinity of this compound for GSK-3. Glycosylation is biologically carried out on 
the tau protein, as discussed earlier, and it is postulated that GSK-3 may have a 
recognition site for GlcNAc. As previously mentioned, peptides are good candidates 
as specific kinase inhibitors, and some have shown moderate inhibition of GSK-3. 
The peptide sequence which was synthesised is based on a portion of the repeating 
sequence identified in the tau protein. Both of the serine moieties in the sequence are 
known to be involved in the dynamic glycosylation/ GSK-3-mediated 
phosphorylation of tau.
[122]
 The peptide synthesis was carried out using solid phase 
methodology, utilising the well-established Fmoc strategy.  
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3.9     Synthesis of Protected Glycosyl-Serine Building Block 3.5 
3.9.1     Synthesis of N-Fmoc Protected Glycosyl Acceptor 3.2 
The Fmoc protecting strategy was chosen for SPPS. The Fmoc protecting group was 
used as it is orthogonal to the other protecting groups in the glycopeptide, and can be 
removed easily in the presence of piperidine. N-Fmoc protected serine has also been 
demonstrated as a good glycosyl acceptor, making it attractive for the synthesis.
[177]
 
N-Fmoc protected serine was treated with benzyl bromide, in the presence of 
DIPEA, to selectively alkylate the acid functionality, resulting in 3.2 (Scheme 3.2). 
This reaction was originally carried out using K2CO3 as the base, but yields were not 
reproducible. The solubility of DIPEA allowed the reaction to proceed at a faster 
rate, resulting in increased and reproducible yields. 
 
Scheme 3.2 Synthesis of N-Fmoc protected glycosyl acceptor. Reagents and conditions: i) BnBr, 
DMF, DIPEA, rt, overnight, 80 % 
3.9.2     Synthesis of Building Block 3.5 
Glycosylation of the protected serine acceptor 3.2 was carried out using the imidate 
donor 2.34, discussed in chapter 2. The reaction was carried out using TMSOTf as 
the promoter to give 3.3. From this glycosylated serine, removal of the N-Troc 
protecting group was carried out, using freshly activated Zn and acetic anhydride, to 
give 3.4. This reaction was initially carried out in the presence of Et3N. The reaction 
proceeded, but with poor yields (30 %). The Fmoc group is base labile, and removal 
of this group accounted for the low yields. The reaction was carried out without 
Et3N, and the yields improved greatly, but with a longer reaction time (from 4 h 
increased to overnight).  The next step in the synthesis was the hydrogenolysis of the 
benzyl ester protecting group, using Pd/C and H2, to give the free acid 3.5, which 
was used as the building block for incorporation into the glycopeptide (Scheme 3.3). 
This building block is often used in the literature for glycopeptide synthesis.
[178]
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Scheme 3.3 Synthesis of glycosyl building block 3.5. Reagents and conditions: i) TMSOTf, DCM, 
overnight, rt, 62 %; ii) Zn, Ac2O, overnight, rt, 80 %; iii) Pd/C, EtOAc, overnight, rt, 70 % 
3.10     Synthesis of Glycopeptides  
A library of novel peptides was synthesised using solid phase peptide synthesis 
(SPPS) techniques, following literature procedures.
[172]
 
3.10.1     Synthesis of Decapeptide 3.6 
 
Figure 3.13 Sequence of decapeptide 3.6 
The first target peptide sequence, shown in Fig. 3.13 above, which was synthesised, 
does not contain any glycosylated amino acid. This was carried out in order to 
investigate the effect that the sugar moiety would have on the affinity for the GSK-3 
kinase.  
2-Chlorotrityl chloride (CTC) resin, also known as Barlos resin, was used for the 
SPPS of our peptides (Fig. 3.14).  
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Figure 3.14 2-Chlorotrityl chloride resin 
This resin has several advantages over other resins. It is less acid labile than the 
closely related trityl chloride resin, yet labile enough to allow cleavage of the 
finished peptide under mild acidic conditions (as low as 1 % TFA in DCM). 
Racemisation is eliminated as loading of the first amino acid (AA) is carried out by 
nucleophilic substitution, and so does not necessitate activation of the acid 
functionality of the AA. A problem encountered with some other resins, such as the 
Wang resin, is formation of diketopiperazine (DKP), 3.7, as shown in Scheme 3.4. 
This usually occurs at the dipeptide stage. The bulky nature of the 2-chlorotrityl 
group prevents any DKP formation. Another advantage of the CTC resin is that it 
can be used for both protected and free peptides.
[179]
 
 
Scheme 3.4 Diketopiperazine formation 
The Fmoc protection strategy was employed for this synthesis. This methodology 
compliments the use of the CTC resin due to Fmoc removal under basic conditions. 
Carrying out the synthesis on the solid-phase has many advantages, as discussed 
earlier, but also poses difficulties not associated with the solution-phase. The main 
disadvantage is that the product of the reaction is bound to the resin until the final 
step. This means that traditional monitoring techniques, such as TLC, don’t lend 
themselves to the synthesis. The Kaiser test is a common system used to determine 
the success of coupling and deprotection steps in SPPS. It is a qualitative test based 
on the reaction of the amine functionality with ninhydrin, to produce a specific 
colour change, depending on the structure of the amine involved, for example, a 
primary amine produces a blue/ purple colour in the Kaiser test. This blue colour 
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indicates successful deprotection of the Fmoc group, or an incomplete coupling 
reaction. An amide or carbamate reacts to produce a yellow/clear colour, indicating a 
successful coupling reaction, or incomplete Fmoc deprotection. It is a useful tool in 
peptide synthesis as it requires a minimum amount of analyte, and gives a quick 
result (within 1 min).
[172]
 
Coupling reactions were carried out by pre-activation of the N-Fmoc protected 
amino acid with TBTU, HOBt, and DIPEA for 15 mins. The activated acid was then 
added to the resin bound free amine, and gently shaken for 1.5 h. The solvent and 
excess reagents were then easily removed by vacuum filtration, and the resin was 
washed with DMF and DCM. The Kaiser test was used to indicate complete 
consumption of the free amino groups. Each of these couplings required one cycle 
for completion, but a second coupling cycle can be performed, if necessary. This 
second cycle was avoided by slightly longer reaction times than is needed (the 
reaction can be complete in 30 mins). This precaution was taken as there are some 
indications in the literature that this second coupling step can cause elimination of 
the N-Fmoc group. This could result in repetition, with coupling of a second amino 
acid to the free amine. In SPPS, an excess of reagents is used, and this helps to 
ensure that the reaction goes to completion. Although the Kaiser test indicated full 
coupling at each step, the resin was capped by reacting with acetic anhydride. Any 
remaining free amine groups were so converted into amides at this step, stopping 
propagation of an incorrect deletion sequence.
[172]
 The N-Fmoc protecting group of 
the terminal amino acid was deprotected at each stage using a 20 % solution of 
piperidine in DMF. The reactive side chains of the amino acids used were suitably 
protected, so that the protecting groups were compatible with N-Fmoc cleavage 
conditions. The amino acids used in this synthesis, and their protected side chains, 
are shown in Fig. 3.15. All amino acids used for this synthesis possess the L 
configuration. 
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Figure 3.15 L-Amino acid residues used in SPPS, and the abbreviation used to denote them 
2-Chlorotrityl-chloride (CTC) resin was selected for the synthesis of the peptides, as 
discussed earlier. Swelling of the resin is important to allow the reagents to access 
the reactive site, and DCM is added to the resin before the reaction. This step was 
also carried out at each stage in which the resin bound peptide had been dried and 
stored. The first amino acid which was attached to the resin was N-Fmoc-Valine-OH. 
This reaction follows an SN1 mechanism. The amino acid was added to the resin in 
the presence of DIPEA, in DCM (Scheme 3.5). DIPEA is used as it is a hindered 
base, and so does not cause removal of the N-Fmoc protecting group. The resin was 
washed with a solution of MeOH/DCM/DIPEA to cap any unreacted CTC groups on 
the resin. 
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Scheme 3.5 Loading of the first amino acid onto the CTC resin. Reagents and conditions:             
i) DIPEA, DCM, 2 h, rt 
Estimation of the amount of amino acid which had attached to the resin was carried 
out by UV analysis. A known quantity of the resin-attached N-Fmoc-AA was 
subjected to N-Fmoc cleavage conditions of DBU. The level of attachment of the N-
Fmoc-AA was judged by measurement of the UV absorbance of dibenzofulvene, 
which is released upon N-Fmoc cleavage, at 304 nm. This was found to be 0.72 
mmol/g (moles of AA per gram of resin), which was in agreement with literature 
values of 0.86 mmol/g for CTC resin.
[180]
 
Removal of the N-Fmoc group was carried out in the presence of piperidine, 
followed by removal of reagents by vacuum filtration and rinsing. The success of 
this reaction was confirmed by the appearance of a blue colour in the Kaiser test. 
Coupling of the second amino acid, N-Fmoc-Lysine-(N-Boc)-OH, was carried out by 
pre-activating the acid in the presence of TBTU, HOBt, and DIPEA for 15 mins, 
followed by addition to the resin bound free amine (Scheme 3.6). Any unreacted, 
resin bound free amine was capped by acetylating with Ac2O in the presence of 
DIPEA. This step was carried out to reduce the likelihood of deletion sequences. 
This method of N-Fmoc deprotection, coupling of the next amino acid, and capping 
of any unreacted, resin bound amino peptide was repeated for each consecutive 
amino acid until the desired decapeptide was synthesised (Fig. 3.13).  
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Scheme 3.6 Coupling of the second amino acid. Reagents and conditions: i) TBTU, HOBt, DIPEA, 
DMF, 1.5 h, rt 
One of the main challenges in peptide synthesis is complete characterisation of the 
peptide intermediate at each step. This is made difficult due to the large number of 
signals which would appear at the same ppm range in NMR spectra, for example the 
amide groups connecting each amino acid. The technique used to monitor the 
presence of the desired peptide intermediates was mass spectrometry (MS). The 
samples were prepared for analysis by collecting a small amount of the resin bound 
peptide, and cleaving the peptide from the resin with a 1 % solution of TFA in DCM. 
This cleavage was first attempted using an aqueous solution of TFA, but was 
unsuccessful. Water did not encourage swelling of the CTC resin, therefore 
preventing cleavage of the peptide.  
After introduction of the last AA (N-Fmoc-Asparagine-(N-Tr)-OH), the peptide was 
subjected to N-Fmoc removal, in the presence of piperidine, followed by acetylation 
of the free amine using Ac2O, in the presence of DIPEA. Cleavage from the resin 
was carried out using a 50 % solution (v/v) of TFA in DCM. These conditions also 
ensured removal of the corresponding side-chain protecting groups. When a more 
dilute solution of TFA was used, complete removal of the acid-labile side chain 
protecting groups was not achieved. The synthesis of the desired, deprotected 
decapeptide 3.6 was confirmed by MS analysis (Calculated for C43H78N13O16 (M + 
Chapter 3: The Synthesis of a Series of Glycopeptides 
Page | 82  
 
H)
+
: 1032.5684, found 1032.5662). Purification of peptide 3.6 was carried out using 
preparative HPLC, with a gradient elution, using H2O with 0.1 % formic acid, and 
MeCN with 0.1 % formic acid as the mobile phase. The detector available for our 
instrument was a UV detector, which made the HPLC analysis difficult due to the 
lack of a strong UV active group in the peptide. None of the constituent AAs of 3.6 
have aromatic groups as their side chains, and so the intensity of the peaks in the 
chromatogram was rather weak, especially when compared to the background 
absorption of the mobile phase. The wavelength of maximum absorption for the 
peptide bond is 190 nm, but measurements are not carried out at this value due to the 
low output of conventional spectrometers at this wavelength. The side chains of 
some AA absorb at 205 nm, for example Trp, His, and Cys, but none of these AAs 
are contained in our peptide sequence.
[181]
 At higher wavelengths the amide bonds 
should be mildly UV active, and so the analysis was carried out at 214 nm.
[182]
 
Fractions were manually collected at 1.5 minute intervals based on the run time, and 
analysed by MS to determine the fraction which contained the desired product. The 
time which it would take for the mobile phase to travel from the detector to the 
collection vessel was estimated at about 50 secs, based on the length and diameter of 
the tubing. Compound 3.6 was detected in two fractions, 6.5-8 mins, and 8-9.5 mins 
of run time. These fractions were concentrated, and the material obtained was re-
dissolved in H2O with 0.1 % formic acid. Further HPLC analysis was investigated 
under several different conditions. Using the gradient elution conditions used 
previously for purification, a stable baseline was unobtainable. MeCN is UV active 
at 214 nm also, and so there was a constant shift in the baseline as the concentration 
of MeCN changed. An isocratic system was also investigated, with a mobile phase of 
MeOH:H2O, at various concentrations of MeOH. Unfortunately, due to the lack of a 
strong chromophore in peptide 3.6, a UV trace could not be attained to show the time 
at which the peptide eluted from the column. As mentioned earlier, the peptide bond 
should be UV active at 214 nm, but measurements at this value are not generally 
used in analysis of peptides and proteins, due to the complexity of absorbance at this 
wavelength. Although, there is no other choice for certain sequences. Also, the 
absorbance at 214 nm is highly dependent on the conformation of the peptide.
[182]
  
To investigate if the acidic content of the mobile phase was necessary to ensure 
elution of the peptide through the column, an isocratic system of MeCN with 1 % 
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formic acid:H2O with 1 % formic acid, at a range of concentrations, was also used. 
While a much more stable baseline was achieved with the isocratic systems, it was 
still difficult to associate a peak in the chromatogram with our peptide. MS detection 
was the only indication of the presence of the peptides. Shown in Fig. 3.16 are the 
total ion chromatograph (TIC), extracted ion chromatograph (EIC), and UV trace 
which were produced when compound 3.6 was detected by MS analysis. The ions 
corresponding to the peptide 3.6 were found to reach the detector at 6.987 mins. 
Examination of the ions which reached the detector between 7.6-8.9 mins also shows 
the presence of the desired peptide, in which the deprotection of the AA side chains 
has not gone to completion. This peptide still has one t-butyl group attached ((M + 
H)
+
: 1088.6357, and (M + 2H)
2+
: 544.8218). 
 
 
 
 
 
 
 
Figure 3.16 a) TIC, b) UV trace, and c) EIC obtained from MS analysis of decapeptide 3.6 
3.10.2     Synthesis of a Library of Glycopeptides, 3.8, 3.9 and 3.10 
Glycosylation in a specific amino acid in a protein has been shown to affect the 
glycosylation/phosphorylation at other sites.
[18]
 In order to investigate the effect of 
glycosylation at a specific site in the desired peptide sequence, glycosylation was 
carried out on the first serine of the sequence, the second serine of the sequence, or 
on both. Introduction of N-acetyl glucosamine into the peptide sequence was carried 
out using the SPPS procedures optimised for the decapeptide 3.6. 
The glycopeptide, 3.8, is glycosylated at the first serine of the sequence (Fig. 3.17). 
Some discussions in the literature indicate that piperidine may be too basic to use for 
N-Fmoc removal in glycopeptide synthesis, with a weak base like morpholine being 
a) 
b) 
c) 
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used instead.
[183]
 Others disagree with this theory, and careful use of piperidine was 
not found to cause β-elimination.[184] Piperidine was used in the first two 
deprotection steps. Introduction of the glycosylated serine building block 3.5 was 
carried out using the standard coupling conditions of TBTU/HOBt in the presence of 
DIPEA, described earlier (Scheme 3.6). The Kaiser test was carried out after 1.5 h, 
the time allowed for standard peptide couplings, and this indicated that the reaction 
had not progressed to completion. For all couplings involving a glycosylated AA the 
reaction was left overnight, and was judged to be complete by the Kaiser test. N-
Methyl morpholine (N-MM) was used to remove the N-Fmoc group at this stage, but 
the reaction was not successful, with failure being indicated by the Kaiser test. The 
deprotection was then carried out successfully, with careful monitoring of the 
reaction time, using piperidine. No elimination of the sugar moiety was observed. 
Subsequent couplings of the remaining AAs led to the synthesis of the complete 
glycopeptide. The finished glycopeptide was subjected to N-Fmoc removal, in the 
presence of piperidine, followed by acetylation of the free amine using Ac2O, in the 
presence of DIPEA. Cleavage from the resin was carried out using a 50 % solution 
(v/v) of TFA in DCM, as optimised for compound 3.6, resulting in glycopeptide 3.8 
(Fig. 3.17). Purification of crude compound 3.8 was carried out using preparative 
HPLC. The same type of complications as described earlier for the purification of 
compound 3.6, were also encountered for 3.8. The sugar moiety of the glycopeptide 
is O-acetyl protected, and these groups are not UV active. Neither are the side chains 
of the other AAs in the sequence of glycopeptide 3.8. Purification was carried out by 
manually collecting fractions at 1 minute intervals based on the run time, and 
analysed by MS to determine the fraction which contained the desired product. The 
glycopeptide was found in fractions collected at both 6-7 mins, and 7-8 mins of run 
time. The presence of glycopeptide 3.8 was confirmed by MS (Calculated for 
C57H98N14O24 (M + 2H)
+2
: 681.8448, found 681.8432). The fractions containing the 
desired product were concentrated, and re-dissolved in MeCN with 1 % TFA. It is 
interesting to note the difference in physicochemical properties, such as solubility, 
which were conferred on the peptide by the presence of the sugar moiety. Further 
HPLC analysis was investigated under each of the elution conditions outlined 
previously for 3.6. As mentioned earlier, glycopeptide 3.8 does not contain a strong 
chromophore, and a UV trace showing the time at which the peptide eluted from the 
column was not obtained. The TIC, EIC and UV trace obtained by LC-MS analysis 
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of compound 3.8 are shown in Fig. 3.18. From the EIC, it can be seen that 3.8 
reached the MS detector at 7.895 mins.  Further analysis of the other ions which 
reached the detector, as observed in the TIC, show the presence of the desired 
glycopeptide, in which one acetyl group has been removed ((M + 2H)
2+
: 660.3405). 
 
Figure 3.17 The sequence of glycopeptide 3.8 
 
Figure 3.18 a) TIC, b) UV trace, and c) EIC from MS analysis of the purified glycopeptide 3.8 
Glycopeptide 3.9 was also synthesised according to the SPPS procedure outlined 
above. This glycopeptide differs from compound 3.8 in that it is glycosylated on the 
second serine of the sequence (Fig. 3.19). As for all of the peptides which were 
synthesised, MS analysis was carried out to confirm the synthesis of the complete, 
Fmoc protected, sequence, before Fmoc removal. A portion of the resin bound 
glycopeptide was treated with a 1 % solution of TFA in DCM (v/v). Both t-butyl 
protecting groups, of the Ser and Thr residues, were removed in the resin cleavage 
stage, while the trityl group on the Asn residue remained attached (MS-ESI/TOF: 
Calculated for C99H142N16O29 (M + 2(NH4))
+2
: 1010.0074 , found 1010.0096). The 
peak in the EIC shows compound 3.9 reaching the MS detector at 12.012 mins. 
Resin-bound glycopeptide 3.9 was subjected to N-Fmoc removal, in the presence of 
piperidine, followed by acetylation of the free amine using Ac2O, in the presence of 
a) 
b) 
c) 
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DIPEA. Cleavage from the resin was carried out using a 50 % solution (v/v) of TFA 
in DCM, as optimised for peptide 3.6. However, the NHAc protected glycopeptide 
could not be confirmed by MS, and any partially side-chain deprotected derivatives 
were also not detected.  
 
Figure 3.19 The sequence of glycopeptide 3.9 
Glycopeptide 3.10 was synthesised according to the procedures outlined above. This 
glycopeptide is glycosylated on both of the serine moieties in the sequence (Fig. 
3.20). The finished glycopeptide was subjected to N-Fmoc removal, in the presence 
of piperidine, followed by acetylation of the free amine using Ac2O, in the presence 
of DIPEA. Cleavage from the resin was carried out using a 50 % solution (v/v) of 
TFA in DCM, resulting in compound 3.10 (Fig. 3.20). Purification of crude 3.10 was 
carried out using preparative HPLC. The same type of complications as described 
earlier for the purification of compounds 3.6 and 3.8, were also encountered for 3.10. 
Purification was carried out by manually collecting fractions at 1 minute intervals 
based on the run time, and analysed by MS to determine the fraction which 
contained the desired product. The glycopeptide was found in the fractions collected 
at 7-8 mins, and 8-9 mins of run time. The presence of glycopeptide 3.10 was 
confirmed by MS (Calculated for C71H117N15O32 (M + 2H)
+2
: 846.4004, found 
846.3983). The fractions containing the desired product were concentrated, and re-
dissolved in MeCN with 1 % TFA. Further HPLC analysis was investigated under 
each of the elution conditions outlined previously for compound 3.6. As mentioned 
earlier, glycopeptide 3.10 does not contain a strong chromophore, and a UV trace 
showing the time at which the peptide eluted from the column was not obtained. The 
TIC, EIC and UV trace obtained by LCMS of glycopeptide 3.10 are shown in Fig. 
3.21. From the EIC, it can be seen that compound 3.10 reached the MS detector at 
7.990 mins. Another major ion which was observed in the TIC of the glycopeptide 
has a mass of 1596, which corresponds to M - 93 of the desired glycopeptide. The 
ion with a mass of 798 corresponds to the (M + 2H)
2+
 of this peak. This mass did not 
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correspond to any obvious incomplete side chain deprotection, or any deletion 
sequence, and could not be assigned. 
 
Figure 3.20 The sequence of glycopeptide 3.10 
 
Figure 3.21 a) TIC, b) UV trace, and c) EIC from MS analysis of the purified glycopeptide 3.10 
Although we initially envisaged hydrolysis of the O-acetyl groups in the sugar 
moiety of glycopeptides 3.8-3.10, the problems encountered throughout purification 
limited considerably the amount of material available for further reactions. We did 
not have enough material to investigate the conditions for the deprotection of the 
alcohol groups, but it is envisaged that a mild strategy, with careful monitoring of 
pH, would be required. Nevertheless, acetylated sugars have shown increased 
absorption through biological membranes, when compared with their deprotected 
analogues.
[185]
 The acetyl groups on the sugar can then be easily hydrolysed by 
esterase enzymes inside the cell. Since peptides are naturally rather hydrophilic, the 
presence of the protected sugar may increase the lipophilicity of these derivatives. 
This would be a desirable feature for potential drug candidates. 
a) 
b) 
c) 
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For future work, it would be advisable to carry out deprotection of the alcohol 
groups, in order to compare the activity of the deprotected sugar with the acetylated 
derivative.  
3.11     Chapter Conclusion 
In conclusion, the synthesis of four decapeptides was achieved, including three 
glycopeptides. The side chains of three of these peptides were deprotected, and the 
peptides were purified by preparative HPLC analysis. A major problem encountered 
during this work was the lack of a strong chromophore in any of the peptides, which 
made the purification difficult. Considering this issue, the peptides were found to be 
relatively pure by MS analysis. Another difficulty was the small amount of sample 
which was obtained after cleavage from the resin, preventing further deprotection of 
the O-acetyl groups. If a larger quantity of the peptides had been obtained, it would 
have been desirable to test these compounds for their affinity for the GSK-3 kinase. 
Future work could aim to improve the yields of these syntheses, and to send the 
peptides for biological evaluation. 
Further work on this type of glycopeptide should incorporate an AA, for example 
Tyr, which has a side chain that absorbs strongly in the UV region. Another option is 
to cleave the peptide from the resin while the Fmoc group is still present, as this is 
also strongly UV active.  
I would also encourage the incorporation of a Pro residue into the glycopeptide, as it 
is known that GSK-3 is a Pro directed kinase. This may increase the binding affinity 
of GSK-3 for the peptide. 
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Chapter 4: Functionalisation at the C-6 Position of 
Glucosamine-Containing Building Blocks 
4.1     Aim 
Carbohydrates provide a useful scaffold for the introduction of a variety of different 
functionalities.
[186]
 The synthesis of such derivatives is complicated by the lack of 
orthogonality presented by several hydroxyl groups, which possess similar reactivity. 
At the same time, these groups may allow selective functionalisation at different 
positions.  
The addition of an aromatic group, or a phosphate moiety to the carbohydrate part of 
the molecule may alter binding interactions between a glycopeptide and its target. 
This type of derivative may modulate the affinity of the glycopeptide for a kinase, 
like GSK-3, which was discussed in chapter 3. Also mentioned previously, was the 
work carried out by Licht-Murava et al, indicating the need for a phosphate group in 
their peptide to illicit an inhibitory effect on GSK-3.
[171]
 For these reasons, the 
introduction of such a functionalisation into a glucosamine-based derivative was 
attractive. 
Extensive investigation was carried out into conditions for the functionalisation of 
different sugar moieties at the C-6 position. This was of interest as it was desirable to 
synthesise an azide containing building block, which could be incorporated into a 
glycopeptide (Fig 4.1). 
 
Figure 4.1 Proposed azide functionalised building blocks 
Another useful purpose for a glycosyl building block which has been functionalised 
with an azide group has been exploited by Bertozzi and co-workers. Biological 
molecules, such as proteins, can be modified experimentally by techniques like 
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genetics and biosynthesis. In the case of glycans, these methods are often not 
applicable, as they don’t have the genetic template and enzymatic activities which 
are associated with proteins. Work carried out by Bertozzi and co-workers has 
utilised bioorthogonal chemistry to incorporate non-natural molecules into living 
systems, without interfering with the biological functioning of the cell. Azide 
containing sugars, such as N-azidoacetyl mannosamine, were introduced into glycans 
by treating cells with the azide functionalised derivative of this natural sugar. These 
were used as tags for visualisation, before flow cytometric analysis was carried out 
on the cells.
[187]
 Later work by this group has shown the incorporation of N-
azidoacetyl galactosamine and N-azidoacetyl glucosamine into glycoproteins, which 
allowed identification of proteins that had become O-GlcNAcylated. This detection 
is not an easy task, as discussed in chapter 1, due to the small amount and neutral 
charge of O-GlcNAc in these glycoproteins.
[188]
 
4.2     Functionalisation at the C-6 Position of the Sugar Moiety 
4.2.1     Differential Protection of the C-6 Position of Glycosyl Derivatives 4.1 
and 4.7 
Initial attempts to selectively functionalise the hydroxy group at the C-6 position 
focused on the N-Troc protected glucosamine, 4.1. The first stage in this synthesis 
involved differentially protecting the C-6 hydroxyl with a group which was 
orthogonal to the other hydroxyl protecting groups (O-acetyl), and also to the N-Troc 
group. A sterically hindered protecting group, such as triphenyl methyl (trityl) ether, 
or tert-butyl dimethylsilyl (TBDMS) ether, would be ideal for this purpose (Scheme 
4.1). The trityl group is removed under acidic conditions, which would make it 
easily deprotected in the presence of the other functionalities. The TBDMS group 
can be deprotected using strongly acidic conditions, but a more attractive method is 
using fluoride ions (for example, from TBAF), which would also be compatible with 
the glycosylated N-Fmoc serine benzyl ester 3.4.  
The different reaction conditions investigated in our attempts to directly 
functionalise 4.1 at the C-6 position are outlined in Table 4.1. 
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Scheme 4.1 Introduction of an orthogonal group at C-6. Reagents and conditions: i) Listed in 
Table 4.1 
Entry Reagents Conditions Outcome 
1 i) TrCl, Et3N, pyr 
ii)Ac2O 
i) 4 h, 70 °C, N2, TrCl (1.2 eq) 
ii) overnight, rt 
Synthesis of 2.26 
5 % yield of 4.2 
2 i) TrCl, DMAP, 
pyr 
ii)Ac2O 
i) 3 h, 70 °C, N2, TrCl (1.2 eq) 
ii) overnight, rt 
 
Synthesis of 2.26 
3 i) TrCl, DMAP, 
pyr 
ii)Ac2O 
i) overnight, 60 °C, N2, TrCl 
(1.2 eq) 
ii) overnight, rt 
Synthesis of 2.26 
4* i) TrCl, Et3N, pyr 
ii)TrocCl 
iii)Ac2O 
i) 3 h, 80 °C, N2, TrCl (1.2 eq) 
ii) 2.5 h, rt 
iii) overnight, rt 
Synthesis of 2.26 
5 i) TBDMSCl, 
imidazole, pyr 
ii) Ac2O, pyr 
i) overnight, rt, TBDMSCl 
(1.2 eq) 
ii) overnight, rt 
26 % yield of 4.3 
2.26 produced 
6 i) TESCl, Et3N, 
pyr 
ii)Ac2O 
i) 0 °C add base → rt, 4 h, 
TESCl (1.2 eq) 
ii) overnight, rt 
None recovered 
7 i) TrCl, Et3N, pyr 
ii) AcCl 
i) 3 h, 95 °C, TrCl (5 eq) 
ii) overnight, 0 °C → rt 
39 % yield of 4.2 
Table 4.1 Various reaction conditions for the functionalisation of the C-6 position of 4.1 (*: note 
that this entry is based on D-glucosamine HCl as the starting material) 
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For each of these entries, the intermediate compounds were not isolated, as it was 
desired to carry out a one-pot reaction to achieve the selectively protected product. 
The progression of the reaction was noted by TLC in each case. For entries 1-3 and 
5-7 the glycoside 4.1 was obtained from glucosamine hydrochloride, by protection of 
the amine with TrocCl, in the presence of NaHCO3. Entry 1 details protection of the 
primary hydroxyl of 4.1 as a trityl ether, using Et3N as the base. This was followed 
by acetylation, using Ac2O. Almost quantitative yield of 2.26 (the per-O-acetylated 
product) resulted, with only a 5 % yield of the desired product 4.2. Entries 2 and 3 
show this reaction carried out in the presence of DMAP, but in this case, there was 
full conversion to 2.26. In entry 4 a different reaction sequence was investigated, 
with protection of the C-6 as the trityl ether, in the presence of Et3N, followed by 
protection of the amine using TrocCl, and acetylation of the remaining hydroxy 
groups. This was carried out to check if the N-Troc group was interfering with the 
reaction, as we had earlier observed the difficulty in removal of the N-Cbz group in 
the presence of N-Troc, as discussed in chapter 2. Again there was full conversion to 
2.26. It was postulated that perhaps some acid which was present in the acetylation 
stage of these reactions may have been able to cleave the trityl group, if it had been 
attached (Table 4.1). There may also have been some H2O remaining from the 
previous reaction, even with careful drying of the starting material. 
The TBDMS group is stable in acidic conditions. Entry 5 gives the details of 
protection using TBDMSCl to form the TBDMS ether, in the presence of imidazole, 
followed by acetylation of the hydroxy groups. This reaction resulted in a 26 % yield 
of the desired product, 4.3, and also formation of 2.26 (Table 4.1). When this 
selectively protected derivative was treated with dimethylamine in an attempt to 
form the anomeric hemiacetal, no reaction occurred. This reaction was also carried 
out in the presence of benzylamine. A change was noted by TLC analysis, but the 
desired product was not isolated, and instead degradation seemed to have occurred.  
As these reactions did not proceed in good yield, it was thought that perhaps the 
trityl and TBDMS groups were too bulky for introduction into the sugar. Entry 6 
shows the reaction carried out using triethyl silyl (TES) chloride, in the presence of 
Et3N. This silyl ether is less bulky than TBDMS, although it is removed under acidic 
conditions, similar to trityl ethers. The reaction did not proceed, with no recovery of 
a glycosidic product (Table 4.1). 
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On consideration of the by-products of acetylation with acetic anhydride which were 
observed for entries 1-4, it was postulated that the acetic acid produced in the 
reaction may have facilitated cleavage of the trityl group. In order to investigate this, 
the reaction was carried out in the presence of an excess of TrCl (5 eq), followed by 
acetylation with acetyl chloride as the acetylating agent (entry 7, Table 4.1 and 
Scheme 4.2).  
 
Scheme 4.2 Acetylation carried out using AcCl. Reagents and conditions: i) TrCl, Et3N, Pyr, 95 °C, 
3 h; ii) AcCl, 0 °C → rt, overnight, 39 % 
The reaction was slightly more successful, producing 4.2 in a yield of 39 %, but this 
was still too low for such an early step in the synthetic scheme, and later attempts at 
the same reaction did not show good reproducibility. It was decided not to continue 
with this route, as the trityl group would most likely not withstand the acidic 
conditions in the later steps of the synthesis, such as the Lewis acid required for 
glycosylation.  
There are very few examples of functionalisation at the C-6 position of glucosamine 
derivatives, of which the anomeric position is a free hydroxy group, in the literature. 
In some cases the C-1 position has been protected, and for this reason the 
glucosamine derivative 4.7 was synthesised, according to literature procedures.
[189]
  
2.26 was prepared as discussed in chapter 2, and was treated with a solution of HBr 
in acetic acid to form the glycosyl bromide 4.5. Interestingly, the presence of the N-
Troc group prevented the formation of an oxazoline-type compound, as was 
observed earlier, with the N-acetyl derivative, 2.32, this is in agreement with the 
literature.
[190]
 The glycosyl bromide was activated using AgCO3, and reacted with 
the glycosyl acceptor, benzyl alcohol, to give 4.6. The acetyl groups of this  
glycoside were deprotected, in the presence of 0.1 M aqueous NaOH and MeOH, 
resulting in the benzyl glycoside, 4.7 (Scheme 4.3). 
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Scheme 4.3 Synthesis of glycosyl derivative 4.7. Reagents and conditions: i) 33 % HBr/AcOH 
solution, DCM, 3.5 h, 0 °C → rt; ii) AgCO3, DCM, BnOH, overnight, rt, 57 % over 2 steps; iii) 0.1 M 
NaOHaq, MeOH, 1 h, rt, 73 % 
The various conditions investigated for functionalisation of the C-6 position of 4.7 
are described below in Table 4.2.  
Entry Reagents Conditions 
1 i) TBDMSCl, imidazole, pyr, 
mol. sieves. ii)Ac2O 
i) rt, 2 days, N2, TBDMSCl (1.4 eq) 
ii) overnight, rt 
2 i) TMSCl, Et3N, THF 
ii)Ac2O, pyr 
i) overnight, rt TMSCl (1.2 eq) 
ii) overnight, rt 
3 i) TESCl, imidazole, DMF 
 ii)Ac2O, pyr 
i) overnight, rt, TESCl (1.2 eq) 
ii) overnight, rt 
4 i) TESCl, imidazole, DMF 
 ii)Ac2O, pyr 
i) overnight, 30 °C, TESCl (1.2 eq), 
followed by TESCl (2 eq) and imidazole (2 
eq) overnight 
ii) overnight, rt 
5 i) FmocCl, pyr 
 ii)Ac2O 
i) N2, 2 h, 0 °C → rt, 4 h, FmocCl (1.5 eq), 
followed by FmocCl (1 eq) overnight 
ii) overnight, rt 
6 i) MOMBr, 
K2CO3, acetone  
 ii)Ac2O, pyr 
i) 55 °C overnight, MOMBr (1.5 eq), 
ii) overnight, rt 
 
Table 4.2 Various conditions for functionalisation of 4.7 
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Entry 1 shows the reaction of 4.7 with TBDMSCl, in the presence of imidazole and 
molecular sieves. The desired reaction did not proceed, and none of the acetylated 
product, 4.6, was recovered. Several products resulted from this reaction, and on 
closer examination we were able to isolate and identify one of them as 4.8 (Fig 4.2). 
This acetylated pyridine derivative is produced by the addition of acetic anhydride to 
pyridine, and has been reported in the literature.
[191]
 MS analysis confirmed the 
presence of this unexpected side-product.  
 
Figure 4.2 Side-product 4.8 
Protection of the C-6 position as a TMS ether was investigated in entry 2, which was 
carried out using TMSCl in the presence of Et3N, followed by acetylation using 
Ac2O. This reaction was unsuccessful, but none of the acetylated product 4.6 was 
recovered either. Entries 3 and 4 detail the reaction to protect the C-6 as a triethyl 
silyl (TES) ether, which has been shown to be more stable to acid hydrolysis then the 
TMS ether. The first attempt carried out at rt overnight, and the second was carried 
out at 30 °C, under a N2 atmosphere, with further equivalents of TESCl being added 
in an attempt to push the reaction. Both reaction mixtures were then subjected to 
acetylation, using Ac2O. Under both conditions the reaction was unsuccessful, and 
no recovery of acetylated product was obtained (Table 4.2). The starting material 4.7 
is water soluble, and so may have been lost during the work-up. 
Some alternative alcohol protecting groups were also investigated. Fmoc protection 
of alcohols has been successfully utilised in the literature.
[192]
 Entry 5 details the 
protection of the C-6 position as an Fmoc carbonate. This was carried out using 
FmocCl, in the presence of pyridine. The desired product was not obtained, but 
again, the acetylated pyridine side-product, 4.8 was observed. Protection of alcohols 
as methoxy-methyl (MOM) ethers has been described in the literature.
[193]
 Entry 6 
shows this protection which was carried out using MOMBr, in the presence of 
K2CO3, followed by acetylation using Ac2O. No sugar derivative was isolated after 
the reaction (Table 4.2).  
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As will be discussed in chapter 5 in more detail, the deprotected sugar 4.7, obtained 
as described in Scheme 4.3, seemed to be unreactive, even with excess amounts of 
reagents. It is thought that H2O or hydroxide salts remained from the previous 
deprotection step, and interfered with the introduction of protecting groups.  
4.3     Differential Protection of the C-6 Position of 3.4  
The various conditions investigated above for functionalisation of the glycosyl 
derivatives failed to deliver the desired products. The reactions which produced the 
desired product were not reproducible, and the yields were very low. The presence of 
a sterically large group at the C-6 position may compromise the glycosylation step, 
and also there are several additional synthetic steps, in which the compatibility of the 
C-6 protecting group would have to be accounted for, in order to reach the desired 
building block. Optimisation of these reactions would not guarantee that the same 
conditions would work on the glycosylated serine building block 3.4. For these 
reasons it was decided to continue the rest of the investigations on the N-Fmoc 
protected building block 3.4. Direct functionalisation at the C-6 position of 3.4 was 
investigated. This strategy is more challenging, as there are several other protecting 
groups present in the molecule which need to be considered, for example, the base 
labile N-Fmoc group. 
4.3.1     Optimisation of Deprotection Conditions of 3.4  
Selective O-deacetylation of 3.4 was attempted under mild conditions of 
MeOH/H2O/Et3N, followed by reaction with TrCl in the presence of DMAP, 
followed by acetylation with Ac2O. This reaction was not successful, with no 
identifiable products isolated. The deprotection was also investigated with slightly 
harsher conditions of 0.1 M NaOH in MeOH, followed by protection with 
TBDMSCl in the presence of imidazole, and acetylation using Ac2O (Scheme 4.4). 
This reaction did not proceed either, with recovery of some of the acetylated starting 
material, and again the appearance of the acetylated pyridine side-product 4.8. This 
compound has been identified in several of these attempted functionalisation 
reactions, even with different protecting groups and sugar derivatives. Perhaps this is 
a reason why, often, even the acetylated product was not isolated. 
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Scheme 4.4 Attempted functionalisation of the C-6 position. Reagents and conditions: i) a) 
MeOH/H2O/Et3N 40 °C, overnight; b) TrCl, DMAP, pyr, rt overnight; c) Ac2O, rt, overnight; ii) a) 
0.1 M NaOH, MeOH, 1 h, rt; b) TBDMSCl, imidazole, pyr, rt, overnight; c) Ac2O, rt, overnight 
It was unclear if the initial deprotection had been carried out, or if the sterically 
hindered protecting groups could not be incorporated into the glycosylated serine. It 
was postulated that the problems encountered with the introduction of trityl or 
TBDMS protection into the C-6 position of 3.4 may have been due to a failure to 
deprotect the O-acetyl groups, without degradation of the glycoside. On review of 
the results obtained, it was decided to try to isolate the deprotected glycoside to 
ensure that deprotection of the O-acetyl groups was being achieved. 
O-Deacetylation of 3.4 was investigated under various different conditions outlined 
in Tables 4.3 and 4.4 below (Scheme 4.5). A more attractive synthesis would involve 
selective deprotection of the primary acetyl only (4.11), and several methods were 
also investigated in an attempt to achieve this. 
 
Scheme 4.5 Deprotection of 3.4. Reagents and conditions: i) As outlined in Tables 4.3 and 4.4 
4.3.2     Enzymatic Deacetylation Methods 
Enzymatic methods of deacetylation have shown great success in the literature, and 
display selective deprotection in the presence of other groups with similar chemical 
reactivity.
[194]
 The family of enzymes which has demonstrated selectivity for the 
removal of acetyl groups from sugar derivatives are known as lipases. There are 
many different kinds of lipase, depending on where they have been isolated from. As 
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with all enzymes, the catalytic ability of lipases is very dependent upon the structure 
of the substrate, and, normally, a panel of lipases are tested. A representative sample 
of two lipases was chosen for this investigation. The enzymes which we used are 
Candida antarctica lipase (CAL B), which is immobilised on a solid support, 
making purification easier, and Candida rugosa lipase (CRL), which is not 
immobilised. These lipases were selected as they have both shown selective 
deacetylation of primary acetyls in carbohydrate substrates.
[194-196]
 The desired 
product of these enzymatic deacetylations is 4.11, where only the primary acetyl has 
been deprotected. Table 4.3 shows the enzymatic deacetylation conditions which we 
investigated. 
Entry Enzyme Conditions 
1 CAL B THF, n-butanol, 20 →50 °C, 2 days 
2 CAL B Ethanol, n-butanol, 20 →50 °C, 2 days 
3 CAL B Ethanol, PBS (tablet), pH 7, 20 →50 °C, 2 days 
4 CAL B THF, PBS (tablet), pH 7, 20 →50 °C, 2 days 
5 CAL B ACN, phosphate buffer, pH 4.5, 25 °C days → 45 °C 2 
days 
6 CAL B Ethanol, phosphate buffer, pH 4.5, 37 °C, overnight 
7 CRL ACN, phosphate buffer, pH 4.5, 25 °C days → 45 °C 2 
days 
8 CRL Ethanol, phosphate buffer, pH 4.5, 37 °C, overnight 
Table 4.3 Investigation of enzymatic deacetylation 
Entries 1 and 2 detail the reaction carried out using Candida antarctica lipase, in 
THF and ethanol, respectively, with the addition of n-butanol. Work carried out by 
Singh et al demonstrated the selective deacetylation of a primary acetyl in the 
presence of a secondary one under these conditions. The reactions were carried out 
on nucleosides, and n-butanol is added as an acetyl acceptor.
[197]
 Enzymatic activity 
is closely related to temperature in many cases, and so a temperature range of 20-50 
°C was used. Full recovery of starting material, 3.4, was achieved. Enzymatic 
reactions can also be effected by the pH of the environment,
[198]
 and so these 
reactions were repeated using phosphate buffered saline (PBS), which was made up 
from a tablet to a specific volume, and was pH 7. The conditions are shown in entries 
3 and 4. The reaction did not proceed, with full recovery of starting material. As pH 
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plays such an important role in enzymatic reactions, more carefully monitored 
reactions were carried out, using a freshly made up phosphate buffer, pH adjusted to 
4.5. Entries 5 and 6 show these reaction conditions using CAL B, in ACN and 
ethanol, respectively. The reaction was unsuccessful, with full recovery of starting 
material. This lipase did not appear to be selective for glycosyl derivative 3.4, and 
another lipase, Candida rugosa lipase, was investigated. Entries 7 and 8 detail the 
use of this enzyme, in ACN and ethanol, respectively, over a range of temperatures. 
This lipase did not show activity with our sugar, and resulted in full recovery of 
starting material, 3.4. Neither of the two lipases tested showed specificity for 3.4 
(Table 4.3). 
4.3.3     Chemical Deacetylation Methods 
As the enzymatic methods were unsuccessful, some chemical deacetylation 
conditions were investigated. Deprotection of 3.4 was carried out using 
MeOH/Et3N/H2O at 40 °C overnight. Examination of the 
1
H NMR data did not yield 
a clear conclusion as to the results of this reaction. TMS-protection of all of the 
hydroxy groups was attempted from this crude product, but this was not successful, 
with the NMR data indicating that some kind of degradation had occurred (Scheme 
4.6). This degradation had, most likely, occurred at the deacetylation stage, with 
removal of the base sensitive N-Fmoc group. 
 
Scheme 4.6 Attempted deacetylation of 3.4 under mild conditions. Reagents and conditions: i) 
MeOH/Et3N/H2O, 40 °C, overnight; ii) TMSCl, pyr, DIPEA, overnight, rt 
In the literature many different methods of chemical deacetylation have been 
described.
[198]
 Several of these strategies were investigated in the hydrolysis of the 
acetyl groups of glycoside 3.4, and these are described in Table 4.4. The structures of 
the various reaction products have been depicted earlier, in Scheme 4.5. 
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Entry Reagents Conditions Outcome 
1 DIPEA/H2O/MeOH Overnight, rt 4.14 
2 KCN, MeOH KCN 5 eq, rt, 
overnight 
4.15 
3 KCN, MeOH KCN 3 eq, 0 °C, 2 
h 
Not conclusive from 
NMR, acetyls still 
present 
4 DBTO, MeOH DBTO 1 eq, 50 °C, 
3 h → rt, overnight 
→ 50 °C, 3 h 
Starting material, 3.4, 
still present. Presence of 
4.13 observed 
5 i) Zeolite clay, 
MeOH, DCM 
iii) AcCl 
i) rt, overnight 
ii) 50 °C overnight 
iii) AcCl 0.2 eq 
Full recovery of starting 
material, 3.4 
 
6 pTsOH, DCM, 
MeOH 
i) pTsOH 1 eq, 3 h, 
rt 
ii) pTsOH extra 1 
eq, overnight, rt 
i) Starting material, 3.4 
ii) Starting material, 3.4. 
Minor presence of 
various deacetylation 
products 
7 AcCl, MeOH i) AcCl 0.1 eq, 3 h, 
rt 
ii) AcCl extra 0.1 
eq, overnight 
iii) AcCl extra 0.2 
eq, overnight 
i) Starting material, 3.4 
ii) Starting material, 3.4 
iii) Starting material, 3.4 
8 AcCl, MeOH i) AcCl 0.5 eq, 
overnight, rt 
ii) AcCl extra 0.5 
eq, overnight, rt 
Minor presence of 4.13. 
Starting material, 3.4 
detected. 
Various deprotection 
products observed. 
9 AcCl, MeOH AcCl 5 eq, 
overnight, rt 
4.13, 4.12, and various 
deprotection products 
observed. 
Table 4.4 Various methods investigated for the chemical  O-deacetylation of 3.4 
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The basic conditions which have been described previously resulted in a loss of the 
N-Fmoc protecting group, and so alternative strategies were investigated. The N-
Fmoc group has been demonstrated earlier to be stable to DIPEA, in an overnight 
reaction during solid phase peptide synthesis. Reaction conditions of 
DIPEA/MeOH/H2O were investigated for the O-deacetylation of glycoside 3.4 
(Entry 1). N-Fmoc deprotection was indicated by a red stain on the TLC in the 
presence of ninhydrin. The 
1
H NMR spectrum indicated deprotection of the O-acetyl 
groups, with the benzyl ester protection remaining intact (4.14) (Table 4.4). 
The use of KCN as a milder method of acetyl hydrolysis has been described.
[199]
 
Entries 2 and 3 show the reaction being carried out using KCN and MeOH. The first 
attempt at this involved 5 eq of KCN, and this appeared to cause hydrolysis of the 
acetyl groups, and also the benzyl ester and N-Fmoc groups. The reaction was 
repeated at 0 °C, with 3 eq of KCN. The 
1
H NMR spectrum of this reaction was 
unclear, but deprotection of the benzyl ester looks to have occurred, indicated by the 
disappearance of the characteristic aromatic protons at approx. 7.3 ppm, with the 
Fmoc and acetyl peaks still present (Table 4.4).  
Entry 4 shows the conditions for deacetylation using dibutyltin oxide (DBTO). This 
procedure has been demonstrated in the literature, for deprotection of glucose 
derivatives.
[200]
 The result of this reaction was partial O-deacetylation, and removal 
of the benzyl ester group. The N-Fmoc group remained intact, and some starting 
material was observed (Table 4.4). 
Entry 5 details the use of a zeolite clay for deacetylation. Zeolite is a catalyst which 
has been used in mild hydrolysis reactions.
[201]
 The type of zeolite which was used in 
this reaction is called montmorillonite K-10. The reaction was unsuccessful, with full 
recovery of starting material, glycoside 3.4 (Table 4.4). 
Entry 6 details the reaction carried out using para-toulenesulfonic acid (pTsOH). 
The hydrolysis of O-acetyl groups by this method has been described in the literature 
for glucose derivatives.
[202]
 For our sugar, there appeared to be some deprotection, 
but mainly starting material, glycoside 3.4, was recovered (Table 4.4). 
The cleavage of O-acetyl groups of glucosamine derivatives with acetyl chloride 
(AcCl) and MeOH has been described by Jung et al.
[203]
 Entry 7 shows the details of 
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how this was attempted with our sugar, 3.4, in the presence of 0.1 eq of AcCl in 
MeOH. This low equivalence of AcCl was used to investigate if selective 
deprotection of the primary alcohol could be carried out in the presence of the 
protected secondary alcohols. The reaction did not proceed after 3 h, and so a further 
0.1 eq of AcCl was added, and allowed to stir overnight. No change was observed by 
TLC, and a further 0.2 eq of AcCl was added (0.4 eq in total). This did not have any 
effect on the sugar, with the starting material, 3.4, being recovered in full. On further 
examination of the literature, it was observed that Yeom et al carry out the 
hydrolysis of O-acetyl groups in the presence of benzyl esters, at 0.15 eq of AcCl. In 
the same work, deacetylation at different positions of glucose and galactose 
derivatives was carried out, but required a slightly higher equivalence of AcCl, 0.3 
eq.
[204]
 Entry 8 details the attempted hydrolysis of the acetyl groups using 0.5 eq of 
AcCl in MeOH. The reaction was allowed to stir overnight, and TLC analysis 
indicated partial deprotection had occurred, but still showed the presence of some 
starting material. An extra 0.5 eq of AcCl was added. This reaction resulted in partial 
deprotection of the alcohols and removal of the benzyl ester group. In order to 
investigate if a large excess of AcCl would facilitate deacetylation, 5 eq of AcCl in 
MeOH was added to the sugar. This is described in entry 9, which shows that 
deprotection of the alcohols was successful, leaving the NHAc intact, but also caused 
the hydrolysis of the benzyl ester protecting group, resulting in what was thought to 
be glycoside 4.13 (Table 4.4).  
4.3.4     Introduction of Azide Functionality at C-6 of Glycosylated Serine 
Building Block 
On review of the above deacetylation reactions, we observed that the selective 
removal of the acetyl esters, in the presence of the benzyl ester, was difficult to 
achieve. Therefore, a new scheme was devised. From compound 3.4, hydrogenolysis 
of the benzyl ester protecting group was carried out, using Pd/C and H2, to give the 
free acid 3.5, which was earlier used for glycopeptide synthesis. This was carried out 
to encourage the formation of a single product upon reaction with AcCl, which was 
the method of deacetylation that had shown the most promising results. The free acid 
3.5 was then treated with an excess of AcCl in MeOH. Although, using these 
conditions, full removal of the O-acetyl groups was achieved, the product of this 
reaction was found to be methyl ester, 4.17. This product was identified by a distinct 
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signal in the 
1
H NMR spectrum which was attributed to the methyl ester CH3, and 
confirmed by MS. On review of 
1
H NMR data from the previous deacetylation 
reactions involving AcCl, as described in Table 4.4, the mild conditions in entry 8 
did not result in formation of the methyl ester. The conditions described in entry 9, 
however, did produce the methyl ester 4.17, among a mixture of products, including 
the benzyl ester, 4.12, and the free acid, 4.13.  
Compound 4.17 was then selectively tosylated at the C-6 position of the sugar 
moiety, by reaction with tosyl chloride at 0 °C, to give glycoside 4.18. The next 
stage in the synthesis was the conversion of the tosyl group to an azide functionality, 
using NaN3 in DMF (Scheme 4.7). These conditions have been shown in the 
literature to be compatible with functionalised GlcNAc derivatives.
[205, 206]
 For our 
sugar, this reaction was not successful, and several degradation products were 
observed. The main product of this reaction had undergone Fmoc cleavage under 
these standard reaction conditions, but otherwise still contained the sugar and serine 
moieties, with the NHAc and OMe groups still intact. Further analysis of this 
compound by IR revealed an absorbance band at 2101 cm
-1
 which indicated that the 
azide had indeed replaced the tosyl group.
[207]
 The conditions required to introduce 
an azide into the C-6 position proved to be too harsh in the presence of the Fmoc 
protecting group. The Fmoc protection is needed if this building block is to be 
suitable for introduction into a glycopeptide, using SPPS methodologies. 
 
Scheme 4.7 Attempted introduction of an azide functionality at the C-6 position. Reagents and 
conditions: i) AcCl, MeOH, overnight, rt, 89 %; ii) TsCl, pyr, 0 °C → rt, overnight, 24 %; iii) NaN3, 
DMF, 75 °C, 2.5 h 
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There is precedence of a linker attached azide being incorporated into a peptide 
molecule for use in biological systems, and so this approach was considered.
[208]
 The 
linker attached azide used in this synthesis was 3-azido-propionic acid, 4.21. This 
was synthesised, following literature procedures, via a substitution reaction from 3-
bromopropionic acid, 4.20, using an excess of NaN3 (Scheme 4.8).
[209]
 
 
Scheme 4.8 Synthesis of linker attached azide 4.21. Reagents and conditions: i) NaN3, MeCN, 
reflux, 3 h, 36 % 
In order to introduce this azide linker into the sugar moiety, the free hydroxy groups 
at the C-3 and C-4 positions needed to be protected to prevent unwanted coupling 
reactions. Fernández et al have shown that trimethyl silyl (TMS) ether protection at 
the C-6 position can be selectively removed in the presence of other TMS groups in 
glucose. This strategy would be compatible for the introduction of the azide 
functionality.
[210]
  
The hydroxy groups of 4.17 were TMS protected, using TMSCl in the presence of 
HMDS, resulting in 4.22. The primary TMS group at the C-6 position of the sugar 
was selectively deprotected, using AcOH, to give 4.23. Using standard coupling 
conditions of TBTU/HOBt in the presence of DIPEA, introduction of the linker 
attached azide, 4.21, into the C-6 position of 4.23 was attempted. However, this 
experiment was not successful, with recovery of 4.17 as the main product (Scheme 
4.9), with no evidence of compounds 4.22 or 4.23. 
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Scheme 4.9 Attempted synthesis of C-6 functionalised 4.24. Reagents and conditions: i) 
TMSCl, HMDS, pyr, 0 °C → rt, overnight, 90 %; ii) AcOH, acetone:MeOH, 0 °C → rt, 7 h, 67 
%; iii) TBTU, HOBt, DIPEA, 4.21, overnight, 0 °C → rt 
Introduction of the azide functionality was also investigated with alternative 
conditions, using DCC as the coupling reagent, in the presence of DMAP (Scheme 
4.10). The product of this reaction was a complicated mixture of products, due to the 
presence of the labile TMS ethers. Some of the desired product, 4.25, was isolated 
from the reaction mixture, with the major product found to be 4.23. The yield of this 
reaction could be greatly improved by increasing the reaction time, for this 
investigation a reaction time of 5 h was allowed, due to the base sensitivity of the 
Fmoc group. No product was found in which the Fmoc group had been deprotected 
during this reaction, and so the DCC mediated coupling seems to be more suitable 
for the formation of 4.24. 
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Scheme 4.10 Introduction of the linker attached azide under DCC coupling conditions. 
Reagents and conditions: i) DCC, DMAP, DCM, 4.21, 0 °C → rt, 5 h, 9 %; ii) 2 % TFA in DCM; 
iii) LiI 
From 4.25, the remaining TMS ethers can be removed with a 2 % solution of TFA in 
DCM. Following this, the acid could be deprotected, using LiI.
[211]
 LiI is anticipated 
to be selective for the methyl ester, and should not hydrolyse the ester bond linking 
the azide to the sugar. These mild deprotection conditions are also suited to the 
presence of the sensitive glycosidic bond. This acid should be ready for introduction 
into a glycopeptide, using SPPS techniques. This functionalised carbohydrate 
derivative would present the opportunity to introduce many different biologically 
relevant moieties into the C-6 position, such as phosphates or aromatic group. This 
may modulate the activity of compounds containing this building block. This type of 
functionalisation may be beneficial in the case of GSK-3. It is known that GSK-3 has 
a binding site for ATP, and many aromatic compounds take advantage of this to 
increase their affinity for the kinase. GSK-3 also has a binding pocket for the 
phosphate portion of ATP, and introduction of a phosphate, or phosphonate, would 
also have the potential to increase the binding affinity of the glycopeptide for GSK-
3. As ATP-competitive inhibitors are often not as kinase selective as those which are 
non-competitive, a combination of a peptide, substrate based sequence, which also 
contains the added binding affinity of the ATP site, may be a successful candidate.  
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4.4     Chapter Conclusion 
Important progress towards the synthesis of building block 4.27 was achieved. 
Selectively functionalised glycoside, 4.27, could be incorporated into a glycopeptide 
using standard SPPS conditions. Many problems were encountered throughout this 
synthesis. The first difficulty was met when attempting to introduce a selective 
orthogonal protecting group into the C-6 position of compound 4.1. This was mostly 
unsuccessful, and, when the desired product was produced, the results were not 
reproducible.  
These problems were not overcome when using the benzyl glycoside, 4.7. Side 
products, such as acetyl pyridinium derivative 4.8, were obtained and identified from 
these attempts. When working with the serine-glycosylated derivative, 3.4, 
incomplete hydrolysis of the O-acetyl groups presented some difficulty. Several 
different deacetylation reactions were investigated, with the use of AcCl in the 
presence of MeOH found to be the most successful method. From the deprotected 
glycoside, 4.16, it was attempted to introduce an azide functionality into the C-6 
position. This did not prove successful, with removal of the Fmoc group occurring. 
Finally, a linker attached azide was investigated. Standard coupling conditions of 
TBTU/HOBt were not found to be suitable for this reaction, with none of the desired 
product being isolated. Alternative coupling conditions of DCC did produce the 
TMS protected building block, 4.25. The yield of this reaction could be improved 
with longer reaction times. 
For future work, this azide containing glycoside can be incorporated into a 
glycopeptide sequence, and the affinity of a kinase, like GSK-3, for this glycopeptide 
can be compared to that of the non-functionalised derivative. 
From work carried out in chapter 5, on a glycosyl-dopamine prodrug, it is thought 
that perhaps a similar approach would be best for introducing an azide into the C-6 
position. Building from a TMS protected glycoside, which has not been 
functionalised with Fmoc protected serine, may allow for introduction of the azide 
under harsher conditions.   
 
 
Chapter 5: The Synthesis of a Glycosylated-Dopamine Prodrug 
Page | 108  
 
Chapter 5: The Synthesis of a Glycosylated-Dopamine 
Prodrug 
5.1     Introduction: Prodrugs 
5.1.1     What is a Prodrug 
A prodrug is a drug which does not have any biological effect, but, once 
administered, will be transformed into a biologically active molecule by metabolic 
reactions in the body. It has been defined as a bioreversible derivative of a drug 
molecule, which will undergo enzymatic or chemical transformation in-vivo to give 
the active drug.
[212]
 Several therapeutically important substances are degraded too 
quickly by the body, or are not delivered to the area where they are needed. 
Disguising these substances in the form of a prodrug can reverse these drawbacks. 
The use of prodrugs has become widespread in the pharmaceutical community, 
including many drugs which are currently on the market. A prodrug must possess 
specific properties: it should not display activity against any pharmaceutical target, 
have high aqueous solubility, be resistant to hydrolysis during the absorption phase, 
be converted into the active drug once it has reached the target location, and any 
groups which are cleaved must be non-toxic.
[213]
 For these reasons, glycosylation has 
become the modification of choice for many products. Examples of glycosylated 
prodrugs are Fabrazyme
®
, which is a treatment for Fabry disease, and also Rebif
®
 
which is used in the treatment of multiple sclerosis.
[214]
 
5.1.2     Improving the Pharmacokinetic Properties of a Drug 
Several advancements have been made in the discovery of new drug treatments. The 
disadvantage is that some of these drugs, especially those which are peptides or 
proteins, display a poor pharmacokinetic profile. Potential drug candidates will 
display good pharmacodynamic properties, but this is not enough to ensure the 
desired response. The pharmacokinetic properties of a compound are an important 
consideration in drug design. This refers to processes like absorption, distribution, 
metabolism, and excretion. Many therapeutics can undergo elimination from the 
body, even before they have had any benefit. This elimination is facilitated by 
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processes such as enzymatic degradation, renal filtration, and liver clearance. 
Accumulation within tissues can also remove the drug from the bloodstream.
[215]
 
One example of a modification carried out on peptide drugs is PEGylation (Fig. 5.1). 
Poly-ethylene-glycol (PEG) has been shown to alter the pharmacokinetic and 
biodistribution properties of protein conjugates. It appears to prolong the life of the 
drug in the body, and to enhance localisation of the drug to specific disease sites. It 
does this in a number of ways, such as size enlargement of the molecule, disguising 
the peptide from glycosylation or other surface modifications which would ordinarily 
occur, and by charge modification. Size enlargement has been demonstrated to slow 
down kidney filtration, allowing the drug more time to reach the target area. The 
prevention of chemical transformations, such as glycosylation, can alter targeting of 
the drug by the immune system, also allowing the drug to have a longer half-life.
[216]
 
 
Figure 5.1 Poly-ethylene-glycol 
Khondee et al have shown that complexation of Keratinocyte Growth Factor-2 
(KGF-2) with PEGylated polyanions has a stabilising effect. KGF-2 is a heparin-
binding protein which has potent regenerative properties. The disadvantage of using 
KGF-2 as a therapeutic is that it unfolds and aggregates at approximately 37 °C. It 
was observed that once KGF-2 had been complexed with the PEGylated polyanions, 
dextrin sulphate or pentosan polysulphate, the melting temperature of the protein was 
increased by 9-17 °C.
[217]
 
5.2     Glycosylation can Enhance Pharmacological Profile of Drugs 
5.2.1     Glycosyl Prodrugs 
Glycosylation has been shown to alter the pharmacokinetic and pharmacodynamic 
profiles of drugs. Attachment of a sugar moiety can increase the amount of drug that 
reaches the target area, for example, via transporters such as the glucose transporter 
(GLUT 1-4). It can also reduce the toxicity of some drugs, allowing a higher dose to 
be administered.
[218]
 Glycosylation of drugs has allowed for targeted delivery to the 
desired site, for example in the treatment of lysosomal diseases, like Gaucher and 
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Fabry disease. The active drug is transported, via receptor-mediated endocytosis, to 
the lysosome, after targeting specific mannose-6-phosphate receptors. This targeting 
is achieved by glyco-engineering of the active proteins to express either mannose or 
mannose-6-phosphate at their termini. While not strictly a prodrug, this illustrates 
how glycosylation could be used to enhance a drugs pharmacological profile.
[214]
 
Larrosa et al have synthesised several glycosyl prodrugs based on the naturally 
occurring polyphenol, reservatol (Fig. 5.2). Reservatol has shown anti-inflammatory 
activity, and has become of interest in the treatment of inflammatory bowel diseases 
(IBD). While reservatol shows promise as a therapeutic due to its pharmacodynamic 
properties, the pharmacokinetic profile is not as attractive. Reservatol is rapidly 
metabolised in the body, lessening its efficacy in the colon. It was found that, by 
conjugating a sugar moiety, this rapid metabolism was prevented, allowing the 
reservatol prodrug to reach its target site, the colon.  An added effect of 
glycosylation was a reduction in mucosal barrier imbalance, preventing diarrhea in 
the subjects, again increasing the amount of active drug which could act on the colon 
tissue.
[219]
 
 
Figure 5.2 Glycosyl reservatol prodrug (Reservatol portion shown in red) 
Glycosyl prodrugs have also been developed for the selective treatment of cancer. 
Duocarmycin is an antibiotic chemotherapeutic, but cannot be administered in high 
enough doses to be effective, without adverse side-effects. Tietz et al have developed 
glucosylated duocarmycin prodrugs which are effectively delivered to the cancer 
tissue through an antibody-directed enzyme prodrug therapy (ADEPT) approach. 
The conjugation of the sugar moiety allowed for localisation of the prodrug in the 
tumor tissues, where the active drug was released through enzymatic hydrolysis of 
the glycosidic bond. The duocarmycin exhibited cytotoxic effects on the cancer 
cells.
[220]
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5.2.2     Barriers to the Treatment of CNS Disorders 
The uptake of solutes into the brain is controlled by the BBB. It separates the central 
nervous system (CNS) from the rest of the systemic circulation, and is the “gate-
keeper” of the brain. The BBB plays a vital role in maintaining homeostasis, 
allowing nutrients into the brain, and protecting the brain from harmful 
substances.
[221]
 The blood capillaries which feed the brain are lined with tight-fitting 
cells, which, unlike other capillaries in the body, do not contain any pores. In 
addition, these cells are covered with a fatty layer, formed by nearby cells. Together, 
this results in the BBB being an effective barrier to substances which may be 
harmful to the brain. In order to enter the brain drugs must be able to pass through 
the fatty cells coating the capillaries, and also though their poreless cell 
membrane.
[222]
  
The treatment of many brain related diseases has been hampered by the inability of 
substances, known to alleviate symptoms, to cross the BBB. It has been estimated 
that 98 % of small-molecular weight drugs, and 100 % of large-molecular weight 
drugs, which have been developed for the treatment of CNS diseases do not readily 
cross the BBB.
[223]
 Many drugs which have shown CNS activity have been discarded 
in the early trial stages, due to their inability to reach their target.
[224]
 
The BBB allows nutrients to enter the brain through transport channels, for example 
the large neutral amino acid transporter (LAT-1) and glucose transporters (GLUT 1-
4) carriers, or by receptor-mediated transport, like insulin. By administering the 
active substance as a prodrug, these transport mechanisms can be exploited to deliver 
the drug into the brain, where the prodrug is broken down into the active substance, 
and a harmless by-product, for example a sugar (Fig. 5.3).
[212]
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Figure 5.3 Illustration of prodrug transport across the BBB 
5.2.3     GLUT Transporter  
One mechanism of glucose delivery across membranes is via the GLUT carrier, and 
there are several different sub-types of this transporter (GLUT 1-4). The transporter 
which has been associated with glycosyl dopamine prodrugs is GLUT-1, which 
carries glucose and other hexoses through the BBB into the brain. The large energy 
demand of the brain is primarily satisfied by glucose, but, in the mammalian brain, 
the cells do not keep a large storage of glycogen. In order to maintain healthy brain 
function there must be a mechanism to take in glucose across the BBB. Cellular 
diffusion of glucose does not occur at any of the membranes in the body, and, as the 
BBB is no exception, a carrier is required to deliver it to the brain. This process is 
carried out by the GLUT-1 transport protein, in a regulated manner. The uptake of 
glucose is very close to the amount of glucose utilised in maintaining brain function. 
GLUT-1 has the highest transport capacity of all the carrier-mediated transporters at 
the BBB.
[225]
 The GLUT transporter generally associated with glucosamine is the 
GLUT-2 carrier.
[226]
 There has also been evidence to demonstrate that a decrease in 
GLUT-1 and GLUT-3 in the BBB is associated with AD and diabetes. This has been 
shown to correlate to a decrease in the level of O-GlcNAcylation of proteins in the 
brain.
[227]
 
This well characterised transporter has been investigated for the delivery of CNS 
active compounds across the BBB.  
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5.2.4     Glycosylated Prodrugs for CNS Targeting 
Work carried out by Gynther et al investigated the ability of glyco-conjugates to 
cross the BBB via GLUT-1. The drugs which they studied were Ketoprofen and 
Indomethacin, which were modified with D-glucose using a bioreversible ester 
linkage (Fig. 5.4). They found that the glyco-conjugates did bind to GLUT-1, and 
also that the prodrug was detected in brain tissue. To further prove that the method of 
delivery to the brain was through GLUT-1 transport, glucose was added to the 
perfusion medium. It was found that this decreased the amount of prodrug which was 
detected in the brain tissue, showing that both D-glucose and the glyco-conjugate 
shared a transport mechanism. These prodrugs were shown to be susceptible to 
hydrolysis by rat brain homogenate, to give glucose and the active substance.
[228]
 
 
Figure 5.4 Ketoprofen glyco-conjugate (Ketoprofen portion shown in red) 
Some studies have shown that GLUT-1 is a bidirectional transporter, mediating both 
blood to brain, and brain to blood transportation of hexoses. This may limit the 
effectiveness of some prodrugs, with elimination from the brain before hydrolysis 
and release of the active drug can occur.
[229]
 In order to investigate if a complex kind 
of linkage would prevent this bidirectional transport from occurring, Fan et al 
synthesised an array of glucosyl thiamine disulfide prodrugs of naproxen (Fig. 5.5). 
The thiamine disulfide moiety is quickly reduced by the abundant disulfide 
reductase, and ring-closed to a thiazolium once it has entered the brain. This 
thiazolium locks the prodrug into the brain, and renders the GLUT-1 transporter 
unidirectional for this substance. The ester linkage then becomes hydrolysed at a 
slower pace, resulting in a sustained release of the active naproxen. The prodrugs 
synthesised and tested in this study were transported across the BBB, and high levels 
of naproxen were measured in the brain.
[230]
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Figure 5.5 Thiamine disulfide derivatives of naproxen (Naproxen portion shown in red) 
5.3     Dopamine 
5.3.1     The Neurotransmitter Dopamine 
Dopamine is a catecholamine neurotransmitter, which plays many roles in the CNS. 
It is derived from the amino acid tyrosine (Scheme 5.1). Dopamine is involved in 
many processes, including movement, learning, and motivation. Dopamine is a 
precursor in the biosynthesis of norepinephrine and epinephrine (Scheme 5.1). It 
plays a part in the regulation of complex processes such as mood, attentiveness and 
emotion.
[231]
  
 
Scheme 5.1 Catecholamine biosynthetic pathway. i) Tyrosine hydroxylase; ii) Aromatic L-amino 
acid decarboxylase; iii) Dopamine β-hydroxylase; iv) Phenylethanolamine N-methyltransferase 
There are two main projections in the brain associated with dopamine; the 
mesolimbic pathway, which can also be activated by most psychoactive substances, 
and the nigrostriatal pathway. Degradation of dopaminergic neurons in the 
nigrostriatal pathway is related to Parkinson’s disease.[232] Five different dopamine 
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receptors are known in the body; D1 – D5. D2 appears to be the main receptor 
involved with Parkinson’s disease. Parkinson’s disease is characterised by a large 
reduction in dopamine levels in the basal ganglia, which occurs as a result of this 
degradation. Dysregulation of dopaminergic activity has also been implicated in 
schizophrenia, with an excessive release of dopamine in the striatum.
[233]
 
Parkinson’s disease is a progressive neurodegenerative disorder, which is 
characterised by a reduction in the levels of dopamine in the brain, as discussed 
above. Symptoms of this disease include tremors, rigidity, slow movement and poor 
balance. As dopamine stimulates the motor neurons involved in muscle movement, 
sufferers of Parkinson’s disease become unable to control movement and 
coordination.
[234]
 Much research has gone into the use of dopamine to treat diseases 
such as Parkinson’s. Dopamine cannot cross the BBB, because of its hydrophilicity 
and the lack of a specific transport system, and so treatment directly with this 
neurotransmitter is not possible, without using intrusive methods.
[235]
 
L-Dopa or Levodopa (L-3,4-dihydroxyphenyl alanine) is the natural precursor of 
dopamine, as illustrated earlier (Scheme 5.1). This has become the prodrug of choice 
in the treatment of the motor impairments of Parkinson’s disease. L-Dopa has the 
ability to cross the BBB though the LAT-1 carrier, and is converted to dopamine in 
the brain. Prolonged treatment with L-Dopa has unwanted side-effects, such as the 
appearance of abnormal involuntary movements (dyskinesia). This has been 
attributed to overstimulation of dopaminergic receptors in the substantia nigra.
[236]
 
Also, L-Dopa can be converted to dopamine in the peripheral tissues, causing 
unwanted side-effects, and reducing the amount of dopamine which reaches the 
brain.
[237]
 New treatments are, therefore, vital to the quality of life of Parkinson’s 
disease sufferers. 
5.3.2     Glycosylation as a Transport Mechanism for Dopamine Delivery 
Fernández et al have synthesised several glycosyl dopamine derivatives as 
antiparkinsonian agents (Fig. 5.6). These prodrugs consist of the active 
neurotransmitter, dopamine, linked to D-glucose through a succinyl linker. The 
compounds contain ester, amide and glycosidic linkages, which can be cleaved by 
enzymes in the brain tissue. The synthesised prodrugs were tested for activity on the 
dopamine D2 receptor, to check if they would be pharmacologically active before 
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enzymatic release of the dopamine molecule. They did not show any binding 
affinity, as expected. This demonstrates that both the amino and phenol groups are 
required for dopamine binding to the D2 receptor. Stability studies were carried out 
to investigate the enzymatic degradation of the ester, amide and glycosidic bonds in 
brain tissue. It was found that the ester bond is cleaved via esterase-catalysed 
hydrolysis, and that the amide bond is then cleaved by amidase or protease activation 
to release dopamine. Glycosidic bonds were broken by glycosidase activity. The 
prodrugs synthesised did not have the desired effect when tested on mouse models of 
Parkinson’s disease. It was thought that either the compounds were not able to cross 
the BBB, or that the bioconversion into dopamine, by enzymatic degradation, was 
occurring too slowly.
[210]
 
 
Figure 5.6 Glucosyl-dopamine prodrugs synthesised by Fernández et al
[210]
 
The same group later synthesised more glycosyl-dopamine prodrugs (Fig. 5.7), 
which also showed affinity for the GLUT-1 carrier. They explored the effects of 
different linkers, or attachment at different positions of the sugar moiety. The 
compound 5.4, containing a carbamate bond, was found not to release dopamine 
when exposed to rat brain tissue. It was thought that perhaps oxidation of the 
catechol ring was happening faster than hydrolysis of the carbamate bond, and so the 
free dopamine molecule was not formed. Glycoside 5.5 exhibited the properties of a 
desired prodrug, in that the dopamine was released upon hydrolysis of the glycosidic 
bond, but did not show affinity for the GLUT-1 carrier. Carbamate 5.6 was the best 
candidate from this study, with a high affinity for GLUT-1, and efficient hydrolysis 
to release dopamine.
[238]
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Figure 5.7 Second generation of glycosyl-dopamine prodrugs synthesised by Fernández et al
[238]
 
Dalpiaz et al have tested the affinity of glucosyl-dopamine, linked at the C-3 
position, for the GLUT-1 transporter (Fig. 5.8). They found that this analogue had a 
greater level of binding to GLUT-1 than some other analogues.
[234]
 
 
Figure 5.8 Glucose-dopamine linked at C-3 
Bonnina et al synthesised some of the same derivatives as Fernández et al, but via a 
different synthetic scheme. They also synthesised the L-Dopa derivatives. It was 
observed that the galactose-dopamine prodrug, 5.7, and the glucose-L-Dopa 
analogue, 5.8, were the best candidates (Fig. 5.9). They were shown to be 
transported across the BBB, utilizing the GLUT-1 carrier, and were hydrolysed in 
brain tissue to release dopamine or L-Dopa. They were active in reducing morphine 
induced locomotion in the mouse model of Parkinson’s.[239] 
 
Figure 5.9 Glycosyl-dopamine derivatives synthesised by Bonina et al
[239]
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Yoon et al have synthesised α-glycosyl-dopamine and α-glycosyl-L-Dopa derivatives 
via enzymatic transglycosylation reactions (Fig. 5.10). The stability profile of these 
compounds under physiological conditions was assessed. It was found that the α-
derivatives were less susceptible to non-enzymatic oxidation than L-Dopa. It was 
postulated that, while the β-anomeric prodrugs synthesised by Fernández et al did 
not induce a strong enough response to be used as therapeutics in Parkinson’s 
disease, the α-anomer might be broken down quicker once it reached the brain. The 
reasoning behind this is that there are more α-glucosidases in the body than β-
glucosidases, and so more dopamine would be released in the brain, over a shorter 
period, than with a β-glycoside. These compounds were not tested for their affinity 
for GLUT-1 in this this study, or their ability to cross the BBB.
[240]
 
 
Figure 5.10 α-Glucosyl-dopamine derivative 
5.3.3     Non-Glycosidic Dopamine Prodrug Approaches 
Alternative approaches utilising other transport mechanisms of the brain have also 
been investigated. 
Trapani et al have used chitosan nanoparticles to encapsulate dopamine. These 
biodegradable carriers have been tested and used to transport anticancer drugs to the 
brain, and so have been shown to be safe. The surface of the chitosan nanoparticle is 
positively charged, and it was hypothesised that this would result in transport across 
the BBB via adsorptive-mediated transcytosis (AMT). This transport mechanism is 
used to allow cationic substances through the BBB. In-vivo experiments on rats 
showed an increase in the levels of dopamine detected in the brain after 
administration of the chitosan/dopamine nanoparticle.
[241]
 
Work carried out by Carafa et al investigated the use of prodrug-loaded liposomes as 
a delivery method. It has been shown that condensation of dopamine with neutral 
amino acids could utilise the LAT-1 transporter to carry the prodrug across the BBB. 
The dopamine prodrug 2-amino-N-[2-(3,4-dihydroxyphenyl)-ethyl]-3-phenyl-
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propionamide (DOPH) employs such a strategy. The downside of DOPH is its low 
bioavailability; it is sensitive to photodegradation, and also to enzymatic 
degradation. DOPH was encapsulated into a liposome made of 
dimiristoylphosphatidylcholine (CMPC). It was found that this process did infer 
protection against photodegradation, and also increased the half-life of DOPH in the 
blood, in-vitro.
[242]
 It is uncertain whether an amino acid linked molecule would be 
able to cross the BBB in patients suffering from Parkinson’s. Ohtsuki et al have 
carried out research into the effect that Parkinson’s has on the BBB transport 
mechanisms. In their mouse model it was observed that the level of substances 
transported via the LAT-1 carrier was severely decreased, while no significant 
decrease was observed in other carriers such as GLUT-1. It was postulated that this 
could be the reason for the low activity of the antiparkinsonian drug levodopa.
[243]
 
5.4     Aim 
The aim of this section was the synthesis and biological evaluation of a novel 
glucosamine-based prodrug, which has potential to improve the pharmacokinetic 
properties of dopamine. This compound includes a succinyl linker bridging the 
dopamine and glucosamine molecules. The target compound 5.9 is shown below 
(Fig 5.11). 
 
Figure 5.11 Glucosamine-based dopamine prodrug 
There were several reasons for selecting GlcNAc as the sugar moiety. Similar 
compounds have been synthesised utilising glucose and galactose to transport the 
dopamine molecule across the BBB, these have been detailed earlier in this chapter. 
We wanted to investigate if a GlcNAc derivative would display an increased affinity 
for the GLUT-1 carrier. Some synthetic carbohydrate receptors have been designed 
by Davis and co-workers, which show an increased affinity for GlcNAc over some 
other sugars, such as glucose.
[244]
 It was postulated that natural receptors may follow 
this trend, perhaps increasing the amount of prodrug, and therefore dopamine, which 
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is transported across the BBB. GlcNAc may also have an alternative mechanism of 
crossing the BBB, which would be more efficient. As mentioned previously, other 
GLUT transporters, including GLUT-2 and -3, have been associated with GlcNAc 
and GlcN. Syntheses of a prodrug involving GlcNAc may therefore be rewarding, 
albeit more challenging. 
5.5     The Synthesis of Glucosamine-Based Dopamine Prodrug 5.9 
5.5.1     The Synthesis of Linker-Attached Dopamine  
Dopamine was attached to a succinic acid linker, following literature procedures.
[210]
 
A succinic linker was chosen as the ester bond between the linker and sugar will be 
easily hydrolysed by enzymes in the brain. The amide bond between the linker and 
dopamine molecules should also be labile, and cleaved in the brain by a protease or 
amidase, as discussed earlier.
[210]
 The first step in this synthesis was the protection of 
the hydroxy groups on the dopamine aromatic ring. Dopamine hydrochloride, 5.10, 
was N-Boc protected using Boc anhydride, in the presence of Et3N. This was carried 
out to prevent the reactive amine from becoming alkylated in the next step. The 
hydroxy groups of the dopamine molecule were then benzylated, by treatment with 
benzyl bromide, in the presence of K2CO3 to give protected dopamine 5.11. The acid 
labile N-Boc group was removed with a 5 % solution of TFA in DCM, resulting in 
the free amine 5.12. This benzyl protected dopamine 5.12 could then carry out 
nucleophilic attack on the carbonyl carbon of succinic anhydride, to give free acid 
5.13 (Scheme 5.2). 
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Scheme 5.2 The synthesis of linker attached dopamine 5.13. Reagents and conditions: i) 
MeOH:Et3N (9:1), Boc anhydride, 1 h, 50 °C; ii) K2CO3, DMF, BnBr, overnight, rt, 43 % over two 
steps; iii) 5 % TFA, DCM, 6 h, rt, 87 %; iv) Succinic anhydride, pyr, 3 h, rt, 82 % 
5.5.2     The Synthesis of Sugar Moiety 5.18 
As mentioned in chapter 4, Fernández et al have used TMS ether protection to 
selectively introduce the succinic acid dopamine derivative, 5.13, into the C-6 
position of glucose and galactose derivatives.
[210]
 According to work by Gervay-
Hague and co-workers, this transformation worked well with most sugars, but, when 
this selective deprotection was carried out on glucosamine, the TMS group at C-1 
was also removed (Scheme 5.3).
[245]
 
 
Scheme 5.3 Selective TMS protection demonstrated by Gervais-Hague and co-workers. 
Reagents and conditions: i) AcOH, Ac2O, pyr,  rt, 48 h 
To avoid unwanted coupling of the dopamine-linker to a free hydroxyl at C-1, it was 
decided to differentially protect the C-1 hydroxy as a benzyl ether. D-Glucosamine 
hydrochloride was N-Troc protected at the amine functionality, by reacting with 
TrocCl, in the presence of NaHCO3, as discussed earlier in chapter 2. This was 
followed by acetylation of the hydroxy groups with acetic anhydride, in the presence 
of pyridine, to give the anomeric mixture of 2.26. The protected glucosamine 2.26 
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was converted into α-glycosyl halide 4.5 by treatment with HBr in AcOH. This 
bromide donor was activated with Ag2CO3, and glycosylation of benzyl alcohol, to 
give 4.6, was carried out. Once the C-1 hydroxy had been orthogonally protected, 
hydrolysis of the acetyl groups was carried out using an aqueous solution of NaOH 
and MeOH, following literature procedures, resulting in 4.7.
[189]
 The deprotected 
glycoside was then TMS protected, using TMSCl in the presence of DIPEA, to give 
5.17. Selective removal of the C-6 trimethyl silyl ether was carried out using AcOH, 
resulting in 5.18 (Scheme 5.4). 
 
Scheme 5.4 Synthetic scheme for glycoside 5.18. Reagents and conditions: i) 33 % HBr/AcOH 
solution, DCM, 3.5 h, 0 °C → rt; ii) AgCO3, DCM, BnOH, overnight, rt, 57 % over 2 steps; iii) 0.1 M 
NaOHaq, MeOH, 1 h, rt, 73 %; iv) TMSCl, pyr, DIPEA, overnight, 0 °C → rt, 35 %; v) AcOH, 
(CH3)2CO, MeOH, 2 h, 0 °C, 72 % 
5.5.3     Synthesis of Glucosyl-Dopamine Prodrug 5.9 
Coupling of the succinic acid dopamine derivative 5.13 to the sugar moiety 5.18 was 
carried out using DCC coupling conditions, resulting in 5.24 (Scheme 5.6). 
Dicyclohexylcarbodiimide (DCC) is a carbodiimide reagent which is often used to 
activate carboxylic acids, especially in peptide coupling.
[246, 247]
 The initial step of 
the coupling reaction is the deprotonation of the acid by a base. This is followed by 
attack on the DCC reagent, 5.20, by this carboxylate, 5.19, to form an activated ester, 
5.21. The activated ester is called an O-acylisourea, and its formation is rapid. The 
carbonyl carbon of 5.21 then undergoes nucleophilic attack by the amine/alcohol 
molecule, to form the amide/ester bond, with elimination of dicyclohexylurea, 5.23, 
as the side product (Scheme 5.5). This side product is insoluble in most solvents, and 
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so purification of the desired product is simple. When used in peptide chemistry, for 
the formation of an amide bond, an additive such as HOBt is generally used to help 
prevent racemisation during the reaction.
[248]
 In our case we are not concerned about 
racemisation, and so HOBt was not required. When this coupling reaction is carried 
out in the presence of DMAP it is known as a Steglich esterification. 
 
Scheme 5.5 Mechanism of ester formation using DCC as the coupling reagent 
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Scheme 5.6 DCC mediated coupling reaction.  Reagents and conditions: i) DCC, DMAP, DCM, 3 
h, rt, 60 % 
Following formation of the ester bond to give 5.24, deprotection of the remaining 
TMS groups was carried out by treating with a 2 % solution of TFA in DCM to give 
5.25. The removal of the N-Troc protecting group was then accomplished using the 
standard conditions of Zn in acetic anhydride. The N-Troc group was successfully 
reduced, but, as well as the amine functionality becoming acetylated, as was desired, 
partial acetylation of the hydroxyl groups was observed (Scheme 5.7). 
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Scheme 5.7 TMS removal, followed by N-Troc reduction. Reagents and conditions: i) 2 % TFA in 
DCM solution, 0 °C, 1 h, 98 %; ii) Zn, Ac2O, overnight, rt; iii) MeOH/H2O/Et3N, 45 °C, overnight 
Hydrolysis of the O-acetyls from 5.26 was attempted using mild conditions of 
MeOH/H2O/Et3N at 45 °C overnight, but no reaction occurred, with full recovery of 
starting material. Mild conditions were required due to the presence of the ester bond 
between the sugar and the succinic linker, which prevented the use of most standard 
deacetylation procedures. 
As this deprotection was posing a problem, removal of the N-Troc group was carried 
out prior to removal of the TMS hydroxy protecting groups (Scheme 5.8). The N-
Troc deprotection was carried out in the presence of Et3N, in an attempt to neutralise 
the Lewis acidic ZnCl2 produced during this reaction, which may have caused 
removal of the TMS groups. Under these conditions, elimination of the TMS groups 
and full acetylation of the free hydroxyl groups was observed, resulting in 5.28.  
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Scheme 5.8 N-Troc deprotection. Reagents and conditions: i) Zn, Et3N, Ac2O, rt, 3 h, 40 %; ii) 
Conditions in Table 5.1; iii) H2, EtOAc/MeOH, overnight, rt, 82 % of 5.29; iv) MeOH/H2O/Et3N, 
overnight, 45 °C 
Selective O-deacetylation was attempted under various different conditions, 
summarised in Table 5.1, but was unsuccessful. Deacetylation carried out using mild 
basic methods of MeOH/H2O/Et3N, shown in entry 1, resulted in recovery of starting 
material. Entries 2 and 3 show the conditions for deacetylation using NaOMe over a 
range of temperatures. Work by Xia et al shows acetyl removal in the presence of a 
pivaloyl ester, at low temperatures using NaOMe,
[249]
 but this did not work for our 
compound. When carried out at very low temperatures of -20 → -15 °C no reaction 
occurred, being confirmed by NMR analysis. When the experiment was carried out 
at higher temperatures of 0 °C, in addition to O-deacetylation of the sugar moiety, 
hydrolysis of the labile ester linkage was observed. Compound 5.34 was isolated 
from the reaction mixture. Entry 4 details this reaction carried out in the presence of 
aqueous NaOH and MeOH, again resulting in hydrolysis of the ester linkage. 
 Enzymatic methods of deprotection have been discussed earlier, in chapter 3. They 
are highly dependent on the structure of the substrate, and usually several different 
enzymes are tested for each compound.
[195]
 Two enzymes were investigated for this 
deacetylation, shown in entries 5 and 6, using Candida rugosa lipase (CRL) and 
Candida antarctica lipase (CAL B) respectively. Neither enzyme had any effect, 
with recovery of starting material.  
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Mild acidic conditions were also investigated, as discussed previously in chapter 3. 
Acetyl chloride has been used for the removal of acetyl groups.
[204]
 When the 
reaction was carried out in the presence of AcCl (entry 7), this resulted in hydrolysis 
of the labile ester linkage, with recovery of deprotected glycoside 5.34.  
Entry Conditions Result 
1 MeOH/H2O/Et3N, 45 °C, overnight Recovery of starting material, 5.28 
2 NaOMe, -20 → -15 °C Recovery of starting material, 5.28 
3 NaOMe, 0 °C Hydrolysis of the ester linkage 
4 NaOHaq, MeOH, 0 °C Hydrolysis of the ester linkage 
5 CRL, phosphate buffer, pH 7.4, 
ACN, 25 → 45 °C 
Recovery of starting material, 5.28 
6 CAL B, ethanol, 45 °C  Recovery of starting material, 5.28 
7 AcCl, MeOH, rt, 2 days Hydrolysis of the ester linkage 
Table 5.1 Conditions investigated for deacetylation 
As an alternative strategy, removal of the benzyl ester protecting groups, under 
standard conditions of Pd/C in EtOAc/MeOH was carried out on 5.28. The benzyl 
protection was easily removed from the hydroxyl groups of the dopamine moiety, 
but the C-1 benzyl protection was not removed under these conditions, resulting in 
5.29. Acetyl deprotection was attempted on this compound using standard conditions 
of MeOH/Et3N/H2O at 45 °C, which had no effect on 5.28. The result was 
degradation of 5.29, with recovery of deprotected glycoside 5.34 (Scheme 5.8).  
As it did not appear to be possible to remove the acetyl groups selectively in the 
presence of the succinate ester linkage, another strategy was considered. From 
compound 5.25, protection of the hydroxy groups with a less labile group than the 
TMS ethers was attempted. The first protecting group investigated was triethyl silyl 
(TES) ether, which is 10-100 times more stable to acid hydrolysis or nucleophilic 
attack than TMS,
[250]
 but this reaction did not proceed, with recovery of starting 
material. Protection as chloro-acetyls was also attempted, but again no reaction 
occurred with recovery of starting material (Scheme 5.9). 
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Scheme 5.9 Protection of hydroxy groups. Reagents and conditions: i) TESCl, imidazole, DMF, rt, 
overnight; ii) AcCl2, pyr, 0 °C → rt, overnight  
N-Troc deprotection at a later stage in the synthesis had proven problematic, and so 
an alternative strategy was devised. Removal of the N-Troc group was carried out at 
a much earlier stage, before introducing the succinic acid dopamine derivative 5.13. 
N-Troc deprotection from 4.6 was carried out, as before, using Zn and acetic 
anhydride, to give 5.33. Deacetylation was carried out in the presence of aqueous 
NaOH and MeOH, to give the deprotected sugar 5.34, which was used as a crude. 
TMS protection of the free hydroxyl groups was attempted, as described earlier, for 
the N-Troc protected sugar (Scheme 5.10). This reaction did not proceed, with 
recovery of starting material in the aqueous layer of the wash. The experiment was 
repeated with more equivalents of TMSCl, but was still unsuccessful. Imidazole is a 
common base used in silyl ether protections.
[250]
 The experiment was then carried out 
in the presence of imidazole, but again, the starting glycoside 5.34 was recovered. 
 
Scheme 5.10 Synthesis of TMS protected glycoside 5.35. Reagents and conditions: i) Ac2O, Zn, 
Et3N, 5 h, rt, 71 %; ii) 0.1 M NaOH, MeOH, 1 h, rt, 80 %; iii) TMSCl, DIPEA, pyr, overnight, 0 °C 
→ rt 
The lack of reactivity of 5.34 was surprising as this compound appears in the 
literature, and is involved in reactions at the hydroxyl groups.
[251]
 The difficulty 
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experienced may have been due to hydroxide salts still present from the 
deacetylation step, which were interfering with the reactions. 
An alternative preparation of 5.34 was followed, according to literature procedures, 
starting with N-acetyl glucosamine 5.36.
[46]
 From this compound, 5.36, the anomeric 
position was selectively protected as the benzyl ether, using 1.2 equivalence of BnBr 
in the presence of NaH, to give 5.34. TMS protection of the free hydroxyl groups 
was then achieved using TMSCl, in the presence of DIPEA in pyridine, to give 5.35. 
This reaction was also carried out using hexamethyldisilazane (HMDS) as the base, 
which resulted in improved yields (44 → 74 %). Selective removal of the TMS ether 
at C-6 was carried out in the presence of AcOH, resulting in an anomeric mixture of 
5.37 (Scheme 5.12).  
 
Scheme 5.12 Synthesis of glycoside 5.37. Reagents and conditions: i) BnBr, NaH, 4 h, 0 °C, 78 %; 
ii) TMSCl, HMDS, pyr, overnight, 0 °C → rt, 74 %; iii) AcOH, MeOH, (CH3)2CO, 0 °C, 2 h, 86 % 
The glycoside 5.37 was then coupled to the dopamine succinyl linker, 5.13, using 
DCC in the presence of DMAP, resulting in 5.38. This was then treated with a 2 % 
solution of TFA in DCM to remove the remaining TMS ether groups, to give 5.39. 
Hydrogenolysis was carried out on 5.39, using Pd/C in a H2 atmosphere, to give the 
deprotected glycoside 5.9, which will serve as the potential glycosyl dopamine 
prodrug (Scheme 5.13). Benzyl deprotection at the dopamine hydroxy groups was 
easily achieved using this method, but the anomeric benzyl ether required a greater 
amount of Pd/C, with H2 bubbled through the reaction mixture, to go to completion. 
Care had to be taken during this step, as, in an earlier trial reaction, using a large 
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excess of Pd/C and longer reaction times, hydrolysis of the amide bond linking the 
dopamine also occurred. 
Scheme 5.13 Synthesis of glycosyl dopamine prodrug 5.9. Reagents and conditions: i) DCC, 
DMAP, DCM, rt, 4 h, 52 %; ii) 2 % solution of TFA in DCM, 0 °C, 1 h, 50 %; iii) Pd/C, H2, MeOH, 
rt, 4 h, 56 % 
The 
1
H NMR spectrum of the deprotected glycosyl prodrug 5.9 is shown in Fig. 
5.12. It is noteworthy that the configuration of the deprotected final product is 
predominantly α. While the anomeric position was protected as a benzyl glycoside, 
in compounds 5.38 and 5.39, the β-anomer was the only one observed.  
Compound 5.9 will be tested for its ability to cross the BBB in mice, and, if 
successful, further studies can be carried out into the mechanism of transport into the 
brain capillaries, the affinity of the molecule for glucose transporters, and the 
subsequent release of the dopamine molecule.  
Chapter 5: The Synthesis of a Glycosylated-Dopamine Prodrug 
Page | 131  
 
 
Figure 5.12 
1
H NMR spectrum of 5.9 carried out in CD3OD 
5.6     Chapter Conclusions 
The glycosylated dopamine prodrug, 5.9, was successfully synthesised. Some 
problems encountered during the synthesis include the difficulty presented by the 
undesired acetylation of the hydroxy groups during the N-Troc deprotection step. 
The removal of these O-acetyl groups was complicated by the presence of the ester 
bond linking the dopamine to the C-6 of the sugar. No method was found which was 
suitable to selectively deprotect the O-acetyl groups, while leaving the ester linker 
intact. An alternative route was devised, which involved coupling of the dopamine 
succinate to a sugar moiety in which the amine was protected as an NHAc instead of 
NHTroc. This synthesis presented its own problems, with the sugar produced from a 
deprotection step proving unreactive. It was found that some side-product of the 
deprotection reaction was preventing the TMS protection of hydroxy groups. Again, 
another route was conceived, synthesising the O-TMS protected sugar moiety, 5.35, 
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from a different starting material, 5.36. This method proved successful, resulting in 
the synthesis of the desired glycosylated dopamine prodrug. 
Future work could involve investigation of a different linker to the succinamide one 
used in this synthesis. Also, testing of 5.9 for its ability to cross the BBB, and an 
investigation into the mechanism of transport into the brain capilliaries, should be 
carried out. 
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Chapter 6: Experimental Details 
6.1     General Procedures 
6.1.1     Reagents 
Reagents used in the experiments were purchased from Sigma Aldrich, Fluka, or 
Novabiochem and used without further purification. All solvents for synthesis, 
extraction and column chromatography were distilled and dried before use, if 
necessary, or bought as anhydrous solvents or reagents, e.g.: DMF, pyridine, and 
Et3N from Sigma Aldrich. Solvents were dried as follows: DCM was distilled over 
calcium hydride, and THF was distilled from sodium wire and benzophenone.  
6.1.2     Equipment 
1
H NMR and 
13
C NMR spectra were recorded on a Bruker Avance 300 MHz 
spectrometer operated at 300 MHz for 
1
H and 75 MHz for 
13
C at 298 K, or on Bruker 
Avance II 600 NMR operated at 600 MHz for 
1
H NMR spectroscopy in Trinity 
College Dublin. NMR spectra were obtained by using CDCl3, CD3OD, C6D5N, or 
(CD3)2SO as the deuterated solvent; chemical shifts are expressed as δ units (ppm) 
relative to respective residual solvent peaks
[252]
. The abbreviations s, d, dd, t, q, m 
and bs refer to singlet, doublet, doublet of doublets, triplet, quartet, multiplet and 
broad singlet signal, respectively, in 
1
H NMR spectroscopic data. In 
13
C NMR data s, 
d, t, and q refer to quaternary C, CH, CH2, and CH3, respectively. COSY (Correlation 
Spectroscopy), HSQC (Heteronuclear Single Quantum Correlation), NOESY 
(Nuclear Overhauser Effect Spectroscopy), and Dept 135 (Distortionless 
Enhancement by Polarization Transfer) were used to aid assignation of 
1
H and 
13
C 
NMR spectra. Mass spectrometry was carried out on samples using a Liquid 
chromatography/Time of flight-mass spectrometer. The LC was a model 1200 Series 
(Agilent Corp, Santa Clara, CA). Standard injection volumes were 1 µL, with a 
mobile phase of A = ACN with 0.1 % formic acid and B = 0.1 % formic acid in 
water (A:B, 0:100 to 50:50 to 100:0 to 50:50 to 0:100 over 20 mins).  The 
spectrometer was a model 6210 Time-Of-Flight LC/MS (Agilent Corp, Santa Clara, 
CA) with an electrospray source both positive and negative (ESI+/-), capillary 3,500 
V, nebuliser spray 30 psig, drying gas 5 L/min, source temperature 325 
°
C. The 
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fragmentor voltage was used at 175 V. Reference masses (Agilent Solution) were 
121.050873, 149.02332, 322.048121, 922.009798, 1221.990633, 1521.971475 and 
2421.91399 m/z. Optical rotations were measured on an ADP410 polarimeter 
(sensitivity one millidegree) at room temperature. The light source was a light 
emitting diode with interface filter (589 nm). The concentrations of solutions 
prepared for [α]D measurements are given in g/ 100 mL of corresponding solvent. 
Column chromatography was performed using Merck silica gel 60 (particle size 
0.040- 0.063 mm). Reactions were monitored by thin layer chromatography (TLC) 
using Merck silica gel 60, F254. Sample spots were visualized by staining with a 
suitable dye followed by charring (either 5 % sulphuric acid in ethanol or 0.5 % 
ninhydrin in ethanol). Infrared spectra were obtained, either as a film on a NaCl plate 
or as a solid in a KBr disc, in the region 4000–400 cm−1 on a Nicolet Impact 400 D 
spectrophotometer. Melting points of recrystallised compounds were obtained using 
a Stuart Scientific Melting Point SMP1, and are uncorrected. Temperatures given for 
experiments requiring heating of the reaction mixture are given in ˚C of the silicon 
oil bath. All air and moisture sensitive reactions were carried out under a nitrogen 
atmosphere. 
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6.2     Experimental Details 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-O-[(2-deoxy-2-acetamino-3,4,6-tri-O-acetyl)- 
β-D-glucopyranosyl]-L-serine-phenylmethyl ester (2.21)[87] 
 
Protected glycoside 2.22 (92 mg, 0.12 mmol) was dissolved in acetic anhydride (3 
mL, 31.8 mmol). Freshly activated zinc powder (171 mg, 2.63 mmol) (activated by 
rinsing twice with 2 M HCl, followed by H2O, acetone, and diethyl ether) and Et3N 
(0.04 mL, 0.26 mmol) were added to the reaction mixture, and this was allowed to 
stir at rt for 4 h. The reaction mixture was filtered through celite to remove the zinc 
salts. The solvent was co-evaporated with toluene under reduced pressure, then the 
remaining residue was dissolved in DCM and washed twice with sat. NaHCO3 
solution, followed by brine, then dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the crude product was purified by column 
chromatography (Hex:EtOAc, 2:1 to 1:1 to MeOH) to give the N-acetyl protected 
glycoside 2.21 as a white solid (70 mg, 86 %). Spectroscopic data was in agreement 
with reported values.  
Rf: 0.2 (Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.40-7.33 (m, 5 H, Ph-
H), 5.69 (d, 1 H, NHC(O)CH3, J = 12 Hz), 5.44 (d, 1 H, NHC(O)OC(CH3)3, J = 9 
Hz), 5.23-5.20 (m, 1 H, H-3), 5.17-5.08 (m, 2 H, Ph-CH2), 5.03 (t, 1 H, H-4, J = 9 
Hz), 4.71 (d, 1 H, H-1, J = 9 Hz), 4.46-4.45 (m, 1 H, α-H), 4.28-4.21 (m, 2 H, 
overlapping β-Ha and H-6a), 4.11-4.06 (m, 1 H, H-6b), 3.86-3.81 (dd, 1 H, β-Hb, J = 3 
Hz, 12 Hz), 3.79-3.75 (m, 1 H, H-2), 3.67-3.63 (m, 1 H, H-5), 2.06, 2.02, 2.01 (each 
s, 9 H, OC(O)CH3), 1.93 (s, 3 H, NHC(O)CH3), 1.43 (s, 9 H, C(CH3)3); (Lit
[87]
: 
1
H 
NMR: (CDCl3, 300 MHz) δ = 7.36-7.28, 5.53, 5.43, 5.24, 5.18, 5.12, 5.00, 4.68, 4.45, 
4.25-4.18, 4.06, 3.79, 3.72, 3.60, 2.03, 2.00, 1.99, 1.91, 1.41);
13
C NMR: (CDCl3, 75 
MHz) δ = 170.8, 170.7, 170.6 (each s, OC(O)CH3), 169.4 (s, NHC(O)CH3), 166.4 
(d, C(O)OBn) 155.4 (NHC(O)OC(CH3)3), 135.4 (s, Ph-C), 128.5, 128.4, 128.2 (d, 
Ph-CH), 100.8 (d, C-1), 80.1 (s, C(CH3)3), 72.0 (d, C-3), 71.9 (d, C-5), 69.4 (t, β-C), 
68.5 (d, C-4), 67.3 (t, Ph-CH2), 62.0 (t, C-6), 54.6 (d, C-2), 54.0 (d, α-C), 28.3 (q, 
C(CH3)3), 22.2 (q, NHC(O)CH3), 20.7, 20.7, 20.6 ( each q, OC(O)CH3); IR: (DCM 
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film on NaCl plate) 3288, 3066, 2978, 1748, 1500, 1231 cm
-1
; MS-ESI/TOF: 
Calculated for C29H41N2O13 (M + H)
+
 : 635.2603, found 625.2600. 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-O-[(2-deoxy-2-[(2,2,2-trichloroethoxy 
carbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-phenylmethyl 
ester  (2.22)
[87]
 
 
Imidate donor 2.34 (1.28 g, 2.06 mmol) and protected serine acceptor 2.24 (490 mg, 
1.72 mmol) were placed under N2, in the presence of 4Å molecular sieves, and 
dissolved in dry DCM (2 mL). A freshly made solution of TMSOTf in dry DCM 
(0.04 M, 4.3 mL, 0.17 mmol) was added, and the reaction was left to stir at rt 
overnight. The reaction was quenched by adding solid NaHCO3 (100 mg) to the 
reaction mixture and allowed to stir for 5 mins. H2O (50 mL) was added to the flask. 
The product was extracted twice with DCM. The organic layers were combined and 
washed with H2O, then dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the remaining residue was purified by 
column chromatography (Hex:EtOAc, 1:1) to give glycoside 2.22 as a yellow oil 
(640 mg, 49 %). Spectroscopic data was in agreement with reported values.  
Rf: 0.8 (Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.37-7.34 (m, 5 H, Ph-
H), 5.28-5.13 (m, 5 H, overlapping H-3, Ph-CH2, NHC(O)OCH2, and 
NHC(O)OC(CH3)3) , 5.00 (t, 1 H, H-4, J = 9 Hz), 4.82-4.77 (m, 1 H, 
NHC(O)OCH2a), 4.67-4.61 (m, 2 H, overlapping NHC(O)OCH2b and H-1), 4.32-
4.31 (m, 1 H, α-H), 4.28-4.13 (m, 2 H, overlapping β-Ha and H-6a), 4.10-4.06 (m, 1 
H, H-6b), 3.84-3.80 (dd, 1 H, β-Hb, J = 3 Hz, 9 Hz), 3.65-3.61 (m, 1 H, H-5), 3.58-
3.51 (m, 1 H, H-2), 2.08, 2.04, 2.02 (each s, 9 H, OC(O)CH3), 1.45 (s, 9 H, 
C(CH3)3); (Lit
[87]
: 
1
H NMR: (CDCl3, 250 MHz) δ = 7.35-7.30, 5.40, 5.22, 5.18, 5.12, 
5.00, 4.77, 4.64, 4.61, 4.45, 4.28, 4.22, 4.06, 3.79, 3.60, 3.50, 2.00, 1.97, 1.42); 
13
C 
NMR: (CDCl3, 75 MHz) δ = 170.6 (s, CHC(O)OBn), 169.9, 169.8, 169.5 (each s, 
OC(O)CH3), 155.5 (s, NHC(O)OC(CH3)3), 154.0 (s, NHC(O)OCH2), 135.4 (s, Ph-
C), 128.6, 128.4, 128.3 (each d, Ph-CH), 100.8 (d, C-1), 95.3 (s, CCl3), 80.3 (s, 
C(CH3)3), 74.5 (t, NHC(O)OCH2), 72.1 (d, C-3), 69.7 (t, β-C), 68.5 (d, C-5), 68.0 (d, 
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C-4), 67.1 (t, Ph-CH2), 62.0 (t, C-6), 56.2 (d, C-2), 54.7 (d, α-C), 28.3 (q, C(CH3)3), 
21.1, 20.7, 20.6 (each q, OC(O)CH3); IR: (DCM film on NaCl plate) 3350, 2978, 
1751, 1234 cm
-1
; MS-ESI/TOF: Calculated for C30H40Cl3N2O14 (M + H)
+
: 757.1540, 
found 757.1567.  
N
α
-[(1,1-Dimethylethoxy)carbonyl]-L-serine-phenylmethyl ester (2.24)
[88, 253] 
 
L-Serine-N
α
-[(1,1dimethylethoxy)carbonyl] (1.50 g, 7.3 mmol) and K2CO3 (1.49 g, 
10 mmol) were placed under N2. Anhydrous DMF (30 mL) was added and the 
resulting suspension was stirred for 5 mins. Benzyl bromide (1.1 mL, 9.3 mmol) was 
added slowly. The reaction mixture was stirred at rt overnight. The solvent was 
evaporated under reduced pressure. The organic layer was concentrated under 
reduced pressure, and the remaining residue was dissolved in DCM, then washed 
with H2O, and brine. The organic phase was then dried (MgSO4), and filtered. The 
solvent was evaporated under reduced pressure to give protected serine derivative 
2.24 as a white solid (1.46 g, 68 %). Spectroscopic data was in agreement with 
reported values.  
Rf: 0.5 (Hex:EtOAc, 2:1); 
1
H-NMR: (CDCl3, 300 MHz): δ =  7.34 (s, 5 H, Ph-H), 
5.57 (d, 1 H, NH, J = 6 Hz), 5.21 (d, 2 H, Ph-CH2, J = 3 Hz), 4.41-4.39 (m, 1 H, α-
H), 3.99-3.88 (m, 2 H, β-H), 2.90 (t, 1 H, OH, J = 6 Hz), 1.43 (s, 9 H, C(CH3)3); 
(Lit
[253]
: 
1
H-NMR: (CDCl3, 300 MHz): δ = 7.35, 5.47, 5.21, 4.42, 3.98-3.88, 2.34, 
2.04); 
13
C-NMR: (CDCl3, 75 MHz):   = 170.8 (s, OC(O)NH), 155.7 (s, OC(O)CH), 
135.3 (s, C(CH3)3), 128.5, 128.3, 128.0 (each d, Ph-C),  80.0 (s, Ph-C), 67.2 (t, Ph-
CH2), 63.2 (t, β-C), 55.9 (d, α-C), 34.6, 28.2, 20.9 (each q, C(CH3)3); IR: (KBr disc)  
3421, 3366, 2980, 1761, 1670, 1527 cm 
-1
; MS-ESI/TOF: Calculated for C15H22NO5 
(M + H)
+
: 296.1492, found 296.1480.   
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(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-1,3,4,6-tetra-O-acetyl)-α/β-
D-glucopyranoside (2.26)
[89, 254]
 
 
D (+) -Glucosamine hydrochloride (2.00 g, 9.0 mmol) and NaHCO3 (2.27 g, 27 
mmol) were suspended/ dissolved in H2O (20 mL). The resulting suspension was 
stirred for 5 mins at rt. Trichloroethoxy carbonyl chloride (TrocCl) (1.45 mL, 10.8 
mmol) was added dropwise. The reaction mixture was stirred at rt for 2 h, then 
neutralized (1 M HCl). The solvent was evaporated under reduced pressure, and the 
remaining residue was dissolved in pyridine (8.9 mL). Acetic anhydride (4.5 mL, 47 
mmol) was added dropwise at 0 ˚C. The reaction mixture was allowed to reach rt, 
and stir overnight. The solvent was evaporated using a rotary evaporator, and the 
remaining residue was dissolved in DCM, and washed with sat. NaHCO3 solution, 
and brine, then dried (MgSO4), and filtered. The organic layer was concentrated 
under reduced pressure, and the remaining residue was purified by column 
chromatography (Hex:EtOAc, 4:1 to 3:1 to 2:1 to 1:1) to leave the protected sugar 
2.26 as an off-white solid (4.08 g, 87 %). Spectroscopic data was in agreement with 
reported values. 2.26 was an anomeric mixture α:β in the ratio of 1:0.3. 
Rf: 0.7 (Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 6.25 (d, 1 H, H-1 (α-
anomer), J = 3 Hz), 5.81-5.76 (m, 2 H, overlapping NHC(O)OCH2 and H-1 (β-
anomer)), 5.35-5.26 (m, 1 H, H-3), 5.22-5.11 (m, 1 H, H-4), 4.86-4.60 (m, 2 H, 
NHC(O)CH2), 4.30-4.19 (m, 2 H, overlapping H-2 and H-6a), 4.09-4.01 (m, 2 H, 
overlapping H-6b and H-5), 2.15, 2.10, 2.07, 2.04 (each s, 12 H, OC(O)CH3); 
(Lit
[254]
: 
1H NMR for β-anomer: (CDCl3, 300 MHz) δ = 5.73, 5.22, 5.11, 5.14, 4.72, 
4.29, 4.10, 3.93, 3.81, 2.10, 2.08, 2.03; Lit
[255]
: 
1H NMR for α-anomer: (CDCl3) δ = 
6.25, 5.28, 4.64, 4.30, 4.22, 4.07, 4.03, 2.22, 2.12, 2.06); 
13
C NMR: (CDCl3, 75 
MHz) δ = 170.6, 170.4, 169.1, 168.6 (each s, OC(O)CH3), 154.2 (s, NHC(O)OCH2),  
95.3 (s, CCl3), 92.2 (d, C-1 (β-anomer)), 90.4 (d, C-1 (α-anomer)), 74.5 (t, 
NHC(O)OCH2), 70.4 (d, C-3), 69.6 (d, C-5), 67.7 (d, C-4), 61.5 (t, C-6), 53.1 (d, C-
2), 20.9, 20.7, 20.5, 20.4 (each q, OC(O)CH3); IR: (film on NaCl) 3327, 2959, 1755, 
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1226 cm
-1
; MS-ESI/TOF: Calculated for C17H26Cl3N2O11 (M + NH4)
+
: 539.0597, 
found 539.0621.  
 (2-Deoxy-2-acetamido-1,3,4,6-tetra-O-acetyl)-α/β-D-glucopyranoside (2.30)[256]  
 
D (+) -Glucosamine hydrochloride (3.00 g, 1.4 mmol) was suspended in pyridine (30 
mL). To this suspension, acetic anhydride (4.2 mL, 44.7 mmol) was added slowly at 
0 ˚C. The reaction mixture was allowed to reach rt and stirred for 48 h. The solvent 
was evaporated under reduced pressure. The resulting residue was dissolved in 
DCM, and washed with 0.5 M HCl, and twice with sat. NaHCO3 solution, followed 
by H2O, dried (MgSO4), and filtered. The solvent was evaporated using a rotary 
evaporator, and the crude product was crystallized (Hex and EtOAc) to give 
peracetylated derivative 2.30 as a white solid (1.82 g, 34 %). Spectroscopic data was 
in agreement with reported values.
 
 
Rf: 0.2 (Hex:EtOAc, 1:2); 
1
H-NMR: (CDCl3, 300 MHz): δ = 6.18 (d, 1 H, H-1, J = 3 
Hz), 5.53 (d, 1 H, N-H, J = 9 Hz), 5.24-5.20 (m, 2 H, overlapping H-3 and H-4), 
4.52-4.46 (m, 1 H, H-2), 4.28-4.22 (dd, 1 H, H-6a, J = 6 Hz, 12 Hz), 4.09-4.04 (dd, 1 
H, H-6b, J = 3 Hz, 12 Hz), 4.01-3.98 (m, 1 H, H-5), 2.19, 2.09, 2.05, 2.04, 1.94 (each 
s, 15 H, NHC(O)CH3 and OC(O)CH3); (Lit
[256]
: 
1
H-NMR: (CDCl3, 400 MHz): δ = 
6.31, 5.70, 5.45, 5.24, 5.15-5.06, 4.27, 4.11-4.06, 3.83, 2.16, 2.10, 2.07, 2.02, 2.01, 
2.00);
 13
C-NMR: (CDCl3, 75 MHz): δ = 171.7, 170.7, 169.9, 169.1, 168.6 (each s, 
NHC(O)CH3 and OC(O)CH3), 90.7 (d, C-1), 70.7 (d, C-4), 69.7 (d, C-5), 67.5 (d, C-
3), 61.5 (t, C-6), 51.1 (d, C-2), 23.1, 20.9, 20.7, 20.7, 20.6 (each q, C(O)CH3); m.p.: 
134-136 ˚C; IR: (KBr disc) 3439, 2953, 1741, 1674, 1519, 1241 cm-1; MS-ESI/TOF: 
Calculated for C16H27N2O10 (M + NH4)
+
: 407.1660, found 407.1676.  
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(2-Deoxy-1-(O:2-N,N-ethylidyne)-3,4,6-tri-O-acetyl)-α-D-glucopyranoside 
(2.32)
[94]
 
 
Peracetylated glucosamine 2.30 (800 mg, 2.1 mmol) was dissolved in dry DCM (4 
mL). HBr (33 % solution in AcOH) (4.0 mL, 70 mmol) was added to the reaction 
mixture at 0 ˚C. The reaction mixture was allowed to reach rt, and stirred overnight. 
The solvent was co-evaporated with toluene under reduced pressure, and the 
remaining residue was dissolved in DCM, and washed with sat. NaHCO3 solution, 
followed by brine, then dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the crude product was purified by column 
chromatography (Hex:EtOAc, 1:2) to give compound 2.32 as a yellow oil (300 mg, 
44 %). Spectroscopic data was in agreement with reported values.  
Rf: 0.1 (Hex:EtOAc, 1:2); 
1
H NMR: (CDCl3, 300 MHz) δ = 5.98 (d, 1 H, H-1, J = 9 
Hz), 5.26 (t, 1 H, H-3, J = 6 Hz), 4.95-4.91 (m, 1 H, H-4), 4.18-4.08 (m, 3 H, 
overlapping H-2 and H-6), 3.64-3.58 (m, 1 H, H-5), 2.11, 2.10, 2.09, 2.08 (each s, 12 
H, N(C)CH3 and OC(O)CH3); (Lit
[94]
: 
1
H NMR: (CDCl3, 60 MHz) δ = 5.9, 5.2, 4.9, 
4.2, 4.1, 3.6, 2.1); IR: (DCM film on NaCl plate) 3340, 2959, 1747, 1660, 1543, 
1230 cm
-1
; MS-ESI/TOF: Calculated for C14H20NO8 (M + H)
+
: 330.1183, found 
330.1192.  
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl)-α/β-D-
glucopyranose (2.33)
[89]
 
 
Method A 
To a solution of protected glycoside 2.26 (2.46 g, 4.7 mmol) in THF (15 mL) 
benzylamine (0.62 mL, 5.6 mmol) was added. The reaction mixture was allowed to 
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stir at 50 ˚C overnight. The solvent was evaporated under reduced pressure to leave a 
brown oil. This residue was dissolved in DCM, then washed with 0.5 M HCl and 
brine, then dried (MgSO4), and filtered. The organic layer was concentrated under 
reduced pressure, and the remaining residue was then purified by column 
chromatography (Hex:EtOAc, 1:1) to give hemiacetal 2.33 as a white solid (1.98 g, 
88 %). Spectroscopic data was in agreement with reported values.  
Method B 
To a solution of protected glycoside 2.26 (5.00 g, 9.5 mmol) in THF (60 mL) 
dimethylamine (2 M solution in THF, 9.5 mL, 19.1 mmol) was added. The reaction 
mixture was allowed to stir at 80 ˚C overnight. The solvent was evaporated under 
reduced pressure to leave a brown oil. This residue was dissolved in DCM, and 
washed with 1.0 M HCl, followed by brine, then dried (MgSO4), and filtered. The 
organic layer was concentrated under reduced pressure, and the remaining residue 
was purified by column chromatography (Hex:EtOAc, 1:1) to give hemiacetal 2.33 
as a white solid (3.69 g, 81 %). Spectroscopic data was in agreement with reported 
values.
  
Method C 
Protected glycoside 2.26 (2.66 g, 5.1 mmol) and hydrazine acetate (550 mg, 6.0 
mmol) were dissolved in anhydrous DMF, under N2. The reaction mixture was 
stirred at rt for 2 h, then further hydrazine acetate (230 mg, 2.6 mmol) was added. 
This was allowed to stir at rt for 2.5 h. The reaction mixture was diluted with EtOAc 
(20 mL), and this was washed twice with H2O. The organic layer was dried (MgSO-
4), and filtered, then concentrated under reduced pressure to give hemiacetal 2.33 as 
a white solid (2.40 g crude, 98 %), which was used without further purification. 
Spectroscopic data was in agreement with reported values. 
Rf: 0.4 and 0.5 (α and β anomers respectively, Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 
300 MHz) δ = 5.66 (d, 1 H, NHC(O)OCH2, J = 9 Hz), 5.37-5.30 (m, 2 H, 
overlapping H-1 and H-3), 5.12 (t, 1 H, H-4, J = 9 Hz), 4.83 (d, 1 H, NHC(O)OCH2a, 
J = 12 Hz), 4.63 (d, 1 H, NHC(O)OCH2b, J = 12 Hz), 4.26-4.01 (m, 4 H, overlapping 
H-2, H-5, and H-6), 2.10, 2.04, 2.01 (each s, 9 H, OC(O)CH3); (Lit
[89]
: 
1
H NMR: 
(CDCl3, 250 MHz) δ = 5.48-5.09, 4.83-4.61, 4.29-4.01, 3.65, 2.21-2.01); 
13
C NMR: 
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(CDCl3, 75 MHz) δ = 171.6, 171.1, 169.6 (each s, OC(O)CH3), 154.3 (s, 
NHC(O)OCH2), 95.4 (s, CCl3), 91.6 (d, C-1), 74.5 (t, NHC(O)OCH2), 70.8 (d, C-5), 
68.3 (d, C-3), 67.6 (d, C-4), 62.0 (t, C-6), 54.2 (d, C-2), 21.0, 20.7, 20.6 (each t, 
OC(O)CH3); IR: (KBr disc) 3583, 3338, 2958, 1747, 1235 cm
-1
; MS-ESI/TOF: 
Calculated for C15H24Cl3N2O10 (M + NH4)
+
: 497.0491, found 497.0509.  
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl-1-
trichloroacetimido)-α-D-glucopyranoside (2.34)[257] 
 
Method A 
Hemiacetal 2.33 (1.60 g, 3.3 mmol) was placed under N2, in the presence of 4 Å 
molecular sieves, and dissolved in dry DCM (15 mL). Cl3CCN (2.34 mL, 2.33 
mmol) was added dropwise. NaH (60 % in mineral oil) (66 mg, 1.6 mmol) was 
carefully added to the reaction mixture, which was allowed to stir under N2, at rt for 
1 h. The reaction mixture was filtered through celite (prewashed with wet DCM).  
The solvent was evaporated under reduced pressure to leave a brown oil, which was 
purified by column chromatography (Hex:EtOAc, 2:1) to give imidate derivative 
2.34 as a yellow oil (1.77 g, 86 %). Spectroscopic data was in agreement with 
reported values. 
Method B 
Hemiacetal 2.33 (3.37 g, 7.03 mmol) was placed under N2, in the presence of 4Å 
molecular sieves, and dissolved in dry DCM (40 mL). Cl3CCN (5.03 mL, 49 mmol) 
was added dropwise, followed by addition of DBU (0.26 mL, 1.75 mmol). The 
reaction mixture was allowed to stir at rt for 4 h. The reaction was filtered to remove 
the molecular sieves, and the solvent was evaporated under reduced pressure. The 
remaining residue was purified by column chromatography (Hex:EtOAc, 2:1 to 1:1) 
to give imidate derivative 2.34 as a yellow oil (2.73 g, 72 %). Spectroscopic data was 
in agreement with reported values. 
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Rf: 0.6 (Hex:EtOAc, 2:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 8.81 (s, 1 H, C(NH)), 
6.43 (d, 1 H, H-1, J = 3 Hz), 5.39-5.21 (m, 3 H, overlapping H-3, H-4, and NH 
C(O)OCH2), 4.72 (d, 2 H, NHC(O)OCH2, J = 3 Hz), 4.31-4.25 (m, 2 H, overlapping 
H-2 and H-6a), 4.10-4.16 (m, 2 H, overlapping H-5 and H-6b), 2.08, 2.06, 2.04 (each 
s, 9 H, OC(O)CH3); (Lit
[257]
: 
1
H NMR: (CDCl3, 400 MHz) δ = 8.80, 6.42, 5.35, 5.25, 
5.19, 4.73, 4.70, 4.29, 4.28, 4.12, 2.08, 2.06); 
13
C NMR: (CDCl3, 75 MHz) δ = 170.6 
(s, C(NH)), 169.3 (s, NHC(O)OCH2), 160.4, 160.4, 154.1 (each s, OC(O)CH3), 95.2 
(s, CCl3), 94.5 (d, C-1), 90.6 (s, CCl3), 74.6 (t, NHC(O)OCH2), 70.3, 70.3 (each s, C-
5 and C-3), 67.4 (s, C-4), 61.4 (t, C-6), 53.9 (s, C-2), 21.0, 20.7, 20.6 (each q, 
OC(O)CH3); IR: (DCM film on a NaCl plate) 3336, 3000, 1728, 1235 cm
-1
; MS-
ESI/TOF: Calculated for C17H20Cl6N2NaO10 (M + Na)
+
: 644.9141, found 644.9163. 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-O-[(2-deoxy-2-[(2,2,2-trichloroethoxy 
carbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-serine (2.38) 
 
Glycoside 2.22 (100 mg, 0.13 mmol) was dissolved in distilled EtOAc (5 mL) and 
placed under N2. 10 % Pd/C (w/w) (10 mg) was added to the reaction mixture, and 
the flask was placed under H2. The reaction mixture was allowed to stir at rt for 1.5 
h. The Pd/C was filtered off over celite. The solvent was evaporated under reduced 
pressure, and the remaining residue was dissolved in DCM and washed twice with 
H2O, then dried (MgSO4), and filtered to give the free acid 2.38 as a white foam (70 
mg, 75 %).  
Rf: 0.3 (DCM:MeOH, 9:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 5.72 (s, 1 H, 
NHC(O)OCH2), 5.52 (s, 1 H, NHC(O)OC(CH3)3), 5.32-5.25 (m, 1 H, H-3), 5.06 (t, 1 
H, H-4, J = 9 Hz), 4.81 (d, 1 H, NHC(O)OCH2a, J = 12 Hz), 4.73-4.66 (m, 2 H, 
overlapping NHC(O)OCH2b and H-1), 4.46 (s, 1 H, α-H), 4.26-4.08 (m, 3 H, 
overlapping β-Ha, and H-6), 3.92 (d, 1 H, β-Hb, J = 9 Hz), 3.73-3.65 (m, 2 H, 
overlapping H-5 and H-2), 2.10, 2.04, 2.03 (each s, 9 H, OC(O)CH3), 1.46 (s, 9 H, 
C(CH3)3); 
13
C NMR: (CDCl3, 75 MHz) δ = 173.2 (s, C(O)OH), 171.1, 170.7, 169.6 
(each s, OC(O)CH3), 155.9 (s, NHC(O)OCH2), 154.4 (s, NHC(O)OC(CH3)3), 101.1 
(d, C-1), 95.5 (s, CCl3), 80.6 (s, C(CH3)3), 74.5 (t, NHC(O)OCH2), 71.9 (d, 
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overlapping C-5 and C-3), 69.6 (t, β-C), 68.6 (d, C-4), 62.0 (t, C-6), 55.9 (d, C-2), 
53.7 (d, α-C), 28.3 (q, C(CH3)3), 20.8, 20.6, 19.2 (each q, OC(O)CH3); IR: (DCM 
film on NaCl plate) 3410, 2980, 2127, 1652, 1250 cm
-1
; [α]D: + 9.3 (c 1.5, CH2Cl2); 
MS-ESI/TOF: Calculated for C46H67Cl6N4O28 (2M + H)
+
: 1333.2068, found 
1333.2131.  
N
α
-[(1,1-Dimethylethoxy)carbonyl]-O-[(2-deoxy-2-[(2,2,2-trichloroethoxy 
carbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-
tetradecylamide (2.39) 
 
Free acid 2.38 (73 mg, 0.11 mmol) was placed under N2, and dissolved in anhydrous 
DMF (2 mL). To this solution, HOBt (16 mg, 0.12 mmol) and TBTU (38 mg, 0.12 
mmol) were added and allowed to stir for 5 mins. Tetradecylamine (25 mg, 0.12 
mmol) and Et3N (0.02 mL, 0.13 mmol) were added to the reaction mixture. This was 
allowed to stir at rt overnight. The solvent was evaporated under reduced pressure, 
and the remaining residue was dissolved in DCM. The organic layer was washed 
with 0.5 M HCl, followed by brine, then dried (MgSO4), and filtered. The organic 
layer was concentrated under reduced pressure, and the crude product was purified 
by column chromatography (Hex:EtOAc, 1:2) to give the tetradecyl derivative 2.39 
as a clear oil (72 mg, 77 %). 
Rf: 0.3 (Pet. Ether: EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 6.52 (s, 1 H, 
C(O)NHCH2), 5.67 (d, 1 H, NHC(O)OCH2, J = 9 Hz), 5.45 (s, 1 H, 
NHC(O)OC(CH3)3), 5.25 (t, 1 H, H-3, J = 9 Hz), 5.04 (t, 1 H, H-4, J = 9 Hz), 4.82 (d, 
1 H, NHC(O)OCH2a, J = 12 Hz), 4.70 (d, 1 H, H-1, J = 9 Hz), 4.63 (d, 1 H, 
NHC(O)OCH2b, J = 12 Hz), 4.28-4.16 (m, 3 H, overlapping α-H and H-6) 4.05-4.02 
(m, 1 H, β-Ha), 3.80-3.69 (m, 3 H, overlapping β-Hb, H-5 and H-2), 3.24 (d, 2 H, 
C(O)NHCH2, J = 9 Hz), 2.09, 2.04, 2.02 (each s, 9 H, OC(O)CH3), 1.44 (s, 9 H, 
C(CH3)3), 1.25 (m, 24 H, (CH2)12), 0.87 (t, 3 H, CH2CH3, J = 6 Hz); 
13
C NMR: 
(CDCl3, 75 MHz) δ = 170.7, 169.6, 169.5 (each s, OC(O)CH3 and C(O)NHCH2), 
155.4 (s, NHC(O)OCH2), 154.4 (s, NHC(O)OC(CH3)3), 102.1 (d, C-1), 95.5 (s, 
CCl3), 80.3 (s, OC(CH3)3), 74.5 (t, NHC(O)OCH2), 72.0 (d, overlapping C-3 and C-
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5), 70.4 (t, β-C), 68.4 (d, C-4), 61.8 (t, C-6), 56.1 (d, C-2), 53.6 (d, α-C), 38.7, 31.9, 
29.7, 29.7, 29.6, 29.4, 29.3, 29.3, 26.9, 23.7, 23.0, 22.7 (each t, CH2), 28.3 (q, 
C(CH3)3), 20.7, 20.6 (each q, OC(O)CH3), 14.1 (q, CH2CH3); IR: (DCM film on 
NaCl plate) 3329, 2925, 1749, 1654, 1552, 1235 cm
-1; [α]D: + 10 (c 0.6, CH2Cl2); 
MS-ESI/TOF: Calculated for C37H63Cl3N3O13 (M + H)
+
: 862.3421, found 862.3434. 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-O-[(2-deoxy-2-[(2,2,2-trichloroethoxy 
carbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-propylamide 
(2.50) 
 
Free acid 2.38 (124 mg, 0.19 mmol) was placed under N2, and dissolved in 
anhydrous DCM (10 mL). To this solution, HOBt (27 mg, 0.20 mmol) and TBTU 
(65 mg, 0.20 mmol) were added and allowed to stir for 5 mins. Propylamine (0.02 
mL, 0.20 mmol) and Et3N (0.03 mL, 0.22 mmol) were added to the reaction mixture, 
and this was allowed to stir at rt overnight. The solvent was evaporated, and the 
remaining residue was dissolved in DCM. The organic layer was washed with 0.5 M 
HCl, followed by brine, then dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the remaining residue was purified by 
column chromatography (Hex:EtOAc, 1:2) to give the propyl derivative 2.50 as a 
white paste (70 mg, 87 %). 
Rf: 0.5 (Hex:EtOAc, 1:2); 
1
H NMR: (CDCl3, 300 MHz) δ = 6.52 (bs, 1 H, 
C(O)NHCH2), 5.58-5.41 (m, 2 H, overlapping peaks NHC(O)OCH2 and 
NHC(O)OC(CH3)3), 5.30-5.20 (m, 1 H, H-3), 5.10-5.01 (m, 1 H, H-4), 4.83- 4.58 
(m, 3 H, overlapping NHC(O)OCH2 and H-1), 4.30-4.08 (m, 3 H, overlapping α-H 
and H-6), 4.01-3.90 (m, 1 H, β-Ha), 3.76-3.64 (m, 3 H, overlapping β-Hb, H-5, and 
H-2), 3.28-3.20 (m, 2 H, NHCH2), 2.09, 2.04, 2.02 (each s, 9 H, OC(O)CH3), 1.58-
1.49 (m, 2 H, NHCH2CH2), 1.44 (s, 9 H, C(CH3)3), 0.94 (t, 3 H, CH2CH3, J  = 6 Hz); 
13
C NMR: (CDCl3, 75 MHz) δ = 170.8, 170.7, 169.7, 169.5 (each s, OC(O)CH3 and 
C(O)NHCH2), 154.4 (s, NHC(O)OCH2), 154.4 (s, NHC(O)OC(CH3)3), 102.1 (d, C-
1), 95.4 (s, CCl3), 80.4 (s, OC(CH3)3), 74.5 (t, NHC(O)OCH2), 72.1 (t, β-C), 72.0, 
71.9 (each d, C-3 and C-5), 68.4 (d, C-4), 61.9 (t, C-6), 56.2 (d, C-2), 52.9 (d, α-C), 
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41.5 (t, C(O)NHCH2), 28.5 (q, C(CH3)3), 22.6 (t, C(O)NHCH2CH2), 20.8, 20.7, 20.7 
(each q, OC(O)CH3), 11.3 (q, CH2CH3); IR: (DCM film on NaCl plate) 3326, 2967, 
1749, 1654, 1538, 1235 cm
-1
; [α]D: - 2.7 (c 0.75, CH2Cl2); MS-ESI/TOF: Calculated 
for C26H41Cl3N3O13 (M + H)
+
: 712.1657, found 712.1689. 
O-[(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-
glucopyranosyl]-L-serine-propylamide (2.51) 
 
Propyl derivative 2.50 (13 mg, 0.02 mmol) was dissolved in DCM (2 mL) and 
cooled to 0 °C. A 50 % (v/v) solution of TFA in DCM (0.03 mL, 1.42 mmol) was 
added to the reaction mixture, and this was allowed to return to rt, then stirred at rt 
overnight. The reaction mixture was washed with a sat. solution of NaHCO3, 
followed by brine. The organic layer was dried (MgSO4), filtered, and concentrated 
under reduced pressure. The remaining residue was purified by column 
chromatography (Hex:EtOAc, 1:1 to 1:3) to give the free amine 2.51 as a clear oil (9 
mg, 97 %). 
Rf: 0.53 (DCM:MeOH, 9:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.51-7.42 (m, 1 H, 
C(O)NHCH2), 5.48 (d, 1H, NHC(O)CH2, J = 9 Hz), 5.24 (t, 1 H, H-3, J = 6 Hz), 
5.07 (t, 1 H, H-4, J = 9 Hz), 4.84-4.59 (m, 3 H, overlapping NHC(O)CH2 and H-1), 
4.30-4.23 (dd, 1 H, H-6a, J = 6 Hz, 15 Hz), 4.16-4.11 (m, 1 H, H-6b), 4.06-3.92 (m, 2 
H, β-H), 3.70-3.62 (m, 2 H, overlapping H-2 and H-5), 3.52-3.49 (m, 1 H, α-H), 
3.22-3.10 (m, 2 H, C(O)NHCH2), 2.09, 2.03 (each s, 9 H, OC(O)CH3), 1.91 (bs, 2 H, 
NH2), 1.57-1.50 (m, 2 H, NHCH2CH2), 0.93 (t, 3 H, CH2CH3, J = 9 Hz); 
13
C NMR: 
(CDCl3, 75 MHz) δ = 169.7, 168.4, 100.1, 94.4, 73.5, 70.9, 67.6, 60.9, 58.0, 55.1, 
53.9, 40.1, 29.9, 21.7, 19.7, 19.6, 10.4; [α]D: - 4.4 (c 0.45, CH2Cl2); MS-ESI/TOF: 
Calculated for C42H64Cl6N6NaO22 (2M + Na)
+
: 1237.2097, found 1237.2160. 
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O-[(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-
glucopyranosyl]-L-serine-phenylmethyl ester (2.52) 
 
Protected glycoside 2.22 (200 mg, 0.26 mmol) was placed under N2, and dissolved in 
dry DCM (5 mL). A 50 % (v/v) solution of TFA in DCM (0.4 mL, 2.63 mmol) was 
added to the reaction at 0 ˚C, and allowed to stir for 1 h. The solvent was evaporated 
under reduced pressure to leave a yellow oil. The reaction mixture was purified by 
column chromatography (Hex:EtOAc, 2:1 to 1:1 to MeOH) to give free amine 2.52 
as a yellow oil (160 mg, 90 %).  
Rf: 0.53 (DCM:MeOH, 9:1); 
1
H NMR: (CD3OD, 300 MHz) δ = 7.43-7.39 (m, 5 H, 
Ph-H), 5.32 (s, 2 H, Ph-CH2), 5.24 (t, 1 H, H-3, J = 9 Hz), 4.98 (t, 1 H, H-4, J = 9 
Hz), 4.92-4.82 (Overlapped by H2O peak: NH2, NHC(O)OCH2 and NHC(O)OCH2a), 
4.75 (d, 1 H, H-1, J = 9 Hz), 4.66 (d, 1 H, NHC(O)OCH2b, J = 12 Hz), 4.36-4.35 (m, 
1 H, α-H), 4.30-4.28 (m, 1 H, β-Ha), 4.25-4.24 (m, 1 H, H-6a), 4.16-4.15 (m, 1 H, H-
6b), 4.12-4.11 (m, 1 H, β-Hb), 3.76-3.73 (m, 1 H, H-5), 3.68-3.62 (m, 1 H, H-2), 2.02 
(s, 6 H, OC(O)CH3), 1.99 (s, 3 H, OC(O)CH3); 
13
C NMR: (CD3OD, 75 MHz) δ = 
170.9, 170.2, 169.6 (each s, OC(O)CH3), 166.6 (s, C(O)OBn), 155.5 (s, 
NHC(O)OCH2), 134.9 (s, Ph-C), 128.4, 128.3, 128.2 (each d, Ph-CH), 100.1 (d, C-
1), 95.6 (s, CCl3), 74.1 (t, NHC(O)OCH2), 72.3 (d, C-3), 71.7 (d, C-5), 68.5 (d, C-4), 
68.0 (t, Ph-CH2), 66.0 (t, β-C), 61.6 (t, C-6), 55.4 (d, C-2), 52.9 (d, α-C), 19.3, 19.2, 
19.2 (each q, OC(O)CH3); IR (DCM film on NaCl plate): 2917, 1750, 1677, 1206 
cm
-1
; [α]D: - 2.4 (c 0.83, CH2Cl2); MS-ESI/TOF: Calculated for C25H32Cl3N2O12 (M 
+ H)
+
: 657.1015, found 657.1026. 
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N
α
-(1-Oxodecyl)-O-[(2-deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-
tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-phenylmethyl ester (2.53) 
 
Decanoic acid (20 mg, 0.13 mmol), TBTU (40 mg, 0.13 mmol), and HOBt (20 mg, 
0.13 mmol) were dissolved in dry DCM (7 mL) under N2, in the presence of 4Å 
molecular sieves. Et3N (0.05 mL, 0.36 mmol) was added to the reaction mixture. 
This was allowed to stir at rt for 15 mins. A solution of free amine 2.52 (80 mg, 0.19 
mmol) in dry DCM (10 mL), and THF (1 mL for solubility) was then added to the 
reaction mixture. This was allowed to stir at rt overnight. The solution was filtered to 
remove the molecular sieves, then washed with a sat. NaHCO3 solution, and 1.0 M 
HCl. The organic layer was dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the remaining residue was purified by 
column chromatography (Hex:EtOAc, 1:1) to give the oxodecyl derivative 2.53 as a 
clear oil (80 mg, 88 %). 
Rf: 0.4 (Hex:EtOAc, 1:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 7.40-7.31 (m, 5 H, Ph-
H), 6.49 (d, 1 H, NHC(O)CH2, J = 6 Hz), 5.43 (d, 1 H, NHC(O)OCH2, J = 9 Hz), 
5.24-5.13 (m, 3 H, overlapping H-3 and Ph-CH2), 5.02 (t, 1 H, H-4, J = 9 Hz), 4.84-
4.64 (m, 4 H, overlapping NHC(O)OCH2, H-1, and α-H), 4.26-4.20 (m, 2 H, 
overlapping H-6a and β-Ha), 4.13-4.07 (m, 1 H, H-6b), 3.92-3.87 (dd, 1 H, β-Hb, J = 
3 Hz, 9 Hz), 3.62-3.52 (m, 2 H, overlapping H-5 and H-2), 2.25 (t, 2 H,  
NHC(O)CH2, J = 6 Hz), 2.05-2.01 (m, 9 H, OC(O)CH3), 1.61 (t, 2 H, C(O)CH2CH2, 
J = 9 Hz), 1.26-1.37 (m, 12 H, (CH2)6), 0.87 (t, 3 H, CH2CH3, J = 9 Hz); 
13
C NMR: 
(CDCl3, 75 MHz) δ = 173.5 (s, NHC(O)CH2), 171.2 (s, C(O)OBn), 170.6, 169.7, 
169.4 (each s, OC(O)CH3), 154.3 (s, NHC(O)OCH2), 135.2 (s, Ph-C), 128.6, 128.5, 
128.3 (each d, Ph-C), 100.3 (d, C-1), 95.4 (s, CCl3), 74.5 (t, NHC(O)OCH2), 71.9 (d, 
C-3), 71.8 (d, C-5), 69.1 (t, β-C), 68.4 (d, C-4), 67.5 (t, CH2-Ph), 61.9 (t, C-6), 56.2 
(d, C-2), 52.3 (d, α-C), 36.4 (t, NHC(O)CH2), 33.8, 31.9, 29.5, 29.4, 29.3, 29.3, 22.6 
(each t, CH2), 25.5 (t, NHC(O)CH2CH2), 20.7, 20.6 (each q, OC(O)CH3), 14.1 (q, 
CH2CH3); IR: (DCM film on NaCl plate) 3308, 2927, 2855, 1752, 1655, 1536, 1234 
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cm
-1; [α]D: -1.1 (c 1.85, CH2Cl2); MS-ESI/TOF: Calculated for C35H49Cl3KN2O13 (M 
+ K)
+
: 849.1932, found 849.1934. 
N
α
-(1-Oxodecyl)-O-[(2-deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-
tri-O-acetyl)-β-D-glucopyranosyl]-L-serine (2.54) 
 
The oxodecyl derivative 2.53 (514 mg, 0.63 mmol) was dissolved in distilled EtOAc 
(15 mL) and placed under N2. 10 % Pd/C (w/w) (100 mg) was added to the reaction 
mixture, and the flask was placed under H2. The reaction mixture was allowed to stir 
at rt for 3 h. The reaction mixture was filtered through celite, and the solvent was 
evaporated under reduced pressure to give the free acid 2.54 as a clear oil (449 mg, 
98 %).  
Rf: 0.26 (DCM:MeOH, 9:1);
 1
H NMR: (CDCl3, 300 MHz) δ =  6.80 (s, 1 H, 
NHC(O)CH2), 6.04 (s, 1 H, NHC(O)OCH2), 5.25 (t, 1 H, H-3, J = 9 Hz), 5.07 (t, 1 
H, H-4, J = 9 Hz), 4.85-4.65 (m, 4 H, overlapping NHC(O)OCH2, H-1 and α-H), 
4.25-4.22 (m, 3 H, overlapping H-6 and β-Ha), 3.99-3.97 (m, 1 H, β-Hb), 3.75-3.69 
(m, 2 H, overlapping H-5 and H-2), 2.27-2.25 (m, 2 H, NHC(O)CH2), 2.05-2.01 (m, 
9 H, OC(O)CH3), 1.61 (bs, 2 H, NHC(O)CH2CH2), 1.26 (m, 12 H, (CH2)6), 0.87 (t, 3 
H, CH2CH3, J = 6 Hz); 
13
C NMR: (CDCl3, 75 MHz) δ =  183.6 (s, C(O)OH), 170.7, 
169.5 (each s, OC(O)CH3 and NHC(O)CH2), 152.6 (s, NHC(O)OCH2), 100.7 (d, C-
1), 95.4 (s, CCl3), 74.6 (t, NHC(O)OCH2), 71.9 (d, C-3 and C-5), 68.5 (d, C-4), 68.3 
(t, β-C), 62.0 (t, C-6), 56.4 (d, C-2), 53.3 (d, α-C), 36.3 (t, NHC(O)CH2), 31.9, 29.5, 
29.4, 29.3, 22.6 (each t, CH2), 25.4 (t, NHC(O)CH2CH2), 20.8, 20.6 ( each q, 
OC(O)CH3), 14.3 (q, CH2CH3); IR: (DCM film on NaCl plate) 3408, 2927, 2856, 
1750, 1649, 1547, 1236 cm
-1; [α]D: - 4 (c 1.0, CH2Cl2); MS-ESI/TOF: Calculated for 
C28H44Cl3N2O13 (M + H)
+
: 721.1903, found 721.1933. 
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N
α
-(1-Oxodecyl)-O-[(2-deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-
tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-tetradecylamide (2.55) 
 
Free acid 2.54 (40 mg, 0.06 mmol), TBTU (20 mg, 0.06 mmol), and HOBt (8 mg, 
0.06 mmol) were dissolved in anhydrous DCM (5 mL) under N2, in the presence of 
3Å molecular sieves. The reaction mixture was allowed to stir at rt for 15 mins. A 
solution of tetradecylamine (13 mg, 0.06 mmol) in anhydrous DCM (3 mL) was then 
added, and the reaction mixture was allowed to stir at rt overnight. The solvent was 
evaporated under reduced pressure, and the remaining residue was washed with 1.0 
M HCl, dried (MgSO4), and filtered. The organic layer was concentrated using a 
rotary evaporator, and the crude product was purified by column chromatography 
(Hex:EtOAc, 1:1) to give glycolipid derivative 2.55 as a cream solid (16 mg, 13 %).  
N
α
-(1-Oxodecyl)-β-dehydroxy-(β,β-dibromo)-L-dehydroserine (2.58) 
 
The free acid 2.54 (40 mg, 0.05 mmol) was dissolved in anhydrous DCM (3 mL). To 
this was added HOBt (7.4 mg, 0.06 mmol), TBTU (17 mg, 0.06 mmol), Et3N (0.01 
mL, 0.06 mmol) and NBS (19 mg, 0.11 mmol). The reaction mixture was allowed to 
stir at rt for 2 h, then washed with H2O. The organic layer was reduced using a rotary 
evaporator, to leave the crude dibrominated product 2.58 and hemiacetal 2.33. 
 
 
 
Chapter 6: Experimental Details 
Page | 151  
 
N
α
-(N
α
-[(1,1-Dimethylethoxy)carbonyl]-L-leucine-)-O-[(2-deoxy-2-[(2,2,2-
trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-
serine (2.59) 
 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-L-leucine (38 mg, 0.17 mmol), TBTU (53 mg, 
0.17 mmol), and HOBt (22 mg, 0.17 mmol) were dissolved in dry DCM (10 mL) 
under N2, in the presence of 4 Å molecular sieves. Et3N (0.06 mL, 0.45 mmol) was 
added to the reaction mixture. This was allowed to stir at rt for 15 mins. A solution 
of free amine 2.52 (89 mg, 0.13 mmol) in dry DCM (5 mL), and THF (1 mL to aid 
solubility) was then added to the reaction mixture. This was allowed to stir at rt 
overnight. The solution was filtered to remove the molecular sieves, then washed 
with a sat. NaHCO3 solution, followed by 1.0 M HCl. The organic layer was dried 
(MgSO4), and filtered. The organic layer was concentrated under reduced pressure, 
and the remaining residue was purified by column chromatography (Hex:EtOAc, 
1:1) to give the benzylated glycoside as a clear oil (64 mg, 56 %). 
Rf: 0.8 (Pet. Ether:EtOAc, 1:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 7.36-7.34 (m, 5 H, 
Ar-H), 7.13, 6.78 (each d, 1 H, N-H, J = 6 Hz), 7.01, 6.70 (each d, 1 H, N-H, J = 9 
Hz), 5.03-4.96 (m, 7 H, overlapping including ph-CH2, H-3, H-4, N-H, and β-Ha), 
4.62-4.58 (m, 2 H, overlapping α-H and β-Hb), 4.50-4.47 (m, 1 H, H-6a), 4.41-4.21 
(m, 5 H, overlapping H-1, NHC(O)CH2a, β-Ha (Leu), α-H (Leu), and H-6b), 4.08-
4.00 (m, 3 H, overlapping including β-Hb (Leu) and NHC(O)CH2b), 3.87-3.77 (m, 1 
H, H-5), 3.57-3.49 (m, 1 H, H-2), 2.04, 2.02, 1.99 (each s, 9 H, OC(O)CH3), 1.71-
1.67 (m, 1 H, CH(CH3)2), 1.48 (s, 9 H, C(CH3)3), 0.96-0.83 (m, 6 H, CH(CH3)2); 
13
C 
NMR: (CDCl3, 75 MHz) δ = 170.7, 169.1, 134.9, 128.7, 128.4, 128.0, 103.3, 95.5, 
80.7, 74.7, 72.2, 71.9, 68.7, 67.7, 62.0, 53.7, 83.4, 41.2, 31.5, 29.0, 28.4, 26.9, 24.8, 
22.6, 20.8, 20.1, 18.8, 14.1; IR: (DCM film on NaCl plate) 3367, 2926, 1751, 1677, 
1527, 1232 cm
-1; [α]D: + 6.7 (c 0.3, CH2Cl2); MS-ESI/TOF: Calculated for 
C36H50Cl3N3NaO15 (M + Na)
+
: 892.2200, found 892.2241. 
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The benzylated glycoside (58 mg, 0.07 mmol) was dissolved in EtOAc (8 mL) and 
10 % Pd/C (w/w) (20 mg) was added. The reaction vessel was placed under a H2 
atmosphere, and the reaction mixture was stirred at rt for 3 h, then filtered over 
celite. The solvent was evaporated under reduced pressure, and the remaining 
residue was purified by column chromatography (EtOAc:Hex, 1:1 to MeOH). 2.59 
was obtained as a white oily solid (30 mg, 60 %). 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-L-serine-tetradecylamide (2.61)
[258]
 
 
N
α
-[(1,1-Dimethylethoxy)carbonyl]-L-serine (300 mg, 1.46 mmol) and TBTU (510 
mg, 1.60 mmol) were dissolved in dry DCM (10 mL) under N2, in the presence of 
4Å molecular sieves. Et3N (0.41 mL, 2.9 mmol) was added to the reaction mixture. 
This was allowed to stir at rt for 15 mins. A solution of tetradecylamine (342 mg, 1.6 
mmol) in dry DCM (5 mL) was then added to the reaction mixture. This was allowed 
to stir at rt overnight. The solution was filtered to remove the molecular sieves, and 
washed with 1.0 M HCl, then dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the remaining residue was purified by 
column chromatography (Hex: EtOAc, 1:1) to give tetradecyl derivative 2.61 as a 
white solid (436 mg, 75 %). Spectroscopic data was in agreement with reported 
values.  
Rf: 0.48 (Hex:EtOAc, 1:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 6.82 (s, 1 H, 
C(O)NHCH2), 5.68 (s, 1 H, NHC(O)OC(CH3)3), 4.13-4.06 (m, 2 H, overlapping α-H 
and β-Ha), 3.66-3.61 (m, 1 H, β-Hb), 3.33-3.12 (m, 3 H, overlapping NHCH2 and 
CH2OH), 1.49-1.46 (m, 11 H, overlapping NHCH2CH2 and C(CH3)3), 1.25 (m, 22 H, 
(CH2)11), 0.88 (t, 3 H, CH2CH3, J = 6 Hz); (Lit
[258]
:
 1
H NMR: (DMSO-d6, 60 MHz) δ 
= 7.70, 6.50, 4.76, 3.88, 3.52, 3.07, 1.40, 1.58-0.74);
 
 
13
C NMR: (CDCl3, 75 MHz) δ 
= 169.6 (s, C(O)NHCH2), 154.9 (s, NHC(O)OCH2), 66.7 (t, β-C), 58.4 (d, α-C), 43.3 
(t, C(O)NHCH2), 35.7, 33.4, 33.4, 33.3, 33.2, 33.1, 33.0, 30.6, 26.4 (each t, CH2), 
32.1 (q, CH2CH3); IR: (DCM film on NaCl plate) 3403, 2921, 2851, 2112, 1653, 
1529, cm
-1
.  
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L-Serine-tetradecylamide (2.62)
[258]
 
 
The Boc protected serine derivative 2.61 (436 mg, 1.09 mmol) was placed under N2, 
and dissolved in dry DCM (10 mL). A 50 % solution (v/v) of TFA in DCM (1.68 
mL, 10 mmol) was added to the reaction at 0 ˚C, and allowed to stir at rt for 5 h. The 
solvent was evaporated under reduced pressure, and the remaining residue was 
purified through a silica plug (Hex:EtOAc, 1:2 to MeOH) to give the free amine 2.62 
as a white solid (300 mg, 91 %). 
Rf: 0.1 (DCM:MeOH, 9:1);
 1
H NMR: ((CD3)2SO, 300 MHz) δ = 8.32 (t, 1 H, 
C(O)NHCH2, J = 6 Hz), 8.07 (s, 2 H, NH2), 5.48 (s, 1 H, OH), 3.74-3.63 (m, 3 H, 
overlapping β-H and α-H), 3.13-3.07 (m, 2 H, C(O)NHCH2), 1.41-1.39 (m, 2 H, 
C(O)NHCH2CH2), 1.24 (m, 22 H, (CH2)11), 0.86 (t, 3 H, CH2CH3, J = 6 Hz); 
(Lit
[258]
: 
1
H NMR: ((CD3)2SO, 60 MHz) δ = 8.35, 8.11, 4.58, 3.71, 3.09, 1.53-0.67); 
13
C NMR: ((CD3)2SO, 75 MHz) δ = 166.3 (s, C(O)NHCH2), 60.2 (t, β-C), 54.2 (d, α-
C), 31.1, 30.6, 28.8, 28.7, 28.5, 26.1, 21.9 (each t, CH2), 13.8 (q, CH2CH3); MS-
ESI/TOF: Calculated for C16H36N2O2 (M + H)
+
:
 
301.285, found 301.286. 
N
α
-(1-Oxodecyl)-L-serine-tetradecylamide (2.63)
[105]
 
 
Decanoic acid (139 mg, 1.1 mmol) and TBTU (353 mg, 1.1 mmol) were dissolved in 
anhydrous DMF (7 mL), under N2, in the presence of 4Å molecular sieves. Et3N 
(0.27 mL, 2.0 mmol) was added to the reaction mixture. This was allowed to stir at rt 
for 15 mins. A solution of the free acid 2.62 (300 mg, 1.0 mmol) in anhydrous DMF 
(10 mL) was then added to the reaction mixture. This was allowed to stir at rt 
overnight. The molecular sieves were removed by filtration. The organic layer was 
concentrated under reduced pressure. The remaining residue was dissolved in DCM, 
Chapter 6: Experimental Details 
Page | 154  
 
and washed with sat. NaHCO3 solution, followed by brine, then dried (MgSO4), and 
filtered. The organic layer was concentrated under reduced pressure, and the crude 
product was purified by column chromatography (Hex:EtOAc, 1:1) to give the lipid 
derivative 2.63 as a white solid (144 mg, 32 %). Spectroscopic data was in 
agreement with reported values.  
Rf: 0.2 (Hex:EtOAc, 1:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 6.87 (bs, 1 H, 
C(O)NHCH2), 6.66 (d, 1 H, NHC(O)CH2, J = 6 Hz), 4.42-4.36 (m, 2 H, overlapping 
CH2OH and α-H), 4.14 (d, 1 H, β-Ha, J = 12 Hz), 3.61-3.56 (dd, 1 H, β-Hb, J = 3 Hz, 
12 Hz), 3.30-3.19 (m, 2 H, C(O)NHCH2), 2.33-2.25 (m, 2 H, NHC(O)CH2), 1.76-
1.61 (m, 2 H, NHC(O)CH2CH2), 1.48-1.44 (m, 2 H, NHCH2CH2), 1.25 (m, 34 H, 
CH2 x 17), 0.88 (t, 6 H, CH2CH3); (Lit
[105]
: 
1
H NMR: (CDCl3, 250 MHz) δ = 6.83, 
6.64, 4.45-4.30, 4.20-4.10, 3.70-3.50, 3.30-3.15, 2.30-2.15, 1.75-1.40, 1.40-1.15, 
0.88); 
13
C NMR: (CDCl3, 75 MHz) δ = 174.5, 173.0 (each s, NHC(O)CH2 and 
C(O)NHCH2), 63.3 (t, β-C), 53.3 (d, α-C), 39.5 (t, C(O)NHCH2), 36.4, 31.9, 31.9, 
29.7, 29.6, 29.5, 29.4, 29.4, 29.3, 29.2, 26.9, 25.6, 22.7 (each t, CH2), 14.1 (q, 
CH2CH3); MS-ESI/TOF: Calculated for C27H54N2O3K2 (M + 2K)
+2 
266.1699, found 
266.1683. 
N
α
-(Benzyloxycarbonyl)-L-serine-tetradecylamide (2.65)
[43]
 
 
N
α
-(Benzyloxycarbonyl)-L-serine (500 mg, 2.09 mmol), TBTU (738 mg, 2.29 mmol) 
and HOBt (309 mg, 2.29 mmol) were dissolved in dry DCM (25 mL), under N2, in 
the presence of 4Å molecular sieves. Et3N (0.58 mL, 4.18 mmol) was added to the 
reaction mixture. This was allowed to stir at room temp for 15 mins. A solution of 
tetradecylamine (488 mg, 2.29 mmol) in dry DCM (5 mL) was then added to the 
reaction mixture, and allowed to stir at rt overnight. The solution was filtered to 
remove the molecular sieves, then dissolved in DCM. The organic layer was washed 
with 1.0 M HCl, followed by brine, then dried (MgSO4), and filtered. The organic 
layer was concentrated under reduced pressure, and the crude product was purified 
by column chromatography (Hex:EtOAc, 2:1 to 1:1) to give the tetradecyl derivative 
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2.65 as an off-white solid (500 g, 55 %). Spectroscopic data was in agreement with 
reported values.
  
Rf: 0.4 (Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.37-7.31 (m, 5 H, Ph-
H), 6.70 (s, 1 H, C(O)NHCH2), 5.99 (d, 1 H, NHC(O)OBn, J = 6 Hz), 5.10 (s, 2 H, 
Ph-CH2), 4.22-4.16 (m, 1 H, α-H), 4.07-4.03 (dd, 1 H, β-Ha, J = 3 Hz, 9 Hz), 3.77-
3.63 (m, 2 H, overlapping β-Hb and CH2OH), 3.24-3.17 (m, 2 H, NHCH2), 1.44 (s, 2 
H, NHCH2CH2), 1.25 (m, 22 H, (CH2)11), 0.87 (t, 3 H, CH2CH3, J = 12 Hz); (Lit
[43]
: 
1
H NMR: (CDCl3, 270 MHz) δ = 7.36, 5.14, 4.15, 3.65, 3.23, 1.47, 1.25, 0.88); 
13
C 
NMR: (CDCl3, 75 MHz) δ = 170.8 (s, C(O)NHCH2), 156.8 (s, NHC(O)OBn), 135.9 
(s, Ph-C), 128.6, 128.3, 128.0 (each d, Ph-CH), 67.3 (t, Ph-CH2), 62.8 (t, β-C), 55.5 
(d, α-C), 39.7 (t, C(O)NHCH2), 31.9 (t, NHCH2CH2), 29.7, 29.6, 29.6, 29.5, 29.4, 
29.3, 29.3, 26.8, 22.7 (each t, CH2), 14.1 (q, CH2CH3); IR: (KBr disc) 3294, 2919, 
2850, 1694, 1650, 1546, 1240 cm
-1
; MS-ESI/TOF: Calculated for C25H43N2O4 (M + 
H)
+
: 437.3278, found 437.3265. 
N
α
-(Benzyloxycarbonyl)-O-[(2-deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-
3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-tetradecylamide (2.67) 
 
Imidate donor 2.34 (425 mg, 0.68 mmol) and protected serine derivative 2.65 (248 
mg, 0.57 mmol) were placed under N2, and dissolved in dry DCM (30 mL), in the 
presence of 3Å molecular sieves. A freshly made solution of 0.04 M TMSOTf (1.42 
mL, 0.06 mmol) was added. The reaction was left to stir at rt overnight. The reaction 
was quenched by adding solid NaHCO3 (100 mg) to the reaction mixture and 
allowed to stir for 5 mins. H2O (50 mL) was added to the flask. The product was 
extracted twice with DCM. The organic layers were combined and washed with 
H2O, dried (MgSO4), and filtered to leave a brown, foamy oil. The crude product 
was purified by column chromatography (Hex:EtOAc, 2:1 to 1:1) to give glycoside 
2.67 as an off-white solid (450 mg, 88 %). 
Rf: 0.6 (Hex:EtOAc, 1:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 7.39-7.31 (m, 5 H, Ph-
H), 6.44 (s, 1 H, C(O)NHCH2), 5.76 (s, 1 H, NHC(O)OBn), 5.46 (s, 1 H, 
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NHC(O)OCH2), 5.25-5.00 (m, 4 H, overlapping H-3, H-4, and Ph-CH2), 4.84-4.47 
(m, 3 H, overlapping NHC(O)OCH2 and H-1), 4.37-4.36 (m, 1 H, α-H), 4.25-4.01 
(m, 3 H, overlapping H-6 and β-Ha), 3.84-3.64 (m, 3 H, overlapping β-Hb, H-5, and 
H-2), 3.28-3.19 (m, 2 H, C(O)NHCH2), 2.05, 2.03, 2.02 (each s, 9 H, OC(O)CH3), 
1.49 (bs, 2 H, NHCH2CH2), 1.25 (m, 22 H, (CH2)11), 0.88 (t, 3 H, CH2CH3, J = 6 
Hz); 
13
C NMR: (CDCl3, 75 MHz) δ = 170.7 (s, C(O)NHCH2), 169.4, 169.1 (each s, 
OC(O)CH3), 154.4 (s, NHC(O)OCH2), 154.4 (s, NHC(O)OBn), 136.1 (s, Ph-C), 
101.9 (d, C-1), 95.4 (s, CCl3), 74.5 (t, NHC(O)OCH2), 72.1 (d, C-5), 71.8 (d, C-3), 
70.2 (t, β-C), 68.3 (d, C-4), 67.2 (t, Ph-CH2), 61.8 (t, C-6), 56.1 (d, C-2), 53.9 (d, α-
C), 39.8 (t, C(O)NHCH2), 31.9, 29.7, 29.7, 29.6, 29.4, 29.3, 29.3, 26.9, 22.7 (each t, 
CH2), 20.7, 20.6 (each q, OC(O)CH3), 14.1 (q, CH2CH3); m.p.: 116-120 ˚C; IR: 
(DCM film on NaCl plate) 3375, 2928, 1748, 1652, 1535, 1233 cm
-1
; [α]D: + 8 (c 
1.0, CH2Cl2); MS-ESI/TOF: Calculated for C40H60Cl3KN3O13 (M + K)
+
: 935.2856, 
found 935.2859.  
N
α
-(Benzyloxycarbonyl)-O-[(2-deoxy-2-acetamido-3,4,6-tri-O-acetyl)-β-D-
glucopyranosyl]-L-serine-tetradecylamide (2.68) 
 
Glycoside 2.67 (225 mg, 0.25 mmol) and freshly activated zinc powder (activated by 
rinsing three times with 2 M HCl, followed by H2O, then acetone, and ether) (330 
mg, 5.0 mmol) were dissolved/ suspended in acetic anhydride (8 mL, 84 mmol) and 
THF (2 mL) was added to aid solubility. Et3N (0.1 mL, 0.70 mmol) was added to the 
reaction mixture. The reaction mixture was allowed to stir at rt for 2 h, and then 
filtered through celite to remove zinc salts. The solvent was evaporated under 
reduced pressure, and the remaining residue was dissolved in DCM. This was 
washed with brine, then dried (MgSO4), and filtered. The organic layer was 
concentrated under reduced pressure, and the crude product was purified by column 
chromatography (Hex:EtOAc, 1:1 to MeOH) to give N-acetyl protected glycoside 
2.68 as an off-white solid (132 mg, 69 %).  
Rf: 0.6 (DCM:MeOH, 9:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.34 (s, 5 H, Ph-H), 
6.56 (s, 1 H, C(O)NHCH2), 6.03 (d, 1 H, NHC(O)CH3, J = 9 Hz), 5.87 (s, 1 H, 
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NHC(O)OBn), 5.19-5.01 (m, 4 H, overlapping H-3, Ph-CH2, and H-4), 4.62 (d, 1 H, 
H-1, J = 6 Hz), 4.36 (s, 1 H, α-H), 4.24-4.11 (m, 2 H, H-6), 4.07-3.96 (m, 2 H, 
overlapping β-Ha and H-2), 3.79-3.73 (m, 2 H, overlapping β-Hb and H-5), 3.21 (t, 2 
H, C(O)NHCH2, J = 6 Hz), 2.05, 2.02, 1.89 (each s, 12 H, OC(O)CH3 and 
NHC(O)CH3), 1.48 (s, 2 H, NHCH2CH2), 1.30 (m, 22 H, (CH2)11), 0.87 (t, 3 H, 
CH2CH3, J = 6 Hz); 
13
C NMR: (CDCl3, 75 MHz) δ = 171.1 (s, NHC(O)CH3), 170.7 
(s, C(O)NHCH2), 169.3, 169.2 (each s, OC(O)CH3), 156.3 (s, NHC(O)OBn), 136.1 
(s, Ph-C), 128.5, 128.3, 128.1 (each d, Ph-CH), 101.8 (d, C-1), 72.4 (d, C-5), 72.0 (d, 
C-3), 69.6 (t, β-C), 68.3 (d, C-4), 67.1 (t, Ph-CH2), 61.9 (t, C-6), 54.1 (d, overlapping 
α-C and C-2), 39.8 (t, C(O)NHCH2), 31.9, 29.7, 29.6, 29.6, 29.4, 29.3, 26.9, 22.7 
(each t, CH2), 23.2 (q, NHC(O)CH3), 20.7, 20.6 (each q, OC(O)CH3), 14.1 (q,  
CH2CH3); m.p.: 156-160 ˚C; IR: (DCM film on NaCl plate) 3431, 2923, 2107, 1742, 
1650, 1239 cm
-1
; [α]D: - 10 (c 0.20 , CH2Cl2); MS-ESI/TOF: Calculated for 
C39H65N4O12 (M + NH4)
+
: 781.4593, found 781.4556. 
O-[(2-Deoxy-2-acetamido-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-serine-
tetradecylamide (2.69)
[83]
 
 
Protected glycoside 2.68 (100 mg, 0.13 mmol) was dissolved in EtOAc (25 mL) and 
placed under N2.  10 % Pd/C (w/w) (50 mg) was added to the reaction mixture, and 
the flask was placed under H2. The reaction mixture was allowed to stir at rt for 5 h. 
The reaction mixture was filtered through celite, and the solvent was evaporated 
under reduced pressure to leave free amine 2.69 as a white solid (80 mg, 98 %). 
Spectroscopic data was in agreement with reported values. 
 
1
H NMR: (CD3OD, 300 MHz) δ = 5.23 (t, 1 H, H-3, J = 9 Hz), 4.99 (t, 1 H, H-4, J = 
9 Hz), 4.73 (d, 1 H, H-1, J = 9 Hz), 4.34-4.28 (dd, 1 H, H-6a, J = 6 Hz, 12 Hz), 4.18-
4.14 (m, 1 H, H-6b), 3.94-3.84 (m, 4 H, overlapping H-2, H-5, and β-H), 3.23-3.15 
(m, 2 H, C(O)NHCH2), 2.07 (s, 3 H, NHC(O)CH3), 2.02, 1.99, 1.94 (each s, 9 H, 
OC(O)CH3), 1.55-1.51 (m, 2 H, NHCH2CH2), 1.17 (m, 22 H, (CH2)11), 0.91 (t, 3 H, 
CH2CH3, J = 6 Hz); (Lit
[83]
: 
1
H NMR: (CDCl3, 270 MHz) δ = 5.71, 5.17, 5.07, 4.59, 
4.25, 4.13, 3.98, 3.90, 3.82, 3.70-3.64, 3.54, 3.26-3.18, 2.09, 2.03, 1.95, 1.50, 1.26, 
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0.88); 
13
C NMR: (CD3OD, 75 MHz) δ = 170.9 (s, NHC(O)CH3), 170.4 (s, 
C(O)NHCH2), 169.0 (s, OC(O)CH3), 100.7 (d, C-1), 72.7 (d, C-5), 71.6 (d, C-3), 
69.7 (t, β-C), 68.7 (d, C-4), 61.8 (t, C-6), 53.9 (d, overlapping α-C and C-2), 39.1 (t, 
C(O)NHCH2), 31.7, 29.4, 29.1, 26.6, 22.3 (each t, CH2), 21.5 (q, NHC(O)CH3), 
19.3, 19.2 (each q, OC(O)CH3), 13.1 (q,  CH2CH3); MS-ESI/TOF: Calculated for 
C62H114N7O20 (2M + NH4)
+
: 1276.8113, found 1276.8155.  
N
α
-(1-Oxodecyl)-O-[(2-deoxy-2-acetamido-3,4,6-tri-O-acetyl)-β-D-
glucopyranosyl]-L-serine-tetradecylamide (2.70) 
 
Decanoic acid (30 mg, 0.19 mmol), TBTU (60 mg, 0.19 mmol), and HOBt (30 mg, 
0.19 mmol) were dissolved in anhydrous DMF (20 mL) under N2, in the presence of 
3Å molecular sieves. Anhydrous Et3N (0.05 mL, 0.34 mmol) was added to the 
reaction mixture. This was allowed to stir at rt for 15 mins. A solution of free amine 
2.69 (106 mg, 0.16 mmol) in anhydrous DMF (5 mL) was then added to the reaction 
mixture, and allowed to stir at rt overnight. The solvent was evaporated under 
reduced pressure, and the remaining residue was washed with 1.0 M HCl, dried 
(MgSO4), and filtered. The organic layer was concentrated using a rotary evaporator, 
and the crude product was purified by column chromatography (Hex:EtOAc, 1:2 to 
DCM:MeOH, 9:1) to give glycolipid derivative 2.70 as a cream solid (96 mg, 72 %).  
Rf: 0.4 (DCM:MeOH, 9:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 6.64-6.60 (m, 2 H, 
overlapping C(O)NHCH2 and NHC(O)CH2), 5.99 (d, 1 H, NHC(O)CH3, J = 9 Hz), 
5.17 (t, 1 H, H-3, J = 9 Hz), 5.06 (t, 1 H, H-4, J = 9 Hz), 4.69 (d, 1 H, H-1, J = 9 Hz), 
4.63-4.57 (m, 1 H, α-H), 4.29-4.23 (dd, 1 H, H-6a, J = 6 Hz, 12 Hz), 4.18-4.14 (m, 1 
H, H-6b), 4.03-3.98 (m, 2 H, overlapping β-Ha and H-2), 3.77-3.71 (m, 2 H, 
overlapping β-Hb and H-5), 3.28-3.15 (m, 2 H, C(O)NHCH2), 2.22 (t, 2 H, 
NHC(O)CH2, J = 6 Hz), 2.08, 2.03, 1.94 (s, 12 H,  OC(O)CH3 and NHC(O)CH3), 
1.61 (s, 2 H, NHC(O)CH2CH2), 1.49 (s, 2 H, NHCH2CH2), 1.30 (m, 34 H, CH2 x 
17), 0.87 (t, 6 H, CH2CH3, J = 6 Hz); 
13
C NMR: (CDCl3, 75 MHz) δ = 172.7 (s, 
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overlapping C(O)NHCH2 and NHC(O)CH2), 170.0 (s, NHC(O)CH3), 169.6, 169.5, 
168.3 (each s, OC(O)CH3), 101.1 (d, C-1), 71.5 (d, C-5), 71.1 (d, C-3), 68.5 (t, β-C), 
67.2 (d, C-4), 60.9 (t, C-6), 53.1 (d, C-2), 51.1(d, α-C), 38.8 (t, C(O)NHCH2), 35.4 
(t, NHC(O)CH2), 30.9 (t, NHCH2CH2), 30.8, 28.7, 28.6, 28.6, 28.4, 28.4, 28.3, 25.9, 
24.6, 21.7 (each t, CH2), 22.3 (q, NHC(O)CH3), 19.7, 19.6 (each q, OC(O)CH3), 13.0 
(q,  CH2CH3); m.p.: 162-168 ˚C; IR: (DCM film on NaCl plate) 3419, 2091, 1641 
cm
-1
; [α]D: - 20 (c 0.1, CH2Cl2); MS-ESI/TOF: Calculated for C41H74N3O11 (M + 
H)
+
: 784.5318, found 784.5316.  
N
α
-(1-Oxodecyl)-O-[(2-deoxy-2-acetamido)-β-D-glucopyranosyl]-L-serine-
tetradecylamide (2.71) 
 
Protected glycolipid 2.70 (48 mg, 0.06 mmol) was dissolved in MeOH (5 mL). H2O 
(2.5 mL) was added, followed by Et3N (0.10 mL). THF (2 mL) was added to aid 
solubility. The reaction mixture was stirred at 40 ˚C overnight. A white precipitate 
crashed out of solution. The solvent was evaporated under reduced pressure to leave 
a yellow oil and a white solid, which were triturated with MeOH (3 x 5 mL) to give 
the deprotected glycolipid 2.71 as a white solid (insoluble in MeOH) (16 mg, 41 %).  
Rf: 0.23 (DCM:MeOH, 9:1);
 1
H NMR: (C5D5N, 600 MHz) δ = 9.00 (d, 1 H, 
NHC(O)CH3, J = 6 Hz), 8.68-8.67 (m, 2 H, overlapping C(O)NHCH2 and 
NHC(O)CH2), 5.36 (d, 1 H, α-H, J = 6 Hz), 5.09 (d, 1 H, H-1, J = 12 Hz), 4.57-4.53 
(m, 1 H, H-2), 4.51-4.48 (m, 2 H, overlapping H-6a and β-Ha), 4.34-4.31 (m, 1 H, β-
Hb), 4.29-4.25 (m, 2 H, overlapping H-3 and H-6b), 4.13 (t, 1 H, H-4, J = 6 Hz), 
3.87-3.84 (m, 1 H, H-5), 3.61-3.41 (m, 2 H, C(O)NHCH2), 2.47 (t, 2 H, 
NHC(O)CH2, J = 6 Hz), 2.16 (s, 3 H, NHC(O)CH3), 1.80-1.77 (m, 2 H, 
NHC(O)CH2CH2), 1.64-1.61 (m, 2 H, NHCH2CH2), 1.33-1.17 (m, 34 H, CH2 x 17), 
0.88-0.83 (m, 6 H, CH2CH3); 
13
C NMR: (C5D5N, 150 MHz) δ = 174.4, 172.2, 171.6 
(each s, C(O)NHCH2, NHC(O)CH2, and NHC(O)CH3), 103.3(d, C-1), 80.1 (d, C-5), 
77.2 (d, C-3), 73.0 (d, C-4), 70.2 (t, β-C), 63.3 (t, C-6), 57.9 (d, C-2), 55.8 (d, α-C), 
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40.7 (t, C(O)NHCH2), 37.2 (t, NHC(O)CH2), 32.8, 32.7, 30.7, 30.6, 30.4, 30.3, 30.2, 
28.0, 26.8, 23.7, 23.6 (each t, CH2), 24.3 (q, NHC(O)CH3), 15.0 (q,  CH2CH3); MS-
ESI/TOF: Calculated for C35H68N3O8 (M + H)
+
: 658.5001, found 658.4972. 
N
α
-(1-Oxotetracosanoyl)-O-[(2-deoxy-2-acetamido-3,4,6-tri-O-acetyl)-β-D-
glucopyranosyl]-L-serine-tetradecylamide (2.73) 
 
Tetracosanoic acid (182 mg, 0.45 mmol), TBTU (159 mg, 0.49 mmol), and HOBt 
(67 mg, 0.49 mmol) were dissolved in anhydrous DMF (15 mL) under N2, in the 
presence of 4Å molecular sieves. Anhydrous Et3N (0.13 mL, 0.9 mmol) was added 
to the reaction mixture. This was allowed to stir at rt for 15 mins. A solution of free 
amine 2.69 (283 mg, 0.45 mmol) in anhydrous DMF (5 mL) was added to the 
reaction mixture, and allowed to stir at rt for 5 h. The solvent was evaporated under 
reduced pressure. The remaining residue was dissolved in DCM and washed with 1.0 
M HCl, then dried (MgSO4), and filtered. The organic layer was concentrated under 
reduced pressure, and the crude product was purified by column chromatography 
(DCM:MeOH, 12:1) to give glycolipid derivative 2.73 as a white solid (63 mg, 17 
%).  
Rf: 0.47 (DCM:MeOH, 12:1);
 1
H NMR: (CDCl3, 300 MHz) δ = 6.58-6.56 (m, 2 H, 
overlapping C(O)NHCH2 and NHC(O)CH2), 5.80 (d, 1 H, NHC(O)CH3, J = 9 Hz), 
5.14-5.07 (m, 2 H, overlapping H-3 and H-4), 4.68 (d, 1 H, H-1, J = 9 Hz), 4.64-4.60 
(m, 1 H, α-H), 4.27-4.14 (m, 2 H, H-6), 4.05-3.98 (m, 2 H, overlapping β-Ha and H-
2), 3.77-3.71 (m, 2 H, overlapping β-Hb and H-5), 3.24-3.20 (m, 2 H, C(O)NHCH2), 
2.24-2.18 (m, 2 H, NHC(O)CH2), 2.08, 2.04, 1.95 (each s, 12 H, OC(O)CH3 and 
NHC(O)CH3), 1.61 (bs, 2 H, NHC(O)CH2CH2), 1.49 (bs, 2 H, NHCH2CH2), 1.25 
(m, 62 H, CH2 x 31), 0.87 (t, 6 H, CH2CH3, J = 6 Hz); 
13
C NMR: (CDCl3, 75 MHz) δ 
= 173.6, 171.2, 170.7, 170.5, 169.4, 169.3 (each s, C(O)NHCH2, NHC(O)CH2, 
NHC(O)CH3, and OC(O)CH3), 102.1 (d, C-1), 72.4 (d, C-3), 72.2 (d, C-5), 69.6 (t, 
β-C), 68.0 (d, C-4), 61.8 (t, C-6), 54.2 (d, C-2), 52.0 (d, α-C), 39.8 (t, C(O)NHCH2), 
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36.5 (t, NHC(O)CH2CH2), 32.0, 29.7, 29.6, 29.4, 29.3, 26.9, 25.6, 22.7 (each t, CH2), 
23.4 (q, NHC(O)CH3), 20.8, 20.7, 20.7 (each q, OC(O)CH3), 14.0 (q,  CH2CH3); 
m.p.: 164-168 ˚C; [α]D: - 23 (c 0.26, CH2Cl2); IR: (DCM film on NaCl plate) 3293, 
2919, 2850, 1745, 1667, 1643, 1554, 1260 cm
-1
; MS-ESI/TOF: Calculated for 
C55H102N3O11 (M + H)
+
: 980.7509, found 980.7513.  
N
α
-(1-Oxotetracosanoyl)-O-[(2-deoxy-2-acetamido)-β-D-glucopyranosyl]-L-
serine-tetradecylamide (2.74) 
 
Protected glycolipid 2.73 (22 mg, 0.02 mmol) was dissolved in warm DCM. MeOH 
(3 mL) and H2O (1.5 mL) were added to the reaction mixture, followed by Et3N 
(0.10 mL). The reaction mixture was stirred at 45 ˚C overnight. The solvent was 
evaporated under reduced pressure to leave a yellow oil and a white solid, which was 
triturated with MeOH (3 x 5 mL) to give deprotected glycolipid 2.74 as a white solid 
(insoluble in MeOH) (11 mg, 57 %).  
Rf: 0.18 (DCM: MeOH, 12:1); 
1
H NMR: (C5D5N, 600 MHz) δ = 9.03 (d, 1 H, 
NHC(O)CH3, J = 6 Hz), 8.67 (m, 2 H, overlapping NHCH2 and NHC(O)CH2, 
partially overlapped by solvent peak), 5.39-5.35 (m, 1 H, α-H), 5.12-5.11 (m, 1 H, 
H-1, overlapped by H2O peak), 4.56-4.35 (m, 3 H, overlapping H-2, H-6a, and β-Ha), 
4.33-4.27 (m, 3 H, overlapping β-Hb, H-3, and H-6b), 4.15 (t, 1 H, H-4, J = 6 Hz), 
3.87-3.84 (m, 1 H, H-5), 3.47-3.43 (m, 2 H, C(O)NHCH2), 2.50 (t, 2 H, 
NHC(O)CH2, J = 6 Hz), 2.18 (s, 3 H, NHC(O)CH3), 1.82-1.77 (m, 2 H, 
NHC(O)CH2CH2), 1.65-1.61 (m, 2 H, NHCH2CH2), 1.41-1.21 (m, 62 H, CH2 x 31), 
0.98-0.86 (m, 6 H, CH2CH3); 
13
C NMR: (C5D5N, 150 MHz) δ = 174.4, 172.2, 171.6 
(each s, C(O)NHCH2, NHC(O)CH2, and NHC(O)CH3), 103.4 (d, C-1), 79.4 (d, C-5), 
77.3 (d, C-3), 73.1 (d, C-4), 70.2 (t, β-C), 63.3 (t, C-6), 58.1 (d, C-2), 54.8 (d, α-C), 
40.7 (t, C(O)NHCH2), 37.2 (t, NHC(O)CH2), 32.9, 30.7, 28.1, 26.9, 23.7 (each t, 
CH2), 24.2 (q, NHC(O)CH3), 15.1 (q, CH2CH3); MS-MALDI-TOF: Calculated for 
C49H95N3O8Na (M + Na)
+
: 876.7017, found 876.7047. 
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N
α
-(9-Fluorenylmethoxycarbonyl)-L-serine-phenylmethyl ester (3.2)
[259]
 
 
Method A 
N
α
-(9-Fluorenylmethoxycarbonyl)-L-serine (800 mg, 2.4 mmol) and K2CO3 (500 mg, 
3.6 mmol) were dissolved/suspended in anhydrous DMF (5 mL). Benzyl bromide 
(0.38 mL, 3.17 mmol) was then added to the reaction, and it was allowed to stir at rt 
overnight. The solvent was concentrated under reduced pressure, and the remaining 
residue washed with 1.0 M HCl and brine, then dried (MgSO4), and filtered. The 
organic layer was concentrated under reduced pressure, and the remaining residue 
was purified by column chromatography (Hex:EtOAc, 2:1 to 1:1) to give benzyl 
protected 3.2 as a white syrup (822 mg, 81 %). Spectroscopic data is in agreement 
with literature values.  
Method B 
N
α
-(9-Fluorenylmethoxycarbonyl)-L-serine (800 mg, 2.4 mmol) and K2CO3 (500 mg, 
3.6 mmol) were dissolved/suspended in anhydrous DMF (5 mL), under N2. 
Tetrabutylammonium iodide (90 mg, 0.24 mmol) was added to the reaction mixture, 
and this was allowed to stir for 10 mins at rt. Benzyl bromide (0.84 mL, 7.32 mmol) 
was then added to the reaction, and it was allowed to stir at rt for 7 h. The solvent 
was concentrated under reduced pressure. The remaining residue was dissolved in 
EtOAc, and washed twice with sat. NaHCO3 solution, then dried (MgSO4), and 
filtered. The organic layer was concentrated under reduced pressure, and the 
remaining residue was purified by column chromatography (Hex:EtOAc, 2:1 to 1:1) 
to give benzyl protected 3.2 as a white syrup (842 mg, 82 %). Spectroscopic data is 
in agreement with literature values.  
Method C 
N
α
-(9-Fluorenylmethoxycarbonyl)-L-serine (680 mg, 2.0 mmol) and DIPEA (0.25 
mL, 3.0 mmol) were dissolved in anhydrous DMF (6 mL). Benzyl bromide (0.32 
mL, 2.7 mmol) was then added to the reaction, and it was allowed to stir at rt 
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overnight. The solvent was concentrated under reduced pressure, and the remaining 
residue was dissolved in DCM, and washed with 1.0 M HCl and brine, then dried 
(MgSO4), and filtered. The organic layer was concentrated under reduced pressure, 
and the remaining residue was purified by column chromatography (Hex:EtOAc, 
1:1) to give benzyl protected 3.2 as a white syrup (722 mg, 85 %). Spectroscopic 
data is in agreement with literature values.  
Rf: 0.6 (Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.79 (d, 2 H, Fmoc-H, J 
= 9 Hz), 7.63 (d, 2 H, Fmoc-H, J = 6 Hz), 7.42-7.28 (m, 9 H, overlapping Fmoc-H 
and Ph-H), 6.01 (d, 1 H, NH-Fmoc, J = 6 Hz), 5.23 (s, 2 H, Ph-CH2), 4.52-4.37 (m, 3 
H, overlapping α-H and Fmoc-CH2), 4.25-4.13 (m, 1 H, Fmoc-CH), 4.02 (bs, 1 H, β-
Ha), 3.94 (bs, 1 H, β-Hb), 2.84 (bs, 1 H, CH2OH);  (Lit
[259]
:
 1
H NMR: (CDCl3, 300 
MHz) δ = 7.77, 7.60, 7.43-7.26, 5.75, 5.23, 4.50-4.20, 4.22, 4.07, 2.15); 13C NMR: 
(CDCl3, 75 MHz) δ = 170.6 (s, C(O)OBn), 156.4 (s, Fmoc-C(O)), 143.8, 143.7, 
141.4, 141.3 (each s, Fmoc-C), 135.2 (s, Ph-C), 128.6, 128.5, 128.3, 128.2, 127.7, 
127.2 (each d, Fmoc-CH and Ph-CH), 125.1, 120.4 (each d, Fmoc-CH), 67.5 (t, Ph-
CH2), 67.3 (t, Fmoc-CH2), 63.2 (t, β-C), 56.3 (d, α-C), 47.1 (d, Fmoc-CH); IR: 
(DCM film on NaCl plate) 3375, 3065, 2950, 1719, 1520, 1450, 1195 cm
-1
; MS-
ESI/TOF: Calculated for C25H24NO5 (M + H)
+ 
: 418.1649, found 418.1654.   
N
α
-(9-Fluorenylmethoxycarbonyl)-O-[(2-deoxy-2-[(2,2,2-
trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl)-β-D-glucopyranosyl]-L-
serine-phenylmethyl ester (3.3)
[178]
 
 
Fmoc protected serine derivative 3.2 (411 mg, 0.97 mmol) and imidate 2.34 (666 
mg, 1.07 mmol) were dissolved in dry DCM, under N2. A freshly made solution of 
0.04 N TMSOTf in dry DCM (2.42 mL, 0.10 mmol) was then added to the reaction 
mixture. This was stirred at rt overnight. The reaction mixture was washed with sat. 
NaHCO3 solution, followed by brine, then the organic layer was dried (MgSO4), and 
filtered. The organic layer was concentrated under reduced pressure, and the crude 
product was purified by column chromatography (Hex:EtOAc, 2:1 to 1:1) to yield 
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glycoside 3.3 as a yellow oil (540 mg, 62 %). Spectroscopic data was in agreement 
with reported values. 
Rf: 0.67 (Hex:EtOAc, 1:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.77 (d, 2 H, Fmoc-H, J 
= 9 Hz), 7.61 (d, 2 H, Fmoc-H, J = 6 Hz), 7.42-7.32 (m, 9 H, overlapping Fmoc-H 
and Ph-H), 5.80 (d, 1 H, NH-Fmoc, J = 6 Hz), 5.29-5.18 (m, 4 H, overlapping H-3, 
NHC(O)OCH2 and Ph-CH2), 5.03 (t, 1 H, H-4, J = 9 Hz), 4.79-4.72 (m, 1 H, 
NHC(O)OCH2a), 4.62-4.50 (m, 4 H, overlapping α-H, H-1, Fmoc-CH2a and 
NHC(O)OCH2b), 4.26-4.20 (m, 4 H, overlapping Fmoc-CH, β-Ha, H-6a and Fmoc-
CH2b ), 4.09 (d, 1 H, H-6b, J = 9 Hz), 3.92-3.89 (m, 1 H, β-Hb), 3.62-3.51 (m, 2 H, 
overlapping H-2 and H-5), 2.03 (s, 9 H, OC(O)CH3); (Lit
[178]
: 
1
H NMR: (CDCl3, 400 
MHz) δ = 7.76, 7.61, 7.42-7.27, 5.81, 5.31-5.17, 5.02, 4.81-4.58, 4.53-4.39, 4.23, 
4.10, 3.92, 3.59, 2.07, 2.03, 2.02); 
13
C NMR: (CDCl3, 75 MHz) δ = 170.6, 170.5, 
169.4 (each s, OC(O)CH3 and C(O)OBn), 156.1 (s, NHC(O)OCH2), 154.1 (s, Fmoc-
C(O)), 143.9, 143.6, 141.3 (each s, Fmoc-C), 135.2 (s, Ph-C), 128.6, 128.5, 128.3, 
127.8, 127.2 (each d, Fmoc-CH and Ph-CH), 125.2, 125.1, 120.0 (each d, Fmoc-
CH), 95.3 (d, C-1), 83.2 (s, CCl3), 74.5 (t, NHC(O)OCH2), 71.9 (d, C-5), 71.7 (d, C-
3), 69.7 (t, β-C), 68.5 (d, C-4), 67.6 (t, Fmoc-CH2), 67.4 (t, Ph-CH2), 61.9 (t, C-6), 
56.4 (d, C-2), 56.1 (d, α-C), 47.1 (d, Fmoc-CH), 20.7, 20.6 (each q, OC(O)CH3); 
m.p.: 46-50 ˚C; IR: (DCM film on NaCl plate) 3342, 3066, 2957, 1750, 1531, 1233 
cm
-1
; MS-ESI/TOF: Calculated for C40H42Cl3N2O14 (M + H)
+
 : 879.1696, found 
879.1678. 
N
α
-(9-Fluorenylmethoxycarbonyl)-O-[(2-deoxy-2-acetamido-3,4,6-tri-O-acetyl)-
β-D-glucopyranosyl]-L-serine-phenylmethyl ester (3.4)[178] 
 
Protected glycoside 3.3 (135 mg, 0.15 mmol) was dissolved in Ac2O (6 mL) and 
freshly activated zinc dust (Activated by rinsing twice with 2 M HCl, followed by 
H2O, then acetone, and ether) (197 mg, 3.0 mmol) was added. The reaction mixture 
was stirred at rt overnight, then filtered over celite to remove the zinc salts. The 
solvent was concentrated under reduced pressure, and the remaining residue was 
purified by column chromatography (Hex:EtOAc, 2:1 to 1:2) to give the N-acetyl 
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derivative 3.4 as a white solid (91 mg, 80 %). Spectroscopic data was in agreement 
with reported values. 
Rf: 0.24 (Hex:EtOAc, 1:2); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.76 (d, 2 H, Fmoc-H, J 
= 9 Hz), 7.63 (d, 2 H, Fmoc-H, J = 9 Hz), 7.41-7.32 (m, 9 H, overlapping Fmoc-H 
and Ph-H), 6.00-5.94 (m, 2 H, overlapping NHC(O)CH3 and NH-Fmoc), 5.29-5.17 
(m, 3 H, overlapping H-3 and Ph-CH2), 5.02 (t, 1 H, H-4, J = 9.6 Hz), 4.67 (d, 1 H, 
H-1, J = 9 Hz), 4.52-4.34 (m, 3 H, overlapping α-H and Fmoc-CH2), 4.20-4.05 (m, 4 
H, overlapping Fmoc-CH, β-Ha, and H-6), 3.86-3.63 (m, 3 H, overlapping β-Hb, H-2 
and H-5), 2.00 (s, 9 H, OC(O)CH3), 1.85 (s, 3 H, NHC(O)CH3); (Lit
[178]
: 
1
H NMR: 
(CDCl3, 400 MHz) δ = 7.77, 7.63, 7.42-7.30, 5.81, 5.37, 5.25, 5.19, 5.02, 4.67, 4.53, 
4.45, 4.23, 4.08, 3.86, 3.70, 3.62, 2.07, 2.04, 2.03, 1.82); 
13
C NMR: (CDCl3, 75 
MHz) δ = 169.9, 169.7, 169.6, 168.6, 168.4 (each s, OC(O)CH3, NHC(O)CH3, and 
C(O)OBn), 155.1 (s, Fmoc-C(O)), 142.8, 140.2 (each s, Fmoc-C), 134.2 (s, Ph-C), 
127.5, 127.4, 127.1, 126.7, 126.1 (each d, Fmoc-CH and Ph-CH), 124.1, 118.9 (each 
d, Fmoc-CH), 99.6 (d, C-1), 71.0 (d, C-3), 70.8 (d, C-5), 67.9 (t, β-C), 67.5 (d, C-4), 
66.4 (t, Fmoc-CH2), 65.9 (t, Ph-CH2), 61.0 (t, C-6), 53.4 (d, α-C), 53.3 (d, C-2), 46.1 
(d, Fmoc-CH), 22.0 (q, NHC(O)CH3), 19.6, 19.5 (each q, OC(O)CH3); IR: (DCM 
film on NaCl plate) 3307, 3065, 2954, 1748, 1663, 1532, 1232 cm
-1
; MS-ESI/TOF: 
Calculated for C39H43N2O13 (M + H)
+
: 747.2760, found 747.2788.   
N
α
-(9-Fluorenylmethoxycarbonyl)-O-[(2-deoxy-2-acetamido-3,4,6-tri-O-acetyl)-
β-D-glucopyranosyl]-L-serine (3.5)[178] 
 
Protected glycoside 3.4 (402 mg, 0.53 mmol) was placed under N2, and dissolved in 
DCM (4 mL). EtOAc (15 mL) was added, followed by 10 % Pd/C (w/w) (20 mg) 
and the flask placed under H2. The reaction was stirred at rt overnight. The Pd/C was 
removed by filtration over celite, and the solvent was evaporated under reduced 
pressure to give free acid 3.5 as a white solid (252 mg, 70 %). Spectroscopic data 
was in agreement with reported values. 
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Rf: 0.2 (DCM:MeOH, 10:1); 
1
H NMR: (CD3OD, 300 MHz) δ = 7.82 (d, 2 H, Fmoc-
H, J = 9 Hz), 7.70 (d, 2 H, Fmoc-H, J = 9 Hz), 7.43-7.31 (m, 4 H, Fmoc-H), 5.27-
5.20 (m, 1 H, H-3), 4.99 (t, 1 H, H-4, J = 9 Hz), 4.74 (d, 1 H, H-1, J = 9 Hz), 4.47-
4.35 (m, 3 H, overlapping α-H and Fmoc-CH2), 4.29-4.23 (m, 2 H, overlapping 
Fmoc-CH and H-6a), 4.16-4.10 (m, 2 H, overlapping β-Ha and H-6b), 3.96-3.91 (dd, 
1 H, β-Hb, J = 6 Hz, 12 Hz), 3.85-3.76 (m, 2 H, overlapping H-2 and H-5), 2.04, 
2.01, 1.99 (each s, 9 H, OC(O)CH3), 1.87 (s, 3 H, NHC(O)CH3); (Lit
[178]
: 
1
H NMR: 
(CD3OD, 400 MHz) δ = 7.94, 7.82, 7.54, 7.47, 5.36, 5.11, 4.83, 4.55, 4.49, 4.43-4.36, 
4.33-4.21, 4.18, 4.04-3.91, 2.17, 2.15, 2.11, 2.00); IR: (DCM film on NaCl plate) 
3427, 2096, 1649 cm
-1
; MS-ESI/TOF: Calculated for C25H24NO5 (M + H)
+
 
657.2290, found 657.2299. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-1,3,4-tri-O-acetyl-6-O-
(triphenylmethyl))-α/β-D-glucopyranoside (4.2) 
 
D (+) -Glucosamine hydrochloride (2.00 g, 9.0 mmol) and solid NaHCO3 (2.27 g, 27 
mmol) were dissolved in H2O (20 mL). The reaction mixture was stirred for 5 mins 
at rt. TrocCl (1.45 mL, 10.8 mmol) was added dropwise. The reaction mixture was 
stirred at rt for 2 h, then neutralized (1 M HCl). The solvent was evaporated under 
reduced pressure. The NH-Troc protected glucosamine was obtained as a cream solid 
which was used without further purification. A portion of this intermediate (150 mg, 
0.46 mmol) was dissolved in dry pyridine (10 mL). Et3N (0.02 mL, 0.12 mmol) and 
TrCl (640 mg, 2.3 mmol) was added to the reaction mixture. This was stirred at 95 
°C for 3 h. The reaction mixture was cooled to 0 °C, then acetyl chloride (0.19 mL, 
2.76 mmol) was added slowly. The reaction mixture was allowed to return to rt, then 
stirred at rt overnight. The solvent was evaporated under reduced pressure, and the 
remaining residue was dissolved in DCM, and washed with brine. The organic layer 
was dried (MgSO4), and filtered, then concentrated under reduced pressure. The 
crude product was purified by column chromatography (Hex:EtOAc, 2:1) to give 
protected glucosamine derivative 4.2 as a clear oil (132 mg, 39 %) (Anomeric 
mixture of α:β in the ratio 1:0.4). 
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Rf: 0.53 (Pet. Ether: EtOAc, 2:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 7.44-7.19 (m, 15 
H, Ph-H), 6.35 (d, 1 H, H-1 (α-anomer), J = 3 Hz), 5.72 (d, 1 H, H-1 (β-anomer), J = 
9 Hz), 5.35 (t, 1 H, H-4, J = 9 Hz), 5.24-5.15 (m, 1 H, H-3), 5.11 (d, 1 H, 
NHC(O)OCH2, J = 9 Hz), 4.83 (d, 1 H, NHC(O)OCH2a (α-anomer), J = 12 Hz), 4.73 
(s, 2 H, NHC(O)OCH2 (β-anomer)), 4.63 (d, 1 H, NHC(O)OCH2b (α-anomer), J = 12 
Hz), 4.27-4.13 (m, 1 H, H-2 (α-anomer)), 4.03-3.97 (m, 1 H, H-2 (β-anomer)), 3.93-
3.86 (m, 1 H, H-5 (α-anomer)), 3.68-3.63 (m, 1 H, H-5 (β-anomer)), 3.35-3.27 (m, 2 
H, H-6a (both anomers)), 3.10-3.01 (m, 2 H, H-6b (both anomers)), 2.17-2.01 (m, 18 
H, OC(O)CH3 (both anomers)); 
13
C NMR: (CDCl3, 75 MHz) δ = 171.5, 169.3, 168.7 
(each s, OC(O)CH3), 154.1 (s, NHC(O)OCH2), 143.5  (s, Ph-C), 128.7, 127.9, 127.8, 
127.3, 127.0 (each d, Ph-H), 95.3 (s, CCl3), 92.6 (s, C(ph)3), 90.7 (d, C-1), 74.7 (t, 
NHC(O)OCH2), 71.2 (d, C-5), 71.0 (d, C-3), 67.8 (d, C-4), 61.4 (t, C-6), 53.4 (d, C-
2), 21.0, 20.7, 20.4 (each q, OC(O)CH3); [α]D: + 41.6 (c 1.2, CH2Cl2); IR: (DCM 
film on NaCl plate) 3421, 3059, 1753, 1647, 1219 cm
-1
; MS-ESI/TOF: Calculated 
for C15H20Cl3NNaO10 (M (-Tr) + Na)
+ 
(Tr removed by formic acid in the mobile 
phase): 502.0045, found 502.0061. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-1,3,4-tri-O-acetyl-6-O-(tert-
butyldimethylsilyl))-α/β-D-glucopyranoside (4.3) 
  
D (+) -Glucosamine hydrochloride (2.00 g, 9.0 mmol) and solid NaHCO3 (2.27 g, 27 
mmol) were dissolved in H2O (20 mL). The reaction mixture was stirred for 5 mins 
at rt. TrocCl (1.45 mL, 10.8 mmol) was added dropwise. The reaction mixture was 
stirred at rt for 2 h, then neutralized (1 M HCl). The solvent was evaporated under 
reduced pressure. The NH-Troc protected glucosamine was obtained as a cream solid 
which was used without further purification. This intermediate (307 mg, 0.85 mmol) 
was dissolved in dry pyridine (3 mL) under N2, in the presence of 3Å molecular 
sieves. Imidazole (63 mg, 0.94 mmol) and TBDMSCl (154 mg, 1.02 mmol) were 
added to the reaction mixture. This was stirred at rt overnight. Acetic anhydride 
(0.48 mL, 5.1 mmol) was added, and the reaction was left to stir at rt overnight. The 
solvent was evaporated under reduced pressure, and the remaining residue was 
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dissolved in DCM, and washed twice with water. The organic layer was dried 
(MgSO4), and filtered, then concentrated under reduced pressure. The crude product 
was purified by column chromatography (Hex:EtOAc, 4:3) to give the protected 
glucosamine derivative 4.3 as a yellow oil (131 mg, 26 %) (Anomeric mixture of α:β 
in the ratio 3:1). 
Rf: 0.9 (Hex:EtOAc, 4:1); 
1
H NMR: (CDCl3, 300 MHz) δ = 6.20 (d, 1 H, H-1 (α-
anomer), J = 3 Hz), 5.68 (d, 1 H, H-1 (β-anomer), J = 9 Hz), 5.44 (d, 1 H, 
NHC(O)OCH2 (β-anomer), J = 9 Hz), 5.27-5.12 (m, 4 H, overlapping H-3, 
NHC(O)OCH2, and H-4 (α-anomer), and H-3 (β-anomer)), 5.12-5.06 (m, 1 H, H-4 
(β-anomer)), 4.78 (d, 1 H, NHC(O)OCH2a (α-anomer), J = 12 Hz), 4.72-4.69 (m, 2 
H, NHC(O)OCH2 (β-anomer)), 4.59 (d, 1 H, NHC(O)OCH2b (α-anomer), J = 12 Hz), 
4.15-4.07 (m, 2 H, overlapping H-2 (α-anomer) and H-6a (β-anomer)) 3.83-3.78 (m, 
2 H, overlapping H-5 (α-anomer) and H-2 (β-anomer)), 3.64-3.60 (m, 4 H, 
overlapping H-5 and H-6b (β-anomer), and H-6 (α-anomer)), 2.14-2.00 (m, 18 H, 
OC(O)CH3 (both anomers)), 0.84 (s, 18 H, SiC(CH3)3 (both anomers)), 0.03- -0.01 
(m, 12 H, SiCH3 (both anomers)); 
13
C NMR: (CDCl3, 75 MHz) δ = 170.4, 169.9, 
168.3, 168.0, 167.7 (each s, OC(O)CH3), 153.1 (s, NHC(O)OCH2), 94.5, 94.3 (each 
s, CCl3 (both anomers)), 91.3 (d, C-1 (β-anomer)), 89.5 (d, C-1 (α-anomer)), 73.9 (t, 
NHC(O)OCH2 (β-anomer)), 73.4 (t, NHC(O)OCH2 (α-anomer)), 71.5 (d, C-5), 69.9 
(d, C-3), 67.5 (d, C-4 (β-anomer)), 67.0 (d, C-4 (α-anomer)), 61.07, 60.8 (each t, C-6 
(both anomers)), 52.3 (d, C-2), 24.8, 24.5 (each q, SiC(CH3)3), 19.9, 19.8, 19.7, 19.6 
(each q, OC(O)CH3), -6.41 (q, SiCH3); IR: (as a DCM film on NaCl plate) 3327, 
2957, 1755, 1538, 1368, 1219 cm
-1
. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-tri-O-acetyl-1-O-
phenylmethyl)-β-D-glucopyranoside (4.6)[189, 260] 
 
Acetylated derivative 2.26 (1.32 g, 2.5 mmol) was dissolved in DCM (10 mL), and 
cooled to 0 ˚C. To this a 33 % solution (v/v) of HBr in AcOH (2.4 mL) was added, 
and the reaction mixture was stirred for 45 mins. The reaction mixture was allowed 
to reach rt, and stirred for 45 mins. A further portion of HBr solution (1.2 mL) was 
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added to the reaction, and this was allowed to stir at rt for 2 h. DCM was added to 
the reaction mixture, and the round bottomed flask was placed on ice. Sat. NaHCO3 
solution was added to the flask. The product was extracted by washing twice with 
DCM. The organic layer was then washed with brine, dried (MgSO4), and filtered. 
The solvent was removed under reduced pressure to give the α-bromide product, 
which was used without further purification. 
This material was placed into a round bottomed flask, which was covered with 
tinfoil. AgCO3 (870 mg, 3.1 mmol) was added, in the presence of 3 Å molecular 
sieves, then the reaction flask was placed under N2, and dry DCM (10 mL) was 
added. To this, benzyl alcohol (0.52 mL, 5.0 mmol) was added, and allowed to stir at 
rt overnight. The silver salts were filtered off over celite, and the filtrate concentrated 
under reduced pressure, and the remaining residue was purified by column 
chromatography (Hex:EtOAc, 3:1 to 2:1) to give benzyl glycoside 4.6 as a white 
solid (800 mg, 57 %). Spectroscopic date is in agreement with literature values.  
Rf: 0.65 (Hex:EtOAc, 1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.38-7.29 (m, 5 H, Ph-
H), 5.23 (t, 1 H, H-3, J = 9 Hz), 5.09 (t, 1 H, H-4, J = 9 Hz), 4.97 (ab d, 1 H, CH2-
Pha, J = 9 Hz), 4.17 (s, 2 H, NHC(O)OCH2), 4.63-4.59 (m, 2 H, overlapping H-1 and 
CH2-Phb), 4.32-4.26 (dd, 1 H, H-6a, J = 6 Hz, 12 Hz), 4.19-4.14 (dd, 1 H, H-6b, J = 3 
Hz, 12 Hz), 3.77-3.63 (m, 2 H, overlapping H-5 and H-2), 2.11 (s, 3 H, OC(O)CH3), 
2.02 (s, 6 H, OC(O)CH3); (Lit
[260]
: 
1
H NMR (CDCl3, 500 MHz): δ = 7.36-7.30, 5.23, 
5.09, 5.03, 4.92, 4.71, 4.62, 4.30, 4.17, 3.73, 3.66, 2.11, 2.02); IR: (KBr disc) 3360, 
2955, 2886, 1752, 1720, 1542, 1230 cm
-1
; MS-ESI/TOF: Calculated for 
C44H52Cl6N2NaO20 (2M + Na)
+
: 1163.1114, found 1163.1128.  
N
α
-(9-Fluorenylmethoxycarbonyl)-O-[(2-deoxy-2-acetamido)-β-D-
glucopyranosyl]-L-serine-methyl ester (4.17) 
 
Protected glycoside 3.5 (271 mg, 0.41 mmol) was dissolved in MeOH (15 mL), and 
AcCl (0.18 mL, 2.47 mmol) was added to the reaction mixture. The reaction was 
allowed to stir overnight at rt. Upon consumption of the starting material, as 
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indicated by TLC, the solvent was evaporated under reduced pressure, and the 
remaining residue was purified by column chromatography (DCM:MeOH, 9:1 to 
7:1) to give glycoside 4.17 as a white solid (198 mg, 89 %). 
Rf: 0.2 (DCM:MeOH, 7:1); 
1
H MNR (CD3OD (a drop of D2O to improve solubility) 
300 MHz): δ = 7.83 (d, 2 H, Ph-H, J = 6 Hz), 7.69 (d, 2 H, Ph-H, J = 9 Hz), 7.46-
7.34 (m, 4 H, Ph-H), 4.49-4.38 (m, 4 H, overlapping H-1, Fmoc-CH2, and α-H), 4.25 
(t, 1 H, Fmoc-CH, J = 6 Hz), 4.18-4.13 (dd, 1 H, β-Ha, J = 6 Hz, 9 Hz), 3.91-3.83 
(m, 2 H, overlapping β-Hb and H-6a), 3.75 (s, 3 H, C(O)OCH3), 3.73-3.61 (m, 2 H, 
overlapping H-2 and H-6b), 3.51-3.45 (m, 1 H, H-3), 3.35-3.30 (m, 2 H, (overlapped 
by MeOH peak) overlapping H-5 and H-4), 1.94 (s, 3 H, NHC(O)CH3); 
13
C NMR: 
(CD3OD (a drop of D2O to improve solubility), 75 MHz) δ = 173.3, 167.5 (each s, 
C(O)OCH3 and NHC(O)CH3), 143.6, 141.1 (each s, Fmoc-C(O) and Ph-C), 127.7, 
127.1, 124.8, 119.7 (each d, Fmoc-CH and Ph-CH), 101.2 (d, C-1), 76.4, 74.1, 70.2, 
66.8, 55.8, 54.3, 52.3, 29.7 (not assigned due to poor solubility of sample), 21.9 (q, 
NHC(O)CH3); IR: (KBr disc) 3319, 2952, 1748, 1690, 1654, 1535 cm
-1
; [α]D: - 1.7 (c 
1.3, CH3OH); MS-ESI/TOF: Calculated for C27H33N2O10 (M + H)
+
: 546.2162, found 
546.2184. 
N
α
-(9-Fluorenylmethoxycarbonyl)-O-[(2-deoxy-2-acetamido-6-O-p-tosyl)-β-D-
glucopyranosyl]-L-serine-methyl ester (4.18) 
 
Glycoside 4.17 (60 mg, 0.11 mmol) was placed under N2 and dissolved in anhydrous 
pyridine (2 mL). The reaction mixture was cooled to 0 °C, and a solution of TsCl 
(100 mg, 0.52 mmol) in anhydrous pyridine (2 mL) was added. The reaction was 
stirred at 0 °C for 1 h, allowed to return to rt, and stirred at rt overnight. The solvent 
was co-evaporated with toluene under reduced pressure, and the remaining residue 
was purified by column chromatography (DCM:MeOH, 15:1 to 10:1) to give the 
tosylated glycoside 4.18 as a clear oil (19 mg, 24 %).  
Rf: 0.5 (DCM:MeOH, 7:1); 
1
H MNR (CDCl3, 300 MHz): δ = 7.74 (t, 4 H, Ph-H, J = 
6 Hz), 7.57 (d, 2 H, Ph-H, J = 6 Hz), 7.37 (t, 2 H, Ph-H, J = 6 Hz), 7.29-7.23 (m, 4 
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H, Ph-H), 6.91 (bs, 1 H, NHC(O)CH3), 5.99 (d, 1 H, NHC(O)OCH2, J = 9 Hz), 4.50-
4.36 (m, 2 H, overlapping H-1 and α-H), 4.27-4.14 (m, 5 H, overlapping H-6, Fmoc-
CH, and Fmoc-CH2), 4.05-4.00 (dd, 1 H, β-Ha, J = 6 Hz, 9 Hz), 3.86-3.83 (m, 1 H, 
β-Hb), 3.72 (s, 3 H, C(O)OCH3), 3.65-3.39 (m, 4 H, overlapping H-2, H-3, H-4, and 
H-5), 2.36 (s, 3 H, Ph-CH3), 1.95 (s, 3 H, NHC(O)CH3); 
13
C NMR: (CDCl3, 75 
MHz) δ = 173.2, 170.4 (each s, C(O)OCH3 and NHC(O)CH3), 156.4 (s, Fmoc-C(O)), 
145.1, 143.7, 143.6, 141.23, 132.48 (each s, Ph-C), 129.9, 127.9, 127.8, 127.1, 
125.1, 120.0 (each d, Fmoc-CH and Ph-CH), 100.3 (d, C-1), 74.9, 73.5, 70.3 (each d, 
C-2, C-3, C-4, and C-5), 69.1, 37.2 (each t, C-6, Fmoc-CH2, and β-C), 53.9 (d, α-C), 
52.89 (q, C(O)OCH3), 23.2 (q, NHC(O)CH3), 21.61 (q, Ph-CH3); IR: (DCM film on 
NaCl plate) 3349, 2984, 1723, 1655, 1548, 1176 cm
-1
; [α]D: - 2.8 (c 0.85, CH2Cl2); 
MS-ESI/TOF: Calculated for C34H39N2O12S (M + H)
+
: 700.2250, found 700.2268. 
3-Azido-propionic acid (4.21)
[209]
 
 
3-Bromopropionic acid (1.50 g, 9.8 mmol) was dissolved in MeCN (4 mL). NaN3 
(956 mg, 14.7 mmol) was added and the reaction mixture, and heated at reflux (85 
°C) for 3 h. The reaction was allowed to return to rt, then carefully washed with 0.1 
M HCl, dried (MgSO4) and filtered. The solvent was evaporated to almost dryness 
under reduced pressure, with care taken that the water bath was not heated. The 
remaining orange oil was used without further purification (400 mg, 36 % crude 
yield). 
1
H NMR: (CDCl3, 300 MHz) δ = 9.87 (bs, 1 H, O-H), 3.58 (t, 2 H, CH2N3, J = 6 
Hz), 2.63 (t, 2 H, OC(O)CH2, J = 6 Hz); (Lit
[209]
: 
1
H NMR: (CDCl3, 400 MHz) δ = 
11.00, 3.60, 2.65); IR: (Liquid IR in CDCl3) 3165, 2941, 2104, 1718 cm
-1
. 
 
 
 
Chapter 6: Experimental Details 
Page | 172  
 
N
α
-(9-Fluorenylmethoxycarbonyl)-O-(2-deoxy-2-acetamido-3,4-di-O-
trimethylsilyl-6-[3-Azido-propionic ester]-β-D-glucopyranosyl)-L-serine methyl 
ester (4.25) 
 
Glycoside 4.17 (60 mg, 0.11 mmol) was dissolved in anhydrous pyridine (4 mL), 
under N2, and cooled to 0 °C. To this, a solution of HMDS (0.06 mL, 0.28 mmol) 
and TMSCl (0.09 mL, 0.71 mmol) was added. The reaction mixture was allowed to 
return to rt, and stirred overnight. The solvent was co-evaporated with toluene using 
a rotary evaporator, then the remaining residue was dissolved in DCM and washed 
with H2O. The organic layer was dried (MgSO4) and filtered, then evaporated under 
reduced pressure to give the TMS protected product, 4.22, as a yellow oil, which was 
used without further purification (75 mg, 90%). 
The crude product, 4.22 (75 mg, 0.09 mmol) was dissolved in an acetone:MeOH 
mixture (1:0.8 mL), and this solution was cooled to 0 °C. AcOH (0.025 mL, 0.2 
mmol) was added to the reaction mixture, and this was stirred at 0 °C for 1 h. As no 
major change was noted by TLC the reaction was allowed to return to rt, and stirred 
for 4 h. A further portion of AcOH (0.025 mL, 0.2 mmol) was added to the reaction 
mixture, and this was allowed to stir at rt for 2 h. When most of the starting material 
had been consumed, as indicated by TLC, the reaction mixture was diluted with 
DCM, and washed with NaHCO3, followed by H2O. The organic layer was dried 
(MgSO4) and filtered, and then concentrated under reduced pressure to give the C-6 
deprotected derivative 4.23 as a clear oil, which was used without further 
purification (45 mg, 67 %).  
Azido propionic acid 4.21 (120 mg, which still contained some MeCN) was 
dissolved in anhydrous DCM under N2, and cooled to 0 °C. DCC (26 mg, 0.13 
mmol) and DMAP (1.5 mg, 0.13 mmol) were added, and the reaction mixture was 
allowed to stir for 5 mins. A solution of the crude TMS protected glycoside, 4.23 (45 
mg, 0.06 mmol) in anhydrous DCM was added slowly to the reaction mixture. This 
was stirred at 0 °C for 20 mins, and then allowed to return to rt. The reaction mixture 
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was stirred at rt for 5 h, and then washed with H2O. The organic layer was dried 
(MgSO4) and filtered, and then concentrated under reduced pressure to almost 
dryness. The remaining oil was purified by column chromatography (Pet. Ether: 
EtOAc, 1:1 →1:2) to give the functionalised glycoside 4.25 as a clear oil (5 mg, 9 
%). 
Rf: 0.7 (Pet. Ether:EtOAc, 1:3); 
1
H NMR (CDCl3, 300 MHz): δ = 7.77 (d, 2 H, Ph-H, 
J = 6 Hz), 7.69-7.65 (m, 2 H, Ph-H), 7.43-7.30 (m, 4 H, Ph-H), 5.91 (d, 1 H, 
NHC(O)OCH2, J = 6 Hz), 5.86 (d, 1 H, NHAc, J = 9 Hz), 4.88 (d, 1 H, H-1, J = 6 
Hz), 4.52-4.43 (m, 3 H, overlapping α-H, β-Ha, and H-6a), 4.38-4.32 (m 1 H, β-Hb), 
4.28-4.13 (m, 3 H, overlapping H-6b and Fmoc-CH2), 3.89 (t, 1 H, H-3, J = 6 Hz), 
3.82-3.77 (m, 1 H, Fmoc-CH), 3.75 (s, 3 H, C(O)OCH3), 3.60-3.49 (m, 4 H, 
overlapping H-4, H-5, and CH2N3), 3.45-3.37 (m, 1 H, H-2), 2.64-2.58 (m, 2 H, 
OC(O)CH2), 1.97 (s, 3 H, NHC(O)CH3), 0.17, 0.16 (each s, 18 H, Si(CH3)3); 
13
C 
NMR (CDCl3, 75 MHz): δ = 155.2, 151.3, 126.7, 126.1, 124.2, 118.9, 99.1, 71.1, 
66.1, 54.9, 53.2, 51.5, 30.1, 28.7, 22.7, -0.3, -0.4; IR: (Liquid IR in CDCl3) 3155, 
2962, 2104, 1816, 1712, 1563, 1249 cm
-1
; [α]D: + 8 (c 0.25, CH2Cl2); MS-ESI/TOF: 
Calculated for C33H44N5O11Si (M (-TMS) + H)
+
: 714.2801, found 714.2818 (1 X 
TMS removed by formic acid in the mobile phase). 
(2-Deoxy-2-acetamido-6-O-[N-(3,4-hydoxyphenylethyl)-succinamide])-α/β-D-
glucopyranose (5.9) 
 
Glycosyl derivative 5.39 (40 mg, 0.06 mmol) was dissolved in MeOH (5 mL), and 
10 % Pd/C (w/w) (40 mg) was added. The reaction was carried out by bubbling H2 
through the reaction mixture, at rt for 4 h. The reaction mixture was filtered through 
celite, and the solvent was removed under reduced pressure. The remaining residue 
was purified by column chromatography (EtOAc:MeOH, 4:1) to give the 
deprotected glycosyl dopamine derivative 5.9 as a white oily solid (14 mg, 56 %). 
(Anomeric ratio 1:0.6, α:β)  
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Rf: 0.3 (EtOAc:AcOH:H2O, 4:1:1); 
1
H NMR (CD3OD, 300 MHz): δ = 6.76-6.66 (m, 
2 H, Ar-H), 6.54 (d, 1 H, Ar-H, J = 6 Hz), 5.09 (d, 1 H, H-1 (α-anomer), J = 3 Hz), 
4.61 (d, 1 H, H-1 (β-anomer), J = 9 Hz), 4.45-4.35 (m, 1 H, H-6a), 4.29-4.20 (m, 1 H, 
H-6b), 4.08-3.98 (m, 1 H, H-5), 3.89-3.84 (dd, 1 H, H-2, J = 3 Hz, 12 Hz), 3.74-3.68 
(m, 1 H, H-3) 3.38-3.30 (m, 3 H, overlapped by CD3OD peak, H-4 and CH2-Ar), 
2.66-2.62 (m, 4 H, overlapping NHCH2 and C(O)CH2), 2.49 (t, 2 H, C(O)CH2, J = 6 
Hz), 2.01 (s, 3 H, NHC(O)CH3); 
13
C NMR (CDCl3, 75 MHz): δ = 172.9, 172.8 (each 
s, NHC(O)CH3 and C(O)CH2), 145.0, 143.3, 130.7 (each s, Ar-C), 119.7, 115.5, 
114.9 (each d, Ar-CH), 91.2 (d, C-1), 73.9, 71.1 (each d, C-3 and C-5), 69.3 (d, C-4), 
63.7 (t, C-6), 54.4 (d, C-2), 40.9 (t, CH2NH), 34.5 (t, C(O)CH2), 30.1 (t, C(O)CH2), 
29.1 (t, CH2-Ar), 21.2 (q, NHC(O)CH3); IR: (DCM film on NaCl plate) 3390, 1702, 
1635, 1557, 1259 cm
-1
; [α]D: + 40 (c 0.2, CH3OH); MS-ESI/TOF: Calculated for 
C20H28O10N2 (M + H)
+
 : 457.1817, found 457.1835. 
N-[(1,1-Dimethylethoxy)carbonyl]-3,4-Dibenzyloxyphenylethylamine (5.11)
[210]
 
 
Dopamine hydrochloride (2.50 g, 0.13 mmol) was dissolved in MeOH:Et3N (9:1 
ratio, 71.5 mL). Boc anhydride (3.17 g, 14.5 mmol) was added to the reaction 
mixture, which was allowed to stir at 50 ˚C for 1 h. The solvent was evaporated, then 
ice-cold 1 M HCl was added to the residue, and allowed to stir for 10 mins. The 
product was extracted by washing twice with EtOAc. The organic layer was dried 
(MgSO4), and filtered, then concentrated under reduced pressure. The crude product 
was purified by column chromatography (Hex:EtOAc:MeOH, 4:1:0.5 to 2:1:0.5), to 
yield N-Boc protected dopamine. Solid K2CO3 (11.00 g, 79 mmol) was added to this 
intermediate, and the flask placed under N2. Anhydrous DMF (20 mL) was added, 
followed by benzyl bromide (3.6 mL, 30 mmol). The reaction mixture was stirred at 
rt overnight, then filtered through celite. The celite was rinsed twice with ether. The 
filtrate and combined ether rinses were washed with ice water, followed by 1 M HCl 
and brine. The organic layer was dried (MgSO4), and filtered. The solvent was 
removed under reduced pressure. The resulting white solid was purified by column 
chromatography (Hex:EtOAc, 7:1 to 3:1) to give the protected dopamine derivative 
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5.11 as a white solid (2.50 g, 43 %). Spectroscopic data was in agreement with 
reported values.  
Rf: 0.4 (Hex:EtOAc, 3:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.37-7.29 (m, 10 H, Ar-
H), 6.87 (d, 1 H, Ar-H, J = 6 Hz), 6.78 (bs, 1 H, Ar-H), 6.71-6.68 (dd, 1 H, Ar-H, J = 
3 Hz, 9 Hz), 5.14, 5.13 (each s, 2 H, CH2-Ph), 4.48 (bs, 1 H, NHCH2), 3.34-3.27 (m, 
2 H, NHCH2), 2.68 (t, 2 H, CH2-Ar, J = 9 Hz), 1.43 (s, 9 H, C(CH3)3); (Lit
[210]
: 
1
H 
NMR (CDCl3, 200 MHz): δ = 7.39, 6.89, 6.71, 5.15, 4.45, 3.32, 2.7, 1.45); 
13
C NMR 
(CDCl3, 75 MHz): δ = 155.8, 149.0, 147.7, 137.5, 137.3, 132.4 (each s, Ar-C and 
NHC(O)OC(CH3)3), 128.5, 127.8, 127.7, 127.4, 127.3, 121.7, 115.9, 115.4 (each d, 
Ar-CH), 71.5, 71.4 (each t, OCH2-Ph), 41.8 (t, NH2CH2), 35.6 (t, CH2-Ph), 28.4 (q, 
C(CH3)3); IR: (KBr disc) 3380, 3003, 2970, 1681, 1592, 1519, 1277, 1240 cm
-1
; MS-
ESI/TOF: Calculated for C54H63N2O8 (2M + H)
+
: 867.4579, found 867.4606. 
3,4-Dibenzyloxyphenylethylamine (5.12)
[210]
 
 
A 5 % solution of TFA in DCM (v/v) (40 ml) was added to Boc protected dopamine 
derivative 5.11 (1.50 g, 3.4 mmol). The reaction mixture was allowed to stir for 6 h 
at rt, then the solvent was co-evaporated with toluene. The remaining solid was 
recrystallised (EtOAc/Hex). The free amine 5.12 was obtained as a white solid (1.00 
g, 87 %). Spectroscopic data was in agreement with reported values. 
Rf: 0.4 (DCM:MeOH, 9:1); 
1
H NMR (CD3OD, 300 MHz): δ = 7.47-7.29 (m, 10 H, 
Ar-H), 7.02-6.96 (m, 2 H, Ar-H), 6.83-6.80 (dd, 1 H, Ar-H, J = 3 Hz, 6 Hz), 5.14, 
5.12 (each s, 2 H, Ph-CH2), 3.12 (t, 2 H, NH2CH2, J = 6 Hz), 2.87 (t, 2 H, CH2-Ar, J 
= 6 Hz); (Lit
[210]
: 
1
H NMR (CD3OD, 300 MHz): δ = 7.65-7.47, 7.20, 7.14, 7.00, 
5.32, 5.30, 3.30, 3.04); 
13
C NMR (CD3OD, 75 MHz,): δ = 149.2, 148.2 (each s, Ar-
C), 137.4, 137.3 (each s, Ar-C) 130.0 (s, Ar-C), 128.1, 127.5, 127.3, 127.2, 121,6, 
115.7, 115.5 (each d, Ar-CH), 71.1 (t, Ph-CH2), 40.6 (t, NH2CH2), 32.7 (t, CH2-Ar); 
IR: (DCM film on NaCl plate) 3438, 3033, 1680, 1514, 1204 cm
-1
; MS-ESI/TOF: 
Calculated for C22H24NO2 (M + H)
+
: 335.1835, found 335.1829. 
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N-(3,4-Dibenzyloxyphenylethyl)-succinamic acid (5.13)
[210]
 
 
The free amine 5.12 (1.00 g, 2.99 mmol) was dissolved in pyridine (2 mL), and 
succinic anhydride (0.54 g, 5.41 mmol) was added to the reaction mixture. This was 
allowed to stir at rt for 3 h. The solvent was co-evaporated with toluene under 
reduced pressure, and the remaining residue was purified by column chromatography 
(DCM:MeOH, 15:1 to 10:1) to give succinyl-dopamine derivative 5.13 as a white 
solid (1.06 g, 82 %). Spectroscopic data was in agreement with reported values.  
Rf: 0.5 (DCM:MeOH, 9:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.43-7.28 (m, 10 H, 
Ar-H), 6.86 (d, 1 H, Ar-H, J = 9 Hz), 6.76 (d, 1 H, Ar-H, J = 3 Hz), 6.68-6.65 (m, 1 
H, Ar-H), 5.71 (bs, 1 H, NHCH2), 5.12, 5.11 (each s, 2 H, Ph-CH2), 3.45-3.39 (m, 2 
H, NHCH2), 2.68 (t, 2 H, CH2-Ar, J = 6 Hz), 2.61 (t, 2 H, C(O)CH2, J = 6 Hz), 2.37 
(t, 2 H, C(O)CH2, J = 6 Hz); (Lit
[210]
: 
1
H NMR (CDCl3, 200 MHz): δ = 7.39, 6.89, 
6.80, 6.71, 5.55, 5.17, 5.15, 3.45, 2.70, 2.65, 2.38); 
13
C NMR (CDCl3, 75 MHz): δ =  
149.0, 147.8 (each s, CH2C(O)), 137.3, 131.9 (each s, Ar-C), 128.5, 127.8, 127.4, 
127.3, 121.7, 115.9, 115.2 (each d, Ar-CH), 40.85 (t, NHCH2), 34.7, 31.7 (each t, 
CH2C(O)), 30.2 (t, CH2-Ph); IR: (KBr disc) 3324, 3035, 2927, 1694, 1640, 1523, 
1266 cm
-1
. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4,6-tri-O-trimethylsilyl-1-
O-phenylmethyl ether)-β-D-glucopyranoside (5.17)  
 
Benzyl glycoside 4.6 (1.04 g, 2.2 mmol) was dissolved in distilled MeOH (18 mL), 
and 0.1 M NaOH(aq) (18 mL) was added. The reaction mixture was stirred at rt for 1 
h, then neutralized with AcOH (10 mL). The organic solvent was evaporated using a 
rotary evaporator, and the remaining aqueous solution was extracted with EtOAc. 
The organic layer was washed twice with sat. NaHCO3 solution, then dried (MgSO4), 
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and filtered. The organic layer was concentrated under reduced pressure, and the 
crude product was purified by column chromatography (EtOAc:MeOH, 4:1) to give 
the deprotected glycoside as a white solid (717 mg, 73 %).  
The deprotected glycoside (717 mg, 1.61 mmol) was dissolved in dry pyridine (30 
mL) under N2. The solution was cooled to 0 ˚C, then a solution of TMSCl (1.23 mL, 
9.66 mmol) and DIPEA (0.56 mL, 3.2 mmol) was added. The reaction was allowed 
to reach rt, then stirred overnight. The solvent was co-evaporated with toluene, and 
the remaining residue was dissolved in DCM. The organic layer was washed with 
H2O, then dried (MgSO4), and filtered. The crude product was purified by column 
chromatography (Pet. Ether:EtOAc, 4:1) to leave TMS protected glycoside 5.17 as a 
white solid (0.37 g, 35 %).  
Rf: 0.75 (Pet. Ether: EtOAc, 4:1);
 1
H NMR (CDCl3, 300 MHz): δ = 7.31 (s, 5 H, Ph-
H), 5.01 (d, 1 H, NHC(O)OCH2, J = 9 Hz), 4.85 (d, 1 H, Ph-CH2a, J = 12 Hz), 4.72-
4.54 (m, 4 H, overlapping H-1, NHC(O)OCH2, and Ph-CH2b), 3.88-3.60 (m, 4 H, 
overlapping H6, H-3 and H-4), 3.45-3.34 (m, 1 H, H-2), 3.26-3.20 (m, 1 H, H-5), 
0.17, 0.13 (each s, 27 H, SiC(CH3)3); 
13
C NMR (CDCl3, 75 MHz): δ = 153.3 (s, 
NHC(O)OCH2), 136.8 (s, Ph-C), 127.7, 127.3, 127.1 (each d, Ph-CH), 98.3 (d, C-1), 
94.7 (s, CCl3), 76.1 (d, C-5), 74.7 (d, C-3), 74.0 (t, NHC(O)OCH2), 71.1 (d, C-4), 
69.5 (t, Ph-CH2), 61.3 (t, C-6), 57.8 (d, C-2), 0.1, 0.0, -0.8 (each q, SiC(CH3)3); m.p.: 
74-78 ˚C ; IR: (DCM film on NaCl plate) 3324, 2955, 1712, 1551, 1250 cm-1; [α]D: - 
15.9 (c 3.15, CH2Cl2); MS-ESI/TOF: Calculated for C25H48Cl3N2O7Si3 (M + NH4)
+
 : 
677.1829, found 677.1849. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4-di-O-trimethylsilyl-1-O-
phenylmethyl ether)-β-D-glucopyranoside (5.18) 
 
TMS protected glycoside 5.17 (483 mg, 0.7 mmol) was dissolved in an 
acetone:MeOH mixture (3:4 mL). The reaction mixture was cooled to 0 ˚C, then 
AcOH (0.08 mL, 1.46 mmol) was added, and this was stirred for 2 h. Solid NaHCO3 
was added to the reaction mixture, and stirred for 10 mins. The reaction mixture was 
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diluted with DCM (20 mL), and the solid NaHCO3 was removed by filtration. The 
filtrate was concentrated under reduced pressure, and the remaining residue was 
purified by column chromatography (Hex:EtOAc, 9:1 to 3:1) to give the selectively 
deprotected glycoside 5.18 as a white solid (298 mg, 72 %).  
Rf: 0.32 (Pet. Ether: EtOAc, 4:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.31-7.26 (m, 5 
H, Ph-H), 5.14 (bs, 1 H, NHC(O)OCH2), 4.85 (d, 1 H, Ph-CH2a, J = 12 Hz), 4.69-
4.66 (m, 3 H, overlapping H-1 and NHC(O)OCH2), 4.59 (d, 1 H, Ph-CH2b, J = 12 
Hz), 3.86-3.65 (m, 3 H, overlapping H6a, H-3 and H-4), 3.56 (t, 1 H, H6b, J = 9 Hz), 
3.41-3.29 (m, 2 H, overlapping H-2 and H-5), 0.17, 0.13 (each s, 18 H, SiC(CH3)3); 
13
C NMR (CDCl3, 75 MHz): δ = 153.4 (s, NHC(O)OCH2), 136.4 (s, Ph-C), 127.7, 
127.2, 127.1 (each d, Ph-CH), 98.8 (d, C-1), 94.5 (s, CCl3), 75.4 (d, C-5), 74.5 (d, C-
3), 74.0 (t, NHC(O)OCH2), 71.5 (d, C-4), 70.3 (t, Ph-CH2), 61.2 (t, C-6), 58.1 (d, C-
2), 0.12, 0.00 (each q, SiC(CH3)3); m.p.: 70- 74 ˚C; [α]D: - 7.3 (c 0.55, CH2Cl2); IR: 
(DCM film on NaCl plate) 3351, 2098, 1642, 1546, 1251 cm
-1
; MS-ESI/TOF: 
Calculated for C22H40Cl3N2O7Si2 (M + NH4)
+
: 607.1409, found 607.1417. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-3,4-di-O-trimethylsilyl-6-O-
[N-(3,4-dibenzyloxyphenylethyl)-succinamyl]-1-O-phenylmethyl)-β-D-
glucopyranoside (5.24) 
 
Benzyl glycoside 5.18 (298 mg, 0.51 mmol) was dissolved in dry DCM (10 mL), 
under N2, and DCC (120 mg, 0.58 mmol) was added. This was then added to a 
solution of the succinyl-dopamine derivative 5.13 (242 mg, 0.56 mmol) in dry DCM 
(25 mL) under N2. DMAP (4.3 mg, 0.03 mmol) was added to the reaction mixture, 
and this was allowed to stir at rt for 3 h. The reaction mixture was filtered through 
celite. The filtrate was diluted with DCM (20 mL) and washed with an aqueous 
solution of 5 % AcOH, followed by H2O. The organic layer was dried (MgSO4), and 
filtered. The crude product was purified by column chromatography (Pet. 
Ether:EtOAc, 4:1 to 2:1) to give the protected glycoside 5.24 as a clear syrup (306 
mg, 60 %). 
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Rf: 0.6 (Pet. Ether: EtOAc, 1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.45-7.25 (m, 15  
H, Ar-H), 6.87 (d, 1 H, Ar-H, J = 9 Hz), 6.79-6.78 (m, 1 H, Ar-H), 6.70-6.66 (dd, 1 
H, Ar-H, J = 3 Hz, 9 Hz), 5.60 (bs, 1 H, NHC(O)CH2), 5.14-5.12 (m, 5 H, 
overlapping Ph-CH2 and NHC(O)OCH2), 4.85 (d, 1 H, Ph-CH2a, J = 12 Hz), 4.67-
4.48 (m, 5 H, overlapping H-1, Ph-CH2b, NHC(O)OCH2 and H-6a), 4.15-4.09 (dd, 1 
H, H-6b, J = 6 Hz, 12 Hz), 3.73 (t, 1 H, H-3, J = 9 Hz), 3.57 (t, 1 H, H-4, J = 9 Hz), 
3.49-3.34 (m, 4 H, overlapping H-5, H-2 and CH2-Ar), 2.73-2.66 (m, 4 H, 
overlapping NHCH2 and C(O)CH2), 2.39-2.35 (m, 2 H, C(O)CH2), 0.15, 0.13 (each 
s, 18 H, SiC(CH3)3) ; 
13
C NMR (CDCl3, 75 MHz): δ = 171.9, 170.3 (each s, 
C(O)CH2), 153.2 (s, NHC(O)OCH2), 148.3, 146.9, 136.7, 136.5, 136.4, 131.6 (each 
s, Ar-C), 127.7, 127.6, 127.5, 127.2, 127.1, 127.0, 126.6, 126.5, 120.9, 115.0, 114.7 
(each d, Ar-CH), 98.4 (d, C-1), 94.5 (s, CCl3), 74.2 (d, C-3), 73.9 (t, NHC(O)OCH2), 
73.2, 57.5 (each d, C-2 and C-5), 71.7 (d, C-4), 70.7, 70.5 (each t, Ph-CH2), 69.8 (t, 
Ph-CH2), 63.0 (t, C-6), 40.0 (t, CH2NH), 34.4, 30.2 (each t, C(O)CH2), 28.7 (t, CH2-
Ph), 0.1, 0.0 (each q, SiC(CH3)3; IR: (DCM film on NaCl plate) 3368, 3065, 2956, 
1737, 1650, 1512, 1252 cm
-1
; [α]D: - 7.3 (c 1.9, CH2Cl2); MS-ESI/TOF: Calculated 
for C42H45Cl3KN2O11 (M + K[– 2 x TMS])
+
 : 897.1721, found 897.1766. 
(2-Deoxy-2-[(2,2,2-trichloroethoxycarbonyl)amino]-6-O-[N-(3,4-dibenzyloxy 
phenylethyl)-succinamyl]-1-O-phenylmethyl)-β-D-glucopyranoside (5.25) 
 
A 2 % solution of TFA in DCM (v/v) (12.25 mL, 3.18 mmol) was added to the 
protected glycoside 5.24 (200 mg, 0.19 mmol) at 0 ˚C, and this was allowed to stir 
for 1 h. To the reaction mixture solid NaHCO3 (400 mg) was added, and stirred for 2 
mins. The solid was removed by gravity filtration, and the filtrate was concentrated 
under reduced pressure. The remaining residue was purified by column 
chromatography (DCM:MeOH, 50:1 to 30:1) to give glycoside 5.25 as a white solid 
(160 mg, 98 %) 
Rf: 0.55 (DCM:MeOH, 9:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.44-7.17 (m, 15 H, 
Ar-H), 6.86 (d, 1 H, Ar-H, J = 9 Hz), 6.78 (d, 1 H, Ar-H, J = 1.8 Hz), 6.68-6.65 (dd, 
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1 H, Ar-H, J = 3 Hz, 9 Hz), 5.74 (t, 1 H, NHC(O)CH2, J = 6 Hz), 5.52 (d, 1 H, 
NHC(O)OCH2, J = 9 Hz), 4.90 (d, 1 H, NHC(O)OCH2a, J = 15 Hz), 4.68-4.50 (m, 5 
H, overlapping H-1, Ph-CH2, NHC(O)OCH2b, and H-6a), 4.27-4.23 (m, 1 H, H-
6b),3.95 (bs, 1 H, OH), 3.66-3.60 (m, 1 H, H-3), 3.52-3.36 (m, 5 H, overlapping H-2, 
H-4, H-5, and CH2NH), 2.70-2.59 (m, 4 H, overlapping CH2-Ar and C(O)CH2), 2.38 
(t, 2 H, C(O)CH2, J = 6 Hz); 
13
C NMR (CDCl3, 75 MHz): δ = 173.3, 171.7, 154.9, 
149.0, 147.7, 137.3, 137.2, 137.0, 132.2 (each s, Ar-C), 128.5, 127.9, 127.8, 127.4, 
127.4, 121.7, 115.9, 115.5 (each d, Ar-CH), 99.8 (d, C-1), 95.5 (s, CCl3), 74.7 (t, 
NHC(O)OCH2), 73.9, 73.7 (each d, C-3 and C-4), 71.5, 71.3 (each t, Ph-CH2), 70.8, 
70.5 (each d, C-2 and C-5), 63.4 (t, C-6), 40.8 (t, CH2NH), 34.9, 30.9 (each t, 
C(O)CH2), 29.5 (t, CH2-Ar); m.p.: 152-154 ˚C; IR: (KBr disc) 3380, 3320, 2962, 
1718, 1638, 1261; [α]D: -30 (c 0.65, CHCl3); MS-ESI/TOF: Calculated for 
C42H45Cl3N2NaO11 (M + Na)
+
 : 883.1963, found 883.1978. 
(2-Deoxy-2-acetamido-3,4-di-O-trimethylsilyl-6-O-[N-(3,4-dibenzyloxy 
phenylethyl)-succinamyl]-1-O-phenylmethyl)-β-D-glucopyranoside (5.28) 
 
N-Troc protected glycoside 5.24 (268 mg, 0.27 mmol) and freshly activated zinc 
powder (activated by rinsing twice with 2 M HCl, followed by H2O, then acetone 
and ether) (171 mg, 2.6 mmol) were dissolved/suspended in Ac2O (15 mL) and 
DCM (3 mL). Et3N (0.1 mL, 0.75 mmol) was added to the reaction mixture, and this 
was allowed to stir for 3 h at rt. The reaction mixture was filtered through celite to 
remove the zinc salts, then the solvent was removed by co-evaporation with toluene 
under reduced pressure. The remaining residue was dissolved in DCM, then washed 
with brine, dried (MgSO4), and filtered. The crude product was purified by column 
chromatography (Pet. Ether:EtOAc, 1:3 to 1:4) to give the N-acetyl derivative 5.28 
as a white solid (88 mg, 40 %).  
Rf: 0.44 (DCM:MeOH, 9:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.45-7.27 (m, 15 H, 
Ar-H), 6.88 (d, 1 H, Ar-CH, J = 9 Hz), 6.80 (d, 1 H, Ar-CH, J = 3 Hz), 6.71-6.67 
(dd, 1 H, Ar-CH, J = 3 Hz, 9 Hz), 5.63 (t, 1 H, NHC(O)CH2, J = 6 Hz), 5.46 (d, 1 H, 
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NHC(O)CH3, J = 9 Hz), 5.21-5.12 (m, 5 H, overlapping H-3 and Ph-CH2), 5.04 (t, 1 
H, H-4, J = 9 Hz), 4.87 (d, 1 H, Ph-CH2a, J = 12 Hz), 4.62-4.55 (m, 2 H, overlapping 
H-1 and PhCH2b), 4.20-4.12 (m, 2 H, H-6), 4.01-3.91 (m, 1 H, H-2), 3.68-3.62 (m, 1 
H, H-5), 3.46-3.39 (m, 2 H, NHCH2), 2.71-2.67 (m, 4 H, overlapping C(O)CH2 and 
CH2-Ar), 2.41-2.33 (m, 2 H, C(O)CH2), 1.99, 1.98 (each s, 6 H, OC(O)CH3), 1.88 (s, 
3 H, NHC(O)CH3); 
13
C NMR (CDCl3, 75 MHz): δ = 172.5, 171.1, 170.9, 170.1, 
169.48 (each s, C(O)CH2, NHC(O)CH3, and OC(O)CH3), 149.0, 147.7, 137.4, 137.3, 
136.9, 132.4 (each s, Ar-C), 128.5, 128.0, 127.8, 127.7, 127.4, 127.3, 121.6, 116.6, 
115.8, 115.5 (each d, Ar-CH), 99.5 (d, C-1), 72.5 (d, C-3), 71.8, 71.5 (each t, Ph-
CH2), 70.7 (d, C-5), 68.7 (d, C-4), 62.4 (t, Ph-CH2), 54.5 (d, C-2), 40.8 (t, NHCH2), 
35.1 (t, C(O)CH2), 30.9 (t, C(O)CH2), 29.4 (t, CH2-Ph), 23.3 (q, NHC(O)CH3), 20.7, 
20.6 (each q, OC(O)CH3); m.p.: 120-124 ˚C; IR: (DCM film on NaCl plate) 3431, 
2100, 1650, 1237 cm
-1; [α]D: -16.5 (c 1.7, CH2Cl2); MS-ESI/TOF: Calculated for 
C45H52N2O12 (M + 2H)
+2
 : 406.1755, found 406.1739 . 
(2-Deoxy-2-acetamido-3,4,6-tri-O-acetyl-1-O-phenylmethyl)-β-D-
glucopyranoside (5.33)
[251, 261]
 
 
N-Troc protected glycoside 3.18 (736 mg, 1.29 mmol) and freshly activated zinc dust 
(activated by rinsing twice with 2 M HCl, then H2O, followed by acetone and ether) 
(1.26 g, 19 mmol) were dissolved/suspended in Ac2O (20 mL). Et3N (0.35 mL, 2.58 
mmol) was added to the reaction mixture, and this was allowed to stir at rt for 5 h. 
The solvent was evaporated, and the remaining residue was purified by column 
chromatography (Hex: EtOAc, 1:1 to EtOAc flush) to give the N-acetyl derivative 
5.33 as a white solid (400 mg, 71 %). Spectroscopic data was in agreement with 
reported values. 
Rf: 0.67 (DCM:MeOH, 9:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.38-7.29 (m, 5 H, 
Ar-H), 5.39 (d, 1 H, NHC(O)CH3, J = 9 Hz), 5.20 (t, 1 H, H-3, J = 9 Hz), 5.09 (t, 1 
H, H-4, J = 9 Hz), 4.89 (d, 1 H, Ph-CH2a, J = 12 Hz), 4.64-4.58 (m, 2 H, overlapping 
Ph-CH2b and H-1), 4.30-25 (dd, 1 H, H-6a, J = 4.8 Hz, 12 Hz), 4.19-4.14 (dd, 1 H, H-
6b, J = 3 Hz, 12 Hz), 4.02-3.92 (m, 1 H, H-2), 3.70-3.64 (m, 1 H, H-5), 2.10, 2.01 
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(each s, 9 H, OC(O)CH3), 1.90 (s, 3 H, NHC(O)CH3); (Lit
[251]
: 
1
H NMR (CDCl3, 200 
MHz): δ = 7.28-7.26, 5.78, 5.21, 5.04, 4.85, 4.64, 4.56, 4.24, 4.12, 3.92, 3.66, 2.05, 
1.97, 1.85); 
13
C NMR (CDCl3, 75 MHz): δ = 170.9, 170.8, 170.3, 169.4 (each s, 
OC(O)CH3 and NHC(O)CH3), 136.9 (s, Ar-C), 128.6, 128.5, 128.3, 128.0 (each d, 
Ar-CH), 99.5 (d, C-1), 72.5 (d, C-3), 71.9 (d, C-5), 70.7 (t, Ph-CH2), 68.7 (d, C-4), 
62.2 (t, C-6), 54.5 (d, C-2), 23.3 (q, NHC(O)CH3), 20.8, 20.7, 20.6 (each q, 
OC(O)CH3); MS-ESI/TOF: Calculated for C21H28NO9 (M + H)
+
: 439.1792, found 
439.1807. 
(2-Deoxy-2-acetamido-1-O-phenylmethyl)-α/β-D-glucopyranoside (5.34)[261, 262]  
 
Method A 
Acetylated derivative 5.33 (140 mg, 0.32 mmol) was dissolved in distilled MeOH 
(10 mL), and H2O (5 mL) was added. The reaction mixture was stirred at 45 °C 
overnight. The organic solvent was evaporated using a rotary evaporator, and the 
remaining aqueous solution was extracted with EtOAc. The organic layer was then 
washed twice with sat. NaHCO3 solution, then dried (MgSO4), and filtered. The 
organic layer was concentrated under reduced pressure, to give the crude deprotected 
product, 5.34, as a white oily solid (80 mg, 80 %). Following this method only the β-
anomer is obtained. 
Method B 
(2-Deoxy-2-acetamido)-β-D-glucopyranose (500 mg, 2.26 mmol) was dissolved in 
anhydrous DMF (5 mL) and placed under N2 at 0 °C. BnBr (0.57 mL, 4.79 mmol) 
and NaH (120 mg, 5.0 mmol) was added to the reaction in four portions, over 2 h, 
then the reaction was allowed to stir at 0 °C for a further 2 h. The reaction mixture 
was filtered through celite. The celite was rinsed with DMF, and the filtrate was 
reduced using a rotary evaporator. The remaining residue was dissolved in H2O and 
washed three times with DCM. The aqueous layer was co-evaporated with toluene 
under reduced pressure to give an anomeric mixture of the benzyl glycoside 5.34 as a 
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white oily solid (547 mg, 78 %). Spectroscopic data is in agreement with literature 
values. (Anomeric ratio 0.5:1, α:β) 
1
H NMR (D2O, 300 MHz): δ = 7.58-7.38 (m, 5 H, Ph-CH), 4.96 (d, 1 H, H-1 (α-
anomer), J = 3 Hz), 4.91 (d, 1 H, Ph-CH2a, J = 12 Hz), 4.70 (d, 1 H, Ph-CH2b, J = 12 
Hz), 4.59-4.54 (m, 2 H, overlapping H-1 (β-anomer) and Ph-CH2b (α-anomer)), 3.99-
3.47 (m, 12 H, overlapping H-3, H-4, H-5, H-6, and H-2 (both anomers)), 1.99, 1.95 
(each s, 3 H, NHC(O)CH3 (both anomers)); (Lit
[262]
: 
1
H NMR (D2O, 300 MHz): δ = 
7.46-7.37, 4.89, 4.68, 4.54, 3.95, 3.76, 3.70-3.46, 1.94); 
13
C NMR (D2O, 75 MHz): δ 
= 174.5, 174.3 (each s, NHC(O)CH3 (both anomers)), 137.0, 136.8 (each s, Ph-C 
(both anomers)), 129.2, 128.7, 128.6, 128.5, 128.4, 128.4 (each d, Ph-CH), 99.9 (d, 
C-1 (β-anomer)), 95.8 (d, C-1 (α-anomer)), (75.9, 73.7, 72.1, 71.6, 71.4, 70.8, 70.1, 
69.9, 60.8, 60.6, 60.5, 55.53, 53.7), 22.1, 21.8 (each q, NHC(O)CH3 (both anomers)); 
IR: (KBr disc) 3291, 2870, 2419, 1651, 1553, 1080 cm
-1
; MS-ESI/TOF: Calculated 
for C15H22NO6 (M + H)
+
: 312.1442, found 312.1449. 
(2-Deoxy-2-acetamido-3,4,6-tri-O-trimethylsilyl-1-O-phenylmethyl)-α/β-D-
glucopyranoside (5.35)  
 
Method A 
Glycoside 5.34 (268 mg, 0.64 mmol) was dissolved in dry pyridine (6 mL). The 
solution was cooled to 0 ˚C, then a solution of TMSCl (0.49 mL, 3.84 mmol) and 
DIPEA (0.30 mL, 1.28 mmol) was added. The reaction was allowed to reach rt, then 
stirred overnight at rt. The solvent was co-evaporated with toluene, and the 
remaining residue was dissolved in DCM. The organic layer was washed with H2O, 
then dried (MgSO4), and filtered. The crude product was purified by column 
chromatography (Pet. Ether:EtOAc, 1:1) to give an anomeric mixture of TMS 
protected glycoside 5.35 as a white solid (150 mg, 44 %).  
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Method B 
Glycoside 5.34 (268 mg, 0.64 mmol) was dissolved in dry pyridine (6 mL). The 
solution was cooled to 0 ˚C, then a solution of TMSCl (0.49 mL, 3.84 mmol) and 
hexamethyldisilazane (0.27 mL, 1.28 mmol) was added. The reaction was allowed to 
reach rt, then stirred overnight at rt. The solvent was co-evaporated with toluene, and 
the remaining residue was dissolved in DCM. The organic layer was washed with 
H2O, then dried (MgSO4), and filtered. The crude product was purified by column 
chromatography (Pet. Ether:EtOAc, 1:1) to give an anomeric mixture of the TMS 
protected glycoside 5.35 as a white solid (250 mg, 74 %). (Anomeric ratio 0.5:1, α:β) 
Rf: 0.8 (Pet. Ether: EtOAc, 1:2);
 1
H NMR (CDCl3, 300 MHz): δ = 7.35-7.26 (m, 10 
H, Ph-H (both anomers)), 5.61 (d, 1 H, NHC(O)CH3 (β-anomer), J = 9 Hz), 5.44 (d, 
1 H, NHC(O)CH3 (α-anomer), J = 9 Hz), 5.05 (d, 1 H, H-1 (α-anomer), J = 3 Hz), 
4.82 (d, 1 H, Ph-CH2a (β-anomer), J = 12 Hz), 4.71-4.65 (m, 2 H, overlapping H-1 
(β-anomer) and Ph-CH2a (α-anomer)), 4.54 (d, 1 H, Ph-CH2b (β-anomer), J = 12 Hz), 
4.43 (d, 1 H, Ph-CH2b (α-anomer), J = 12 Hz), 4.14-3.99 (m, 2 H, overlapping H-2 
(both anomers)), 3.98-3.54 (m, 8 H, overlapping H-6, H-3 and H-4 (both anomers)), 
3.34-3.23 (m, 2 H, H-5 (both anomers)), 1.93, 1.92 (each s, 6 H, NHC(O)CH3 (both 
anomers)) 0.16, 0.14, 0.13, 0.12, 0.01, 0.09 (each s, 54 H, SiC(CH3)3 (both 
anomers)); 
13
C NMR (CDCl3, 75 MHz): δ = 170.0, 169.9 (each s, NHC(O)CH3 (both 
anomers)), 138.1, 137.6 (each s, Ph-C (both anomers)), 128.7, 128.6, 128.5, 128.4, 
128.2, 128.0, 127.7 (each d, Ph-CH (both anomers)), 99.4 (d, C-1 (β-anomer)), 92.8 
(d, C-1 (α-anomer)), 76.9 (d, C-5), 75.1, 74.5, 73.1, 71.9 (each d, C-3 and C-4 (both 
anomers)), 70.2, 69.5 (each t, Ph-CH2 (both anomers)), 62.3, 61.9 (each t, C-6 (both 
anomers)), 54.8 (d, C-2 (α-anomer)), 53.9 (d, C-2 (β-anomer)), 1.3, 1.2, 1.1, 1.0, 0.9, 
0.8 (each q, SiC(CH3)3 (both anomers)); IR: (DCM film on NaCl plate) 3288, 2956, 
1655, 1562, 1250 cm
-1
; [α]D: + 10 (c 1.0, CH2Cl2); MS-ESI/TOF: Calculated for 
C21H36NO6Si2 (M (-TMS) – H)
-
 (1 x TMS removed by formic acid in mobile phase): 
454.2087, found 454.2089. 
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(2-Deoxy-2-acetamido-3,4-di-O-trimethylsilyl-1-O-phenylmethyl)-α/β-D-
glucopyranoside (5.37)  
 
TMS protected glycoside 5.35 (51 mg, 0.10 mmol) was dissolved in an 
acetone:MeOH mixture (0.8:0.6 mL). The reaction mixture was cooled to 0 ˚C, then 
AcOH (0.01 mL, 0.2 mmol) was added, and this was stirred for 2 h at 0 ˚C. Solid 
NaHCO3 (10 mg) was added and stirred for 10 mins. The reaction mixture was 
diluted with DCM (20 mL), and the solid NaHCO3 was removed by filtration. The 
filtrate was washed with a sat. solution of NaHCO3, then dried (MgSO4) and filtered. 
The organic layer was concentrated under reduced pressure, and the remaining 
residue was purified by column chromatography (Pet. Ether:EtOAc, 1:1) to give the 
selectively deprotected derivative 5.37 as a clear oil (38 mg, 86 %). (Anomeric ratio 
0.6:1, α:β) 
Rf: 0.6 (Pet. Ether: EtOAc, 1:2); 
1
H NMR (CDCl3, 300 MHz): δ = 7.35-7.30 (m, 10 
H, Ph-H (both anomers)), 5.50 (d, 1 H, NHC(O)CH3 (β-anomer), J = 9 Hz), 5.31 (d, 
1 H, NHC(O)CH3 (α-anomer), J = 6 Hz), 5.09 (d, 1 H, H-1 (α-anomer), J = 3 Hz), 
4.89-4.82 (m, 2 H, overlapping H-1 (β-anomer) and Ph-CH2a), 4.59 (d, 1 H, Ph-
CH2b, J = 12 Hz),  4.06-3.99 (td, 1 H, H-2 (α-anomer), J = 9 Hz, 15 Hz), 3.96-3.89 
(dd, 1 H, H-3 (β-anomer), J = 9 Hz, 12 Hz), 3.85-3.80 (dd, 1 H, H-6a (β-anomer), J = 
3 Hz, 9 Hz),), 3.73-3.59 (m, 5 H, overlapping H-6b (β-anomer), H-3, H-4 and H-6 (α-
anomer)), 3.53 (t, 1 H, H-4 (β-anomer), J = 9 Hz), 3.44-3.32 (m, 2 H, overlapping H-
2 and H-5 (β-anomer)), 1.99, 1.94 (each s, 6 H, NHC(O)CH3 (both anomers)), 0.18, 
0.16, 0.13, 0.10 (each s, 36 H, SiC(CH3)3 (both anomers)); 
13
C NMR (CDCl3, 75 
MHz): δ = 169.5, 168.9 (each s, NHC(O)CH3 (both anomers)), 136.8 (s, Ph-C), 
127.7, 127.2, 127.1 (each d, Ph-CH), 98.7 (d, C-1 (β-anomer)), 91.8 (d, C-1 (α-
anomer)), 75.4 (d, C-5), 74.0 (d, C-3), 71.6 (d, C-4), 70.4 (t, Ph-CH2), 61.4, 60.9 
(each t, C-6 (both anomers)), 57.3 (d, C-2 (β-anomer)), 53.8 (d, C-2 (α-anomer)), 
23.2, 22.9 (each q, NHC(O)CH3 (both anomers)), 0.3, 0.2, 0.1, -0.9 (each q, SiC(CH-
3)3 (both anomers)); IR: (DCM film on NaCl plate) 3431, 2925, 1625, 1243 cm
-1
; 
[α]D: - 9.4 (c 0.85, CH3OH); MS-ESI/TOF: Calculated for C15H20NO6 (M (-2 x 
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TMS) - H)
-
 (TMS removed by formic acid mobile phase): 310.1296, found 
310.1310.  
(2-Deoxy-2-acetamido-6-O-[N-(3,4-dibenzyloxyphenylethyl)-succinamyl]-1-O-
phenylmethyl)-β-D-glucopyranoside (5.39) 
 
Glycoside 5.37 (100 mg, 0.21 mmol) was dissolved in dry DCM (4 mL), under N2, 
and DCC (52 mg, 0.25 mmol) was added. This was then added to a solution of 5.13 
(104 mg, 0.24 mmol) in dry DCM (2 mL) under N2. DMAP (1.8 mg, 0.001 mmol) 
was then added to the reaction mixture, and this was allowed to stir at rt for 4 h. The 
reaction mixture was filtered through celite. The filtrate was diluted with DCM and 
washed with an aqueous solution of 5 % AcOH (v/v), followed by H2O. The organic 
layer was dried (MgSO4), and filtered. The crude product was purified by column 
chromatography (Pet. Ether:EtOAc, 1:1) to give glycosyl-dopamine derivative 5.38 
as a clear syrup (100 mg, 52 %). 
This glycosyl-dopamine derivative 5.38 (100 mg, 0.11 mmol) was dissolved in a 2 % 
solution of TFA (v/v) in DCM (7.5 mL) at 0 °C. The reaction mixture was allowed 
to stir at 0 °C for 1 h, then solid NaHCO3 (50 mg) was added, and stirred for 5 mins. 
The reaction mixture was diluted with DCM, then filtered by gravity to remove the 
NaHCO3. The filtrate was concentrated under reduced pressure, and purified by 
column chromatography (DCM:MeOH, 30:1 to 20:1 to 9:1) to give glycoside 5.39 as 
a clear oil (44 mg, 50 %). 
Rf: 0.5 (DCM:MeOH, 9:1); 
1
H NMR (CDCl3 with a drop of CD3OD, 300 MHz): δ = 
7.46-7.25 (m, 15  H, Ar-H), 6.87 (d, 1 H, Ar-H, J = 6 Hz), 6.81 (d, 1 H, Ar-H, J = 
2.1 Hz), 6.71-6.68 (dd, 1 H, Ar-H, J = 3 Hz, 6 Hz), 5.14, 5.11 (each s, 4 H, Ph-CH2), 
4.86 (d, 1 H, Ph-CH2a, J = 15 Hz), 4.56 (d, 1 H, Ph-CH2b, J = 15 Hz), 4.48 (d, 1 H, 
H-1, J = 9 Hz), 4.44 (bs, 2 H, H-6), 3.66 (t, 1 H, H-2, J = 9 Hz), 3.52-3.35 (m, 5 H, 
overlapping H-4, H-5, H-3 and CH2-Ar), 2.70-2.65 (m, 4 H, overlapping NHCH2 and 
C(O)CH2), 2.41 (t, 2 H, C(O)CH2, J = 6 Hz), 1.95 (s, 3 H, NHC(O)CH3); 
13
C NMR 
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(CDCl3, 75 MHz): δ = 173.2 (s, NHC(O)CH3) 172.4, 172.1 (each s, C(O)CH2), 
148.9, 147.6, 137.3, 137.2, 132.5 (each s, Ar-C), 128.5, 128.4, 128.0, 127.9, 127.9, 
127.5, 127.4, 121.7, 115.8, 115.5 (each d, Ar-CH), 99.8 (d, C-1), 74.4 (d, C-3), 73.8 
(d, C-5), 71.5, 71.4 (each t, Ph-CH2), 70.7 (t, Ph-CH2), 70.4 (d, C-4), 63.5 (t, C-6), 
56.3 (d, C-2), 40.9 (t, CH2NH), 35.0 (t, C(O)CH2), 30.6 (t, C(O)CH2), 29.4 (t, CH2-
Ar), 23.0 (q, NHC(O)CH3); IR: (DCM film on NaCl plate) 3299, 2984, 1736, 1641, 
1554, 1260 cm
-1
; [α]D: - 21.5 (c 0.65, CH3OH). 
6.3    General Procedures for Solid Phase Peptide Synthesis 
(SPPS)
[172]
 
6.3.1     Swelling of the Resin 
2-Chlorotrityl chloride (CTC) resin (300 mg) was placed into SPPS apparatus. Dry 
DCM (3 mL) was added, and the vessel was gently shaken for 15 mins. The solvent 
was removed by vacuum filtration. This was repeated twice.  
6.3.2     Introduction of the First Amino Acid (AA) 
The recommended loading of CTC resin is 1.0-1.6 mmol AA/g of resin. The first 
NHFmoc-AA (0.42 mmol) was dissolved in dry DCM (3 mL), and DIPEA (0.28 mL, 
4 eq to carboxylic acid, 1.68 mmol) was added. This solution was gently syringed 
onto the swollen resin, and stirred for 1.75 h. The liquid was then removed by 
vacuum filtration.  
6.3.3     Capping of the First AA 
The resin was washed with 3 x DCM/ MeOH/ DIPEA (17:2:1 mL), followed by 3 x 
DCM (2 mL), 2 x DMF (2 mL), 2 x DCM (2 mL), then dried by vacuum filtration. 
6.3.4     Estimation of Loading of the First AA
[180]
 
The resin (50 mg) was weighed into a 100 mL beaker, DMF (20 mL) was added. 
This suspension was stirred for 30 min, then DBU (0.4 mL) was added. (This gave a 
2 % DBU/DMF soln.) The mixture was stirred for 30 mins then diluted to 100 mL 
with acetonitrile. 2 mL of this solution was transferred to a 25 mL beaker and diluted 
with acetonitrile to 25 mL. A reference solution was prepared in the same way, 
without addition of the resin. The sample and reference solutions were measured by 
UV in quartz cuvettes at 294 and 304 nm, and the absorbance resulting from the 
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dibenzofulvene released upon Fmoc cleavage was used to calculate the level of 
loading of the first AA (Fig. 6.1). 
 
Figure 6.1 Equation for the calculation of the level of attachment of the first AA 
The literature value for CTC resin loading is 0.86 mmol/g. 
6.3.5     Removal of Fmoc Protecting Group 
Swelling of the resin was carried out, as described above. A 20 % piperidine solution 
in DMF (v/v) (1.5 mL) was added to the resin, and gently shaken for 1 min. The 
liquid was removed by vacuum filtration, and a further 1.5 mL of this solution was 
added. The resin was gently shaken for 10 mins, then the liquid removed. The resin 
was washed with DMF x 7 (2 mL).  
6.3.6     Monitoring Fmoc Removal/ Coupling of AA – The Kaiser Test: 
 
Figure 6.2 Reagents required for the Kaiser test 
A few beads were transferred to a glass vial and washed three times with EtOH 
(EtOH added, swirled, then decanted). Each of the above solutions (0.10 mL of A 
and 0.10 mL of B) was added to the beads, and the vial was heated with a heat gun 
for 2 mins (Fig. 6.2). The colour change of the beads was noted (Fig. 6.3). It is 
important to take note of the colour of the resin, and not the liquid. This test can be 
carried out with pyridine and reagent A, but the colour change may be different. 
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Figure 6.3 Colour changes in the Kaiser test 
The Kaiser test was also used to monitor the success of coupling reactions, as 
denoted by a colour change to clear or yellow. The Kaiser test became less useful for 
glycopeptides with colour changes of red being observed at certain stages.  
6.3.7     Coupling of the Second, and Each Consecutive AA 
NHFmoc-AA (0.42 mmol), TBTU (148 mg, 1.1 eq, 0.46 mmol), and HOBt (62 mg, 
1.1 eq) were dissolved in DMF (3 mL). DIPEA (0.15 mL, 2 eq) was added to the 
mixture. This was allowed to react for 10 mins, then added to the pre-swelled resin. 
The resin was gently shaken for 1.5 h, then filtered. The liquid was removed from 
the resin by vacuum filtration, and the resin was washed with DMF (2 mL x 7 
times), followed by DCM (3 mL x 3 times). (Wash with DCM ensures removal of 
DMF which may cause unwanted Fmoc removal over time). 
6.3.8     Capping of the Second, and Consecutive AA After Coupling 
Capping of any unreacted free amines was carried out after each coupling. The resin 
was swelled, then DMF (1.4 mL), DIPEA (0.2 mL), and Ac2O (0.2 mL) were added. 
The resin was gently shaken for 15 mins, then filtered. The resin was washed with 
DMF (2 mL x 7 times). 
6.3.9     Cleavage from the Resin for Mass Spectrometry and for Final Peptide 
Monitoring of the intermediates of each stage in the synthesis was carried out by 
removing a few beads from the reaction vessel. These were washed with EtOH x 3 
times. A 1 % TFA solution (v/v) in DCM (3 mL) was added to the resin and left to 
react at rt for 10 mins. The liquid was removed (filtered through cotton wool to 
remove the beads) and concentrated under reduced pressure. The resulting oil was 
dissolved in DMF or DCM and sent for analysis. 
The cleavage of the final glycopeptide was carried out with 50 % TFA (v/v) in 
DCM, for 1 h. Purification of the final glycopeptides was carried out by HPLC. 
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Peptide 3.6: 
The bulk of the peptide was cleaved from the resin as described above, to give a 
mixture of crude products. The solvent was evaporated under reduced pressure, and 
the remaining residue was triturated with a 10 % solution of TFA in DCM (4 x 5 
mL). The combined DCM/TFA extracts were concentrated under reduced pressure to 
give a clear oil (12 mg, 16 % crude yield). This oil was redissolved in a 10 % 
solution of TFA in DCM, and purified by RP-HPLC. Preparative HPLC was carried 
out using an Agilent Zorbex Eclipse XDB-C18 column, using a mobile phase of A = 
H2O with 0.1 % formic acid, and B = MeCN with 0.1 % formic acid, gradient elution 
was used (A:B, 100:0 to 50:50 to 0:100 to 50:50 to 100:0 over 20 mins). The 
presence of the peptide, 3.6, was confirmed by MS analysis in fractions collected at 
6.5-8 and 8-9.5 mins run time. 
Glycopeptide 3.8: 
The bulk of the peptide was cleaved from the resin as described above, to give a 
crude mixture of products. The solvent was evaporated under reduced pressure, and 
the remaining residue was triturated with a 10 % solution of TFA in DCM (4 x 5 
mL). The combined DCM/TFA extracts were concentrated under reduced pressure to 
give a yellow oil (12 mg, 30 % crude yield). This oil was redissolved in a 10 % 
solution of TFA in DCM, and purified by RP-HPLC. Preparative HPLC was carried 
out using an Agilent Zorbex Eclipse XDB-C18 column, using a mobile phase of A = 
H2O with 0.1 % formic acid, and B = MeCN with 0.1 % formic acid, gradient elution 
was used (A:B, 100:0 to 50:50 to 0:100 to 50:50 to 100:0 over 20 mins). The 
presence of the peptide, 3.8, was confirmed by MS analysis in fractions collected at 
6-7 and 7-8 mins run time. 
Glycopeptide 3.10: 
The bulk of the peptide was cleaved from the resin as described above, to give a 
crude mixture of products. The solvent was evaporated under reduced pressure, and 
the remaining residue was triturated with a 10 % solution of TFA in DCM (4 x 5 
mL). The combined DCM/TFA extracts were concentrated under reduced pressure to 
give a yellow oil (13 mg, 26 % crude yield). This oil was redissolved in a 10 % 
solution of TFA in DCM, and purified by RP-HPLC. Preparative HPLC was carried 
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out using an Agilent Zorbex Eclipse XDB-C18 column, using a mobile phase of A = 
H2O with 0.1 % formic acid, and B = MeCN with 0.1 % formic acid, gradient elution 
was used (A:B, 100:0 to 50:50 to 0:100 to 50:50 to 100:0 over 20 mins). The 
presence of the peptide, 3.10, was confirmed by MS analysis in fractions collected at 
7-8 and 8-9 mins run time. 
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Chapter 7: Appendices  
7.1     Appendix 1: Assignation of 
1
H NMR data for Glycoside 5.37 
1
H NMR spectral data for glycoside 5.37 was assigned with the aid of the 2 D 
techniques HSQC and COSY. The 
1
H NMR spectrum for this compound is shown in 
Fig 7.1, with the COSY in Fig 7.2 and the HSQC displayed in Fig. 7.3. This 
compound was obtained as a mixture of anomers, in the ratio of 0.6:1, α:β.  
The first step in the analysis of this spectral data was the assignation of the H-1 
proton signal. For sugars, the carbon which is attached to this proton resonates at ≈ 
90-105 ppm.
[263]
 By examining the HSQC data (Fig. 7.3), there are two signals in 
this region, at 98.65 and 91.80 ppm. The signal resulting from the β-anomer will 
resonate at a slightly higher ppm than the corresponding α-anomer in the 13C NMR. 
Following these two signals on the HSQC shows interaction with two peaks on the 
1
H NMR. The signal at 98.65 ppm is associated with a proton resonance at ≈ 4.85 
ppm. In the 
1
H NMR spectrum, the H-1 of the β-anomer will resonate at a slightly 
lower ppm than the α-anomer, and will also have a larger J value. In this spectrum it 
is difficult to ascertain the J value, due to overlapping of the signals for H-1 and the 
CH2 of the benzyl group. The other C-1 signal in the HSQC shows an interation with 
a resonance at 5.09 ppm. The J value for the H-1 signal at 5.09 is 3 Hz, which is a 
relatively small value, and this signal corresponds to the α-anomer. Now that the 
signals for H-1 have been assigned, the data from the COSY can be examined. 
Looking at the H-1 signal from the α-anomer, for example, it can be seen that there 
is one crosspeak, representing interactions between the H-1 and the neighbouring 
proton, H-2. Following this crosspeak it can be deduced that H-2 (α-anomer) 
resonates at 4.03 ppm. H-2 shows crosspeak interactions with 3 protons, H-1, H-3, 
and the amide proton from NHAc. The amide proton should be a doublet, while the 
H-3 proton should be a dd, and so the amide proton can be assigned to the signal at 
5.31 ppm. The signal representing H-3 is found in the multiplet at 3.73-3.59 ppm. 
The COSY is followed in this manner to assign all of the sugar protons. A signal at 
7.35-7.30 ppm is indicative of aromatic protons, and it is observed that this signal 
integrates for 10 H. This is assigned as the aromatic protons from the benzyl group 
of both anomers. The protons belonging to the TMS ether protection have been 
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assigned to the singlets at 0.18-0.10 ppm. Due to the presence of the electropositive 
Si atom these protons are very shielded, and so resonate at almost 0 ppm. The acetyl 
CH3 are assigned to the singlets at 1.99 and 1.94 ppm (both anomers). CH3 signals 
typically appear at a slightly lower ppm, but due to the presence of the 
electronegative oxygen of the acetyl group these protons resonate further downfield.  
 
Figure 7.1
1
 H NMR spectrum for glycoside 5.37 
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Figure 7.2 COSY of glycoside 5.37 
 
Figure 7.3 HSQC of glycoside 5.37 
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7.2     Appendix 2: Experimental Data for Attempted Reactions 
Table 2.1 Attempted synthesis of 2.55 using acetyl chloride coupling methology 
The free acid 2.54 (100 mg, 0.14 mmol) was dissolved in anhydrous DCM (5 mL) 
and placed under a N2 atmosphere at 0 °C, in the presence of 3.4 Å molecular sieves. 
Oxalyl chloride (0.01 mL, 0.15 mmol) and DMF (0.005 mL) were added to the 
reaction mixture. This was allowed to stir at 0 °C for 1 h. A solution of 
tetradecylamine (29 mg, 0.14 mmol) and pyridine (0.012 mL, 0.15 mmol) in DCM 
(3 mL) was added dropwise to the reaction mixture, which was allowed to return to 
rt. The reaction mixture was stirred at rt for 4.5 h, then the solvent was evaporated 
under reduced pressure. The remaining residue was dissolved in DCM, and washed 
with 1.0 M HCl. The organic layer was evaportated using a rotary evaporator. This 
reaction failed to yield the desired product. 
Scheme 2.17 Attempted direct glycosylation of acceptor 2.63 
Imidate donor 2.34 (18 mg, 0.03 mmol) and lipid acceptor 2.63 (11 mg, 0.02 mmol) 
were dissolved in anhydrous DCM (5 mL) under a N2 atmosphere, in the presence of 
3.4 Å molecular sieves. To this BF3OEt2 (0.002 mL, 0.01 mmol) was added, and the 
reaction mixture was allowed to stir at rt for 3 h. The solvent was evaporated under 
reduced pressure to leave a white oily solid. The desired product was not 
synthesised, and hemiacetal 2.33 and lipid starting material 2.63 were recovered. 
Scheme 2.21 N-Cbz removal from Troc protected derivative 2.67 
Troc protected derivative 2.67 (230 mg, 0.3 mmol) was dissolved in EtOAc (13 mL). 
Pd/C 10 % (w/w) (100 mg) was added and the reaction mixture was placed under a 
H2 atmosphere, then stirred at rt overnight. The reaction did not proceed with 
recovery of starting material. The reaction mixture was filtered to remove the Pd/C, 
then the experiment was repeated for a further 24 h. Full recovery of starting 
material 2.67 was achieved, with non of the desired product synthesised. 
Table 4.1 Attempted tritylation of 4.1 
The Troc protected glucosamine 4.1 (400 mg, 1.1 mmol) was dissolved in dry 
pyridine (15 mL). Et3N (0.02 mL, 0.12 mmol) and TrCl (379 mg, 1.4 mmol) was 
added to the reaction mixture. This was stirred at 70 °C for 4 h. The reaction mixture 
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was cooled to 0 °C, then Ac2O (0.64 mL, 6.8 mmol) was added slowly. The reaction 
mixture was allowed to return to rt, then stirred at rt overnight. The solvent was 
evaporated under reduced pressure, and the remaining residue was dissolved in 
DCM, and washed with brine. The organic layer was dried (MgSO4), and filtered, 
then concentrated under reduced pressure. The crude product was purified by column 
chromatography (Hex:EtOAc, 2:1) to give protected glucosamine derivative 4.2 as a 
clear oil (83 mg, 5 %), and mainly the acetylated derivative 2.26. 
Table 4.2 i) Attempted O-Fmoc protection of the C-6 position 
Glycoside 4.7 (55 mg, 0.12 mmol) was dissolved in anhydrous pyridine (10 mL) 
under a N2 atmosphere, and cooled to 0 °C. Fmoc-Cl (47 mg, 0.19 mmol) was added 
to the reaction mixture, and this was allowed to stir at 0 °C for 2 h. The reaction 
mixture was allowed to return to rt, then stirred for a further 4 h. Another equivalent 
of Fmoc-Cl was added (32 mg), and the reaction mixture was allowed to stir at rt 
overnight. Ac2O (8 mL) was added, and the reaction mixture was allowed to stir for 
4 h. The solvent was evaporated under reduced pressure, and the remaining residue 
was dissolved in DCM then washed with 1.0 M HCl, followed by a sat. solution of 
NaHCO3. The organic layer was concentrated under reduced pressure. The desired 
product was not obtained from this experiment. 
Table 4.2 ii) Attempted O-MOM protection of the C-6 position 
Glycoside 4.7 (55 mg, 0.12 mmol) was dissolved in acetone (10 mL) and K2CO3 (62 
mg, 0.45 mmol) was added. MOM-Br (0.14 mL mg, 0.17 mmol) was added 
dropwise to the reaction mixture, and this was heated at reflux (56 °C) overnight. 
The reaction mixture was allowed to return to rt, then MeOH (6 mL) was added to 
quench the remaining MOM-Br. The solvent was evaporated under reduced pressure, 
and the remaining reside dissolved in pyridine (6 Ml). Ac2O (6 mL) was added, and 
the reaction mixture was allowed to stir at rt overnight. The solvent was evaporated 
under reduced pressure, and the remaining residue was dissolved in DCM then 
washed with 1.0 M HCl, followed by a sat. solution of NaHCO3. The organic layer 
was concentrated under reduced pressure. The desired product was not obtained from 
this experiment. 
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Table 4.3 Attempted enzymatic deacetylation (general procedure) 
Glycoside 3.4 (83 mg, 0.11 mmol) was dissolved in ethanol or ACN (10 mL). 
Phosphate buffer was added to adjust the pH of the reaction mixture to the desired 
value. Enzyme (CRL or CAL B) (42 mg) was added to the reaction mixture, and this 
was gently shaken in a temperature controlled water bath (temperature range from 20 
→ 50 °C) for 2 days. None of these enzymatic experiments yielded the desired 
product, with full recovery of starting material 3.4 in all cases. 
Table 4.4 i) Attempted chemical deacetylation using DBTO 
Glycoside 3.4 (22 mg, 0.03 mmol) was dissolved in MeOH (5 mL) and DBTO (7.3 
mg, 0.03 mmol) was added. The reaction mixture was heated to 50 °C and allowed 
to stir for 3 h. The reaction mixture was allowed to return to rt, then stirred 
overnight. The reaction had not gone to completion, and was again heated to 50 °C, 
and stirred for 3 h. Partial deacetylation was observed, with mainly the starting 
material recovered. 
Table 4.4 ii) Attempted chemical deacetylation using KCN 
Glycoside 3.4 (22 mg, 0.03 mmol) was dissolved in MeOH (5 mL) and cooled to 0 
°C. KCN (5.7 mg, 0.09 mmol) was added and the reaction mixture was stirred at 0 
°C for 0.5 h. The reaction mixture was allowed to return to rt, then stirred for 1.5 h. 
The solvent was evaporated under reduced pressure. The desired product was not 
obtained under these reaction conditions. 
Scheme 4.7 Attempted introduction of azide functionality into 4.18 
Tosyl protected glycoside 4.18 (20 mg, 0.03 mmol) was dissolved in DMF (5 mL) 
and NaN3 (18 mg, 0.3 mmol) was added. The reaction mixture was heated to 70 °C 
and allowed to stir for 2.5 h. The solvent was evaporated under reduced pressure, 
and the remaining residue was purified by column chromatography (DCM:MeOH, 
15:1 to 10:1 to 8:2). The desired product was not synthesised, and removal of the 
Fmoc group was noted by NMR. 
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Scheme 4.9 Attempted introduction of linker attached azide into 4.23 using 
TBTU/HOBt methodology 
TMS protected glycoside 4.23  
Azido propionic acid 4.21 (110 mg, which still contained some MeCN) was 
dissolved in anhydrous DCM (3 mL) under N2, and cooled to 0 °C. HOBt (17 mg, 
0.13 mmol), TBTU (41 mg, 0.13 mmol) and DIPEA (0.02 mL, 0.13 mmol) were 
added to the reaction mixture, and this was allowed to stir for 5 mins. A solution of 
the crude TMS protected glycoside, 4.23 (45 mg, 0.06 mmol) in anhydrous DCM 
was added slowly to the reaction mixture. This was stirred at 0 °C for 1.5 h, and then 
allowed to return to rt. The reaction mixture was stirred at rt overnight, and then 
washed with H2O. The organic layer was concentrated under reduced pressure to 
almost dryness. The remaining oil was purified by column chromatography 
(DCM:MeOH, 15:1 to 9:1). The desired product was not synthesised under these 
reaction conditions. 
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